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Ac acetyl 
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calc. calculated 
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conc concentrated 
COF covalent organic framework 
Cy cyclohexyl 
dba trans,trans-
dibenzylideneacetone 
DME 1,2-dimethoxyethane 
DMF N,N-dimethylformamide 
equiv equivalent 
E electrophile 
Et ethyl 
FCC flash column 
chromatography 
FG functional group 
FRET Förster type energy transfer 
GC gas chromatography 
h hour 
HR-MS high resolution mass 
spectroscopy 
iPr isopropyl 
IR infra-red 
J coupling constant (NMR) 
M molar 
m meta 
Me methyl 
min minute 
mp melting point 
Mbs 4-methoxybenzenesulfonyl 
MOM methoxymethyl 
MS mass spectroscopy 
nBu butyl 
NMR nuclear magnetic resonance 
NMP N-methyl-2-pyrrolidine 
o ortho 
OLED organic light emitting diode 
p para 
PIP piperidyl 
pKa acid dissociation constant 
PG protecting group 
Ph phenyl 
R organic substituent 
Rf ribofuranosyl 
sat saturated 
SPhos 2-dicyclohexylphosphino-
2’,6’-dimethoxybiphenyl 
tBu tert-butyl 
TLC thin layer chromatography 
THF tetrahydrofuran 
THP 2,2,3,3-tetrahydropyranyl 
TMP 2,2,6,6-tetramethylpiperidyl 
TMS trimethylsilyl 
Ts 4-toluenesulfonyl 
TP typical procedure 
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1. Overview 
 
Modern life is unthinkable without the epochal achievements that have been made in 
chemistry and especially in organic chemistry. In terms of synthetics, glues, fuel, fuel 
additives, dyes, pharmaceuticals, fertilizer and food additives chemistry is all-around. Still, 
there is a significant demand for fundamental research, as well as for the development of new 
and more efficient synthetic methods. Due to the higher complexity of the target molecules 
nowadays, the new processes should provide a high functional group tolerance, selectivity and 
atom efficiency. A wide sphere of novel syntheses was found in 1849 by Frankland1 who 
synthesized diethylzinc as the first organometallic compound. Since that time, organometallic 
chemistry became an important and diverse part of the organic and inorganic chemistry and 
several nobel prizes have been awarded in this field of research. In the beginning, 
organolithium2 and organomagnesium3 derivatives were mainly investigated and they are still 
very important intermediates for carbon-carbon bond formation.4 Organozinc reagents are 
more stable and easier to handle, but therefor less reactive. For this reason, the interest in 
organozinc compounds grew not before they were found to react nearly quantitative with acid 
chlorides5 and their reactivity was found to be tunable by addition of lewis acids.6 More 
recently, the discovery of transmetalation reactions with various transition metal salts7,8 
became the breakthrough in organozinc chemistry as these results have shown the diverse 
reactivity in addition to an excellent functional group tolerance. 
  
                                                 
1
 (a) Frankland, E. Liebigs Ann. Chem. 1848-49, 71, 171; (b) Frankland, E. J. Chem. Soc. 1848-49, 2, 263. 
2
 (a) Schlenk, W.; Holtz, J. Chem. Ber. 1917, 50, 262; (b) Ziegler, K.; Colonius, H. Liebigs Ann. Chem. 1930, 
479, 135. 
3
 Grignard, V. Compt. Rend. 1900, 130, 1322. 
4
 (a) Li, B.; Wu, Z.; Gu, Y.; Sun, C.; Wang, B.; Shi, Z. Angew. Chem Int. Ed. 2011, 50, 1109; (b) Shao, Z.; Peng, 
F. Angew. Chem. Int. Ed. 2010, 49, 9566; (c) Boyce, G.; Johnson, J. Angew. Chem. Int. Ed. 2010, 49, 8930. 
5
 Klein, H.; Neff, H. Angew. Chem. 1956, 68, 681. 
6
 Marx, B.; Henry-Basch, E.; Freon, P. Compt. Rend. 1967, 264, 527. 
7
 Negishi, E.; King, A. O.; Okukado, N. J. Org. Chem. 1977, 42, 1821. 
8
 (a) Knochel, P.; Yeh, M., Berk, S.; Talbert, J. J. Org. Chem. 1988, 53, 2390; (b) Dübner, F.; Knochel, P. 
Angew. Chem. Int. Ed. 1999, 38, 379. 
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2. General preparation of functionalized organomagnesium 
and organozinc intermediates 
 
2.1. Metal insertion into organic halides 
 
2.1.1. Magnesium insertion 
 
The initiation of the organomagnesium chemistry is strongly associated with the name 
Grignard who generated organomagnesium compounds via oxidative insertion of magnesium 
into organic halides in 1901.9 The synthesis of those Grignard reagents is made in polar and 
aprotic solvents like THF or diethyl ether and is illustrated in Scheme 1. 
 
 
Scheme 1: General reaction scheme for the generation of a Grignard reagent via oxidative insertion. 
 
Due to the normally used reflux conditions, the functional group tolerance of this reaction is 
very low and can be improved by the use of activated Rieke magnesium (Mg*). Thereby, 
stable functional groups like tert-butylesters or nitriles are tolerated (Scheme 2).10 
 
                                                 
9
 Grignard, V. Ann. Chim. 1901, 24, 433. 
10
 (a) Rieke, R.; Li, T.; Burns, T.; Uhm, S. J. Org. Chem. 1981, 46, 4323; (b) Burns, T.; Rieke, R. J. Org. Chem. 
1987, 52, 3674; (c) Rieke, R. Science 1989, 246, 1260; (d) Rieke, R.; Sell, M.; Klein, W.; Chen, T.; Brown, J.; 
Hansan, M. Active Metals (Ed.: A. Fuerstner), Wiley-VCH, Weinheim, 1995; (e) Lee, J.; Velarde-Ortiz, R.; 
Guijarro, A.; Wurst, J.; Rieke, R. J. Org. Chem. 2000, 65, 5428. 
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Scheme 2: Examples for the synthesis of Grignard reagents with Rieke magnesium (Mg*) and subsequent 
reaction with electrophiles. 
 
Even though the oxidative insertion provides a simple and atom efficient route to magnesium 
reagents, the functional group tolerance is still restricted and Rieke magnesium has to be 
freshly prepared by the treatment of MgCl2 with lithium in the presence of 20 mol% 
naphthalene. Recently, Knochel and co-workers found the LiCl promoted insertion of 
magnesium into aromatic or heteroaromatic chlorides and bromides to be a very mild method 
for the generation of highly functionalized magnesium reagents (Scheme 3).11 
 
 
Scheme 3: Examples for the generation of Grignard reagents in the presence of LiCl and subsequent reaction 
with electrophiles. 
 
                                                 
11
 Piller, F.; Appukkuttan, P.; Gavryushin, A.; Helm, M.; Knochel, P. Angew. Chem. Int. Ed. 2008, 47, 6802. 
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Even more sensitive functionalities are tolerated if the magnesium insertion is made in the 
presence of ZnCl2 and the corresponding zinc reagent is formed in situ (Scheme 4). 
 
 
Scheme 4: Examples for the generation of zinc reagents via magnesium insertion in the presence of LiCl and 
subsequent reaction with electrophiles. 
 
2.1.2. Zinc insertion 
 
The zinc insertion is proceeding similarly to the magnesium insertion (Scheme 5). One of the 
most important differences is the additional activation of the zinc metal with 1,2-
dibromoethane and TMSCl, which is essential because of the passivated surface.12 Generally, 
the reaction times of the zinc insertion are longer and almost all functional groups can be 
tolerated.13 
 
 
Scheme 5: General reaction scheme for the oxidative zinc insertion. 
 
                                                 
12
 (a) Gaudemar, M. Bull. Soc. Chim. Fr. 1962, 5, 974; (b) Erdik, E. Tetrahedron 1987, 43, 2203. 
13
 Knochel, P.; Yeh, M.; Berk, S.; Talbert, J. J. Org. Chem. 1988, 53, 2390 
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Even though this provides a general access to organozinc reagents it was almost exclusively 
limited to organic iodides in the beginning. Rieke developed highly activated zinc metal, 
which is freshly prepared in a reaction of ZnCl2 with lithium naphthalenide and therefore 
much more reactive.10 In 2006, Knochel found another possibility for speeding up the zinc 
insertion by addition of LiCl.14 Thus, reaction times became shorter, reaction temperatures 
became lower and even the insertion into organic bromides became accessible (Scheme 6). 
Another important advantage is the influence of the LiCl on the solubility of the formed zinc 
reagents. 
 
Zn
THF
I ZnILiCl
I
CO2Et
ZnILiCl
CO2Et
Zn
THF
Zn (3 equiv) at 50 °C, 24 h: 5%
ZnLiCl (1.5 equiv) at 50 °C, 24 h: >98%
Zn (2 equiv) at 70 °C, 24 h: <5%
ZnLiCl (1.4 equiv) at 25 °C, 24 h: >98%
1) CuCN2LiCl (20 mol%)
2) tBuCOCl (1.1 equiv)
allyl bromide (1.1 equiv)
CuCN2LiCl (0.4 mol%)
CO2Et
O tBu
90%
94%
 
Scheme 6: Examples for the preparation of arylzinc halides in the absence and in the presence of stoichiometric 
amounts of LiCl. 
 
2.2. Halogen/ magnesium exchange 
 
Problems which occure due to the heterogeneous reaction conditions of metal insertion 
reactions can be avoided with the halogen/ magnesium exchange reaction that was first 
observed by Prévost in 1931 as shown in Scheme 7.15 
 
                                                 
14
 (a) Boudet, N.; Sase, S.; Sinha, P.; Liu, C.; Krasovskiy, A.; Knochel, P. J. Am. Chem. Soc. 2007, 129, 12358; 
(b) Krasovskiy, A.; Malakhov, V.; Gavryushin, A.; Knochel, P. Angew. Chem. Int. Ed. 2006, 45, 6040. 
15
 Prévost, C. Bull. Soc. Chim. Fr. 1931, 49, 1372. 
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Scheme 7: Bromine/ magnesium exchange with cinnamylbromide by Prévost. 
 
In 1971, Tamborski and Moore have shown that the halogen/ magnesium exchange highly 
depends on the halogen as well as on the nature of the organic compound that is used.16 The 
higher the polarizability of the halogen and the lower the bond strength of the carbon-halogen 
bond, the higher is the reactivity as shown in Scheme 8. Therefore, the reaction with chlorines 
only occures on highly activated substrates like chloro pentafluorobenzene. The dependency 
of the reactivity on the number of electron withdrawing substituents like fluorine was shown 
by Knochel (Scheme 8).17 
 
 
Scheme 8: Celerity of the halogen/ magnesium exchange reaction depending on the halogen and on the 
substrate. 
 
The further development of the iodine/ magnesium exchange at low temperatures has shown 
an excellent functional group tolerance beside a good reactivity of the organometallic reagents 
(Scheme 9).18  
                                                 
16
 Tamborski, C.; Moore, G. J. Organomet. Chem. 1971, 26, 153. 
17
 Abarbri, M; Dehmel, F.; Knochel, P. Tetrahedron Lett. 1999, 40, 7449. 
18
 a) Boymond, L.; Rottländer, M.; Cahiez, G.; Knochel, P. Angew. Chem. Int. Ed. 1998, 37, 1701; b) Boudier, 
A.; Bromm, L.; Lotz, M.; Knochel, P. Angew. Chem. Int. Ed. 2000, 39, 4415; c) Sapountzis, I.; Knochel, P. 
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Scheme 9: General reaction scheme for the iodine/ magnesium exchange pointing out the functional group 
tolerance. 
 
At that time, the halogen/ magnesium exchange on non-activated substrates was restricted to 
iodinated aryl or heteroaryl19 compounds which normally are more expensive and less stable 
than the corresponding brominated derivatives. In 2004, Knochel discovered a new method 
for speeding up the bromine/ magnesium exchange by the addition of LiCl which breaks the 
aggregated iPrMgCl (Scheme 10).20 
 
 
Scheme 10: Celerity of the bromine/ magnesium exchange reaction by the addition of LiCl. 
                                                                                                                                                        
Angew. Chem. Int. Ed. 2002, 41, 1610; d) Knochel, P.; Dohle, W.; Gommermann, N.; Kneisel, F.; Kopp, F.; 
Korn, T.; Sapountzis, I.; Vu, V. Angew. Chem. Int. Ed. 2003, 42, 4302. 
19
 a) Bérillon, L.; Leprêtre, A.; Turck, A.; Plé, N.; Quéguiner, G.; Cahiez, G.; Knochel, P. Synlett 1998, 1359; b) 
Abarbri, M.; Dehmel, F.; Knochel, P. Tetrahedron Lett. 1999, 40, 7449; c) Abarbri, M.; Thibonnet, J.; Bérillon, 
L.; Dehmel, F.; Rottländer, M.; Knochel, P. J. Org. Chem. 2000, 65, 4618. 
20
 Krasovskiy, A.; Knochel, P. Angew. Chem. 2004, 116, 3369; Angew. Chem. Int. Ed. 2004, 43, 3333. 
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2.3. Directed metalation with amide-bases 
 
2.3.1. Directed metalation with magnesium amides 
The deprotonation of organic compounds is an elegant method for the metalation as no 
halogenated substrate is required. As organomagnesium reagents are kinetically weak bases 
this method is limited to coordinating substrates. Amides and coordinating functional groups 
are used to minimize the intrinsic barrier and to break up the aggregated organometallic 
reagents.21 In 1989, Eaton reported ortho- and double-magnesiation on aromatics with Hauser 
bases (R2NMgBr) and magnesium bisamides ((R2N)2Mg) (Scheme 11).22 
 
 
Scheme 11: Examples for directed metalation with magnesium bisamides by Eaton. 
 
In 1995, Mulzer developed the regioselective magnesiation of mono- and disubstituted 
pyridines with TMPMgCl,23 but due to the low solubility and the required large quantity of 
base the scope was quite narrow. The directed magnesiation became more prevalent when 
Knochel reported mixed lithium-magnesium amide bases, which are readily soluble and are 
therefore used in stoichiometric amounts.24 The preparation of the first synthesized bases and 
                                                 
21
 Baron, O.; Dissertation, Ludwig-Maximilians-Universität München, 2006. 
22
 Eaton, P.; Lee, C.; Xiong, Y. J. Am. Chem. Soc. 1989, 111, 8016. 
23
 Schlecker, W.; Huth, A.; Ottow, E.; Mulzer, J. J. Org. Chem. 1995, 60, 8414. 
24
 (a) Krasovskiy, A.; Krasovskaya, V.; Knochel, P. Angew. Chem. Int. Ed. 2006, 45, 2958; (b) Lin, W.; Baron, 
O.; Knochel, P. Org. Lett. 2006, 8, 5673. 
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some examples for the deprotonation of aromatic or heteroaromatic substrates with 
TMPMgCl·LiCl are shown in Scheme 12. 
 
 
Scheme 12: Preparation of mixed lithium-magnesium amide bases and some examples for the use of 
TMPMgCl·LiCl in deprotonation reactions. 
 
In continuation to this work it was shown that the bisamide TMP2Mg·2LiCl has an improved 
kinetic basicity even though its solubility is lower (Scheme 13).25  
 
                                                 
25
 (a) Clososki, G.; Rohbogner, C.; Knochel, P. Angew. Chem. 2007, 119, 7825; Angew. Chem. Int. Ed. 2007, 46, 
7681; (b) Rohbogner, C.; Wagner, A.; Clososki, G.; Knochel, P. Org. Synth. 2009, 86, 374. 
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Scheme 13: Preparation of TMP2Mg·2LiCl and its reactivity compared to TMPMgCl·LiCl. 
 
2.3.2. Directed metalation with zinc amides 
The first directed metalation reactions with zincate bases were published by Kondo in 1999. 
The synthesis of TMPZnR2Li is shown in Scheme 14 and some examples for the 
deprotonation of aryls and heteroaryls with subsequent iodination in Scheme 15.26  
 
 
Scheme 14: Synthesis of zincate bases published by Kondo. 
                                                 
26
 (a) Kondo, Y.; Shilai, H; Uchiyama, M.; Sakamoto, T. J. Am. Chem. Soc. 1999, 121, 3539; (b) Imahori, T.; 
Uchiyama, M.; Kondo, Y. Chem. Commun. 2001, 2450; (c) Uchiyama, M.; Miyoshi, T.; Kajihara, Y.; Sakamoto, 
T.; Otami, Y.; Ohwada, T.; Kondo, Y. J. Am. Chem. Soc. 2002, 124, 8514. 
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Scheme 15: First directed metalation reactions with a zincate base published by Kondo. 
 
If the deprotonation occured ortho to a bromine atom the corresponding benzyne was formed 
at 25 to 66 °C.27 Moreover, these highly reactive zincates were not compatible with very 
sensitive heterocycles like 1,3,4-oxadiazole derivatives and functional groups like aldehydes 
and nitro groups. To achieve the directed metalation in those cases Knochel and co-workers 
developed pathways using either an in situ method with TMP2Mg·2LiCl in the presence of 
ZnCl228 (Scheme 16) or new bisamide zinc bases29 (Scheme 17). These bases are even stable 
at higher temperatures and can therefore be used under microwave irradiation up to 120 °C.30 
 
 
Scheme 16: In situ method with TMP2Mg·2LiCl in the presence of ZnCl2 by Knochel. 
                                                 
27
 Uchiyama, M.; Kobayashi, Y.; Furuyama, T.; Nakamura, S.; Kajihara, Y.; Miyoshi, T.; Sakamoto, T.; Kondo, 
Y.; Morokuma, K. J. Am. Chem. Soc. 2008, 130, 472. 
28
 Dong, Z.; Clososki, G.; Wunderlich, S.; Unsinn, A.; Li, J.; Knochel, P. Chem. Eur. J. 2009, 15, 457. 
29
 (a) Wunderlich, S.; Knochel, P. Angew. Chem. Int. Ed. 2007, 46, 7685; (b) Rohbogner, C.; Wunderlich, S.; 
Clososki, G.; Knochel, P. Eur. J. Org. Chem. 2009, 1781. 
30
 Wunderlich, S.; Knochel, P. Org. Lett. 2008, 10, 4705. 
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Scheme 17: Synthesis of new bisamide zinc bases for the generation of bisheteroarylzinc reagents and 
subsequent reaction with electrophiles. 
 
The LiCl is an essential component for the solubility of these bases as already mentioned for 
the metal insertion, the halogen/ magnesium exchange and the directed metalation with 
magnesium amides. Moreover, the MgCl2 increases the kinetic basicity.29a However, in the 
case of some electron-poor functionalized aromatics and heteroaromatics the already 
mentioned zinc bases reach their limits or have to be used at low temperatures. Recently, a 
milder and more selective zinc base (TMPZnCl·LiCl) was published which is normally used 
at ambient temperature31 and can be used up to 160 °C under microwave conditions.32 The 
preparation of this base and its reactivity compared to TMP2Zn·2MgCl2·2LiCl  is shown in 
Scheme 18. 
 
                                                 
31
 (a) Mosrin, M.; Knochel, P. Org. Lett. 2009, 11, 1837; (b) Mosrin, M.; Bresser, T.; Knochel, P. Org. Lett. 
2009, 11, 3406; (c) Bresser, T.; Mosrin, M.; Monzon, G.; Knochel, P. J. Org. Chem. 2010, 75, 4686; (d) Bresser, 
T.; Monzon, G.; Mosrin, M.; Knochel, P. Org. Process Res. Dev. 2010, 14, 1299. 
32
 Mosrin, M.; Monzon, G.; Bresser, T.; Knochel, P. Chem. Commun. 2009, 37, 5615. 
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TMP2Zn2MgCl22LiCl
(0.55 equiv)
THF, 25 °C, 4 h
O
O
Zn2MgCl2
O
O
2
TMPZnClLiCl
(1.1 equiv)
THF, 25 °C, 7 d or
mw, 80 °C, 1 h
O
ZnClLiCl
O
Pd (cat)
25 °C, 2 h
O O
I
CO2Et Ar
Pd (cat)
25 °C, 2 h
O O
Ar
I CF3
83%
85%
N
H
TMPZnClLiCl
1) nBuLi (1 equiv)
2) ZnCl2 (1.1 equiv)
1.3 M in THF
NCl
O2N
2LiCl
TMP2Zn2MgCl22LiCl
(0.55 equiv)
THF, -40 °C, 1.5 h
N
Cl Zn2MgCl2
2
TMPZnClLiCl
(1.1 equiv)
THF, 25 °C, 45 min N
Cl ZnClLiCl
CuCN2LiCl
(cat)
2LiCl
Br
NO2
NO2
CuCN2LiCl
(cat)
Br
N
Cl
NO2
N
Cl
NO2
80%
73%
 
Scheme 18: Synthesis of TMPZnCl·LiCl and its reactivity compared to TMP2Zn·2MgCl2·2LiCl. 
 
 
3. Functionalization of heterocycles 
 
Condensed heterocycles gain importance due to their applications in biological and material 
science. Therefore, their functionalization is an active research field what is still affecting the 
demand on new synthetic methods.33 
 
                                                 
33
 (a) Kienle, M.; Wagner, A. J.; Dunst, C.; Knochel, P. Chem. Asian. J. 2011, 6, 517; (b) Zhu, J.; Xie, H.; Chen, 
Z.; Li, S.; Wu, Y. Chem. Commun. 2011, 47, 1512; (c) Kim, S. H.; Chang, S. Org. Lett. 2010, 12, 1868. 
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3.1. Functionalization of the purine scaffold 
 
Purine itself is a synthetic compound which was named in 188434 and synthesized the first 
time 14 years later from uric acid35 by E. Fischer (Scheme 19). Its naturally occuring 
derivatives are omnipresent as it’s part of the DNA and of lots of co-factors. 
 
 
Scheme 19: Purine synthesis by E. Fischer. 
 
As a result of the vast quantity of biologically active compounds bearing this heterocyclic unit 
the purine scaffold became an important class of pharmacophores that has been extensively 
explored in the last decades.36 For example, the 2-morpholino purine I and the 2-
benzimidazolo purine II are potential kinase inhibitors37 or display immunosuppressant38 
activity, the purine derivative III is a potential pharmaceutical for psychiatric disorders and 
neurological diseases (Scheme 20).  
 
                                                 
34
 E. Fischer Berichte der Deutschen Chemischen Gesellschaft 1884, 17, 328. 
35
 E. Fischer Berichte der Deutschen Chemischen Gesellschaft 1898, 31, 2550. 
36
 Reviews: (a) Legraverend, M. Tetrahedron 2008, 64, 8585; (b) Brændvang, M.; Gundersen, L. Bioorg. Med. 
Chem. 2007, 15, 7144; (c) Legraverend, M.; Grierson, D. S. Bioorg. Med. Chem. 2006, 14, 3987; (d) Rosemeyer, 
H. Chem. Biodiv. 2004, 1, 361. 
37
 Chen, D.; Nagaraj, H. K. M.; Williams, M. WO 2010/114494, 2010. 
38
 Neagu, I.; Diller, D.; Kingsbury, C.; Bohnstedt, A. C.; Ohlmeyer, M. J.; Paradkar, V.; Ansari, N. US 
20080214580, 2008. 
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Scheme 20: Biologically active purine derivatives. 
 
Large combinatorial libraries of several types of substituted purines have been prepared by 
heterocyclizations,39 direct C-H arylations,40 or by regioselective nucleophilic substitutions of 
dihalopurines with amines in combination with cross-coupling reactions.41 For the 
introduction of C-substituents to the 2-, 6-, and 8-positions of the purine moiety transition 
metal-catalyzed cross-coupling reactions of purine halides are usually used as shown in 
Scheme 21.40b Hereby, the functional group tolerance is restricted to methoxy- and fluorine-
substituents. 
 
 
Scheme 21: General reaction scheme for the triple cross-coupling sequence published by Hocek. 
                                                 
39
 (a) Kalla, R. V.; Elzei, E.; Perry, T.; Li, X.; Gimbel, A.; Yang, M.; Zeng, D; Zablocki, J. Bioorg. Med. Chem. 
Lett. 2008, 18, 1397; (b) He, R.; Ching, S. M.; Lam, Y. J. Comb. Chem. 2006, 8, 923; (c) Lin, X.; Robins, M. J. 
Collect. Czech. Chem. Commun. 2006, 71, 1029. 
40
 (a) Čerňa, I.; Pohl, R.; Klepetářová, B.; Hocek, M. J. Org. Chem. 2010, 75, 2302; (b) Čerňa, I.; Pohl, R.; 
Klepetářová, B.; Hocek, M. J. Org. Chem. 2008, 73, 9048. 
41
 (a) Piguel, S.; Legraverend, M. J. Org. Chem. 2007, 72, 7026; (b) Hocek, M.; Pohl, R. Synthesis 2004, 2869; 
(c) Hocek, M.; Hocková, D.; Dvořáková, H. Synthesis 2004, 889. 
A. Introduction 
 
17 
 
 
Scheme 22: Reported metalations of single positions of the purine scaffold. 
 
The opposite approach, coupling of metalated purine derivatives with appropriate C-
electrophiles, has been less developed and is only known for single positions of the purine 
scaffold (Scheme 22). The preparation and the reactivity of lithiated purines via 
halogen/ lithium exchange or deprotonation,42 magnesiated purines via iodine/ magnesium 
exchange,43 and 6-zincated purines via zinc insertion44 have been reported. 
                                                 
42
 a) Leonard, N. J.; Bryant, D. J. J. Org. Chem. 1979, 44, 4612; b) Tanaka, H.; Uchida, Y.; Shinozaki, M.; 
Hayakawa, H.; Matsuda, A.; Miyasaka, T. Chem. Pharm. Bull. 1983, 31, 787; c) Kato, K.; Hayakawa, H.; 
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While the organolithium compounds are only stable at very low temperatures and have low 
functional group tolerance, the exchange reactions with iPrMgCl and the Zn-insertion require 
iodinated purines which can be exclusively synthesized under harsh reaction conditions. Thus, 
there’s still a lack of methodology for new and easy accessible multi or even full 
functionalized purine derivatives with a high functional group tolerance. 
 
 
3.2. Functionalization of the benzo[c][1,2,5]thiadiazole scaffold 
 
The benzothiadiazole scaffold is part of many important compounds such as the muscle 
relaxant tizanidine (Scheme 23) which is used for the treatment of chronical migraine and as 
antispastic agent.45 Moreover, it is a suitable building block for semi-conducting polymers 
and copolymers46 as well as for printable organic semiconductors (Scheme 23)47 which find 
application as organic thin film transistors (OTFT), organic photovoltaic cells (OPV), light-
emitting diodes (LED) or as fluorescent probes for bio-imaging.48  
 
                                                                                                                                                        
Tanaka, H.; Kumamoto, H.; Shindoh, S.; Shuto, S.; Miyasaka, T. J. Org. Chem. 1997, 62, 6833; d) Ghosh, A. K.; 
Lagisetty, P.; Zajc, B. J. Org. Chem. 2007, 72, 8222. 
43
 a) Tobrman, T.; Dvořák, D. Org. Lett. 2003, 5, 4289; b) Tobrman, T.; Dvořák, D. Org. Lett. 2006, 8, 1291; c) 
Klečka, M.; Tobrman, T.; Dvořák, D. Collect. Czech. Chem. Commun. 2006, 71, 1221. 
44
 a) Stevenson, T. M.; Prasad, A. S. B.; Citineni, J. R.; Knochel P. Tetrahedron Lett. 1996, 37, 8375; b) Prasad, 
A. S. B.; Stevenson, T. M.; Citineni, J. R.; Nyzam, V.; Knochel, P. Tetrahedron 1997, 53, 7237. 
45
 (a) Lovell, B. V.; Marmura, M. J. Current Opinion in Neurology 2010, 23, 254; (b) Kamen, L.; Henney III, H. 
R.; Runyan, J. D. Current Medical Research and Opinion 2008, 24, 425. 
46
 (a) Zheng, Q.; Chen, S.; Zhang, B.; Wang, L.; Tang, C.; Katz, H. E. Org. Lett. 2011, 13, 324; (b) Xu, E.; 
Zhong, H.; Lai, H.; Zeng, D.; Zhang, J.; Zhu, W.; Fang, Q. Macromol. Chem. Phys. 2010, 211, 651; (c) Clarke, 
T.; Ballantyne, A.; Jamieson, F.; Brabec, C.; Nelson, J.; Durrante, J. Chem. Commun. 2009, 89. 
47
 Sonar, P.; Soh, M. S.; Cheng, Y. H.; Henssler, J. T.; Sellinger, A. Org. Lett. 2010, 12, 3292. 
48
 Pu, K.-Y.; Li, K.; Liu, B. Adv. Funct. Mater. 2010, 20, 2770. 
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Scheme 23: Examples for a biologically active benzo[c][1,2,5]thiadiazole derivative and printable organic 
semiconductor. 
 
Despite their versatile use, only few methods for the direct functionalization of this 
heterocycle have been reported.49 The most common methods are the bromination50 
(Scheme 24) and the nitration51 (Scheme 25) with further functionalization by transformation 
 
 
Scheme 24: Synthesis of benzo[c][1,2,5]thiadiazole and its bromination reaction.  
                                                 
49
 (a) Du, J.; Xu, E.; Zhong, H.; Yu, F.; Liu, C.; Wu, H.; Zeng, D.; Ren, S.; Sun, J.; Liu, Y.; Cao, A.; Fang, Q. J. 
Polym. Sci., Part A: Polym. Chem. 2008, 46, 1376; (b) Ju, J. U.; Jung, S. O.; Zhao, Q. H.; Kim, Y. H.; Je, J. T.; 
Kwon, S. K. Bull. Korean Chem. Soc. 2008, 29, 335; (c) Lash, T. D.; Wijesinghe, C.; Osuma, A. T.; Patel, J. R. 
Tetrahedron Lett. 1997, 38, 2031; (d) Takagi, K.; Tomoeda, M. Chem. Pharm. Bull. 1980, 28, 1909; (e) Komin, 
A. P.; Carmack, M. J. Heterocycl. Chem. 1975, 12, 829. 
50
 Pilgram, K.; Skiles, R. D. J. Heterocycl. Chem. 1970, 7, 629. 
51
 (a) Uno, T.; Takagi, K.; Tomoeda, M. Chem. Pharm. Bull. 1980, 28, 1909; (b) Uno, T.; Takagi, K.; Tomoeda, 
M. Chem. Pharm. Bull. 1978, 26, 3896; (c) Komin, A. P.; Carmack, M. J. Heterocycl. Chem. 1075, 12, 829. 
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of these substituents. The synthesis of some unsymmetrically functionalized 
benzo[c][1,2,5]thiadiazoles has also been reported.52 
 
N
S
N
N
S
N
Br
Br
N
S
N
Br
Br
N
S
N
HNO3
H2SO4
10 °C, 3 h
O2N
NO2
HNO3
H2SO4
5 °C, 3 h
N
S
N
Br
Br
N
S
N
Br
Br
O2N
HNO3
H2SO4
25 °C, 2 h O2N
71%
95%
20%
 
Scheme 25: Nitration of the benzo[c][1,2,5]thiadiazole scaffold. 
 
Usually, 4,7-dibromobenzo[c][1,2,5]thiadiazole is used in cross-coupling reactions to provide 
the corresponding polymers or copolymers as shown for one example in Scheme 26.53  
 
                                                 
52
 (a) Bijleveld, J. C.; Shahid, M.; Gilot, J.; Wienk, M. M.; Janssen, R. A. J. Adv. Funct. Mater. 2009, 19, 3262; 
(b) Sonar, P.; Singh, S. P.; Leclère, P.; Surin, M.; Lazzaroni, R.; Lin, T. T.; Dodabalapur, A.; Sellinger, A. J. 
Mater. Chem. 2009, 19, 3228; (c) Wunderlich, S. H.; Kienle, M.; Knochel, P. Angew. Chem. Int. Ed. 2009, 48, 
7256; (d) Jørgensen, M.; Krebs, F. C. J. Org. Chem. 2005, 70, 6004; (e) Pilgram, K.; Zupan, M. J. Org. Chem. 
1971, 36, 207. 
53
 (a) Lu, Y.; Chen, H.; Hou, X.; Hu, X.; Ng, S.-C. Synth. Met. 2010, 160, 1438; (b) Zoombelt, A. P.; Fonrodona, 
M.; Wienk, M. M.; Sieval, A. B.; Hummelen, J. C.; Janssen, R. A. J. Org. Lett. 2009, 11, 903; (c) Melucci, M.; 
Favaretto, L.; Bettini, C.; Gazzano, M.; Camaioni, N.; Maccagnani, P.; Ostoja, P.; Monari, M.; Barbarella, G. 
Chem. Eur. J. 2007, 13, 10046; (d) Zhang, M.; Tsao, H. N.; Pisula, W.; Yang, C.; Mishra, A. K.; Müllen, K.  J. 
Am. Chem. Soc. 2007, 129, 3472; (e) Yao, Y.-H.; Kung, L.-R.; Hsu, C.-S. J. Polym. Res. 2006, 13, 277; (f) van 
Mullekom, H. A. M.; Vekemans, J. A. J. M.; Meijer, E. W. Chem. Eur. J. 1998, 4, 1235. 
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Scheme 26: Example for the copolymerization of 4,7-dibromobenzo[c][1,2,5]thiadiazole. 
 
 
4. Objectives 
 
As the purine scaffold is known for providing many biologically active compounds the 
development of a general process to build up full functionalized purines via organometallic 
intermediates had to be accomplished. Thus, a versatile tool with a high functional group 
tolerance should be created.  
 
 
Scheme 27: General reaction scheme for the functionalization of the purine scaffold via organometallic 
intermediates using TMP-bases. 
 
The second project was to explore the functionalization of benzo[c][1,2,5]thiadiazole 
derivatives for the development of new materials for electronic and optic applications. The 
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synthesis of a bisboronic acid used as a linear linker for the fornation of a new covalent 
organic framework (COF) based on benzothiadiazole should be explored. 
 
 
Scheme 28: Synthesis of a benzo[c][1,2,5]thiadiazole derived linker for the generation of a new covalent organic 
framework with potential electronic properties. 
 
Different substitution patterns should be investigated for the application in the field of new 
fluorescent benzothiadiazoloperylene dyes. 
 
 
Scheme 29: Synthesis of new benzo[c][1,2,5]thiadiazoloperylene dyes. 
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1. Functionalization of the Purine scaffold 
 
As mentioned in a publication of Fu and Guo54 who calculated amongst others the pKa values 
of 9-methyl-9H-purine 2 (Scheme 30) in DMSO, the acidity of the three protons is disparate 
and therefore the regioselective deprotonation may represent a facile access to 
polyfunctionalized purines. Though, the successive functionalization of positions 8, 6 and 2 of 
one certain purine building block using organometallic intermediates is complicated and 
depends highly on the choice of the masked functional groups A, B and C at these positions as 
well as the protecting group (PG) of the purine 1 (Scheme 30).  
 
 
Scheme 30: General figure of a purine precursor (1) and calculated pKa values of 9-methyl-9H-purine (2) in 
DMSO. 
 
 
1.1. Selection of the protection group 
 
As most of the biologically active purine derivatives bear a ribofuranosyl (Rf) or 
ribofuranosyl-like backbone at position 7 or 9 it would be important to use a protecting group 
(PG) that is easily removed in the end of the functionalization pathway without touching the 
functional groups. Still, it has to be stable against organometallic reagents and further reaction 
conditions with various electrophiles. Thus, it would be possible to attach a functionalized and 
therefore expensive group to the finally functionalized purine building block, while this group 
has not to be stable against organometallic reagents.  
4-Methoxybenzenesulfonyl (Mbs) is an interesting option as PG due to its high stability in 
acidic media. Unfortunatly, the deprotonation of position 8 of the purine scaffold was not 
achieved using either TMPZn- or TMPMg-bases (Table 1, entry 1). The benzylic PG (Bn) has 
a similar stability (entry 2) and purine derivatives bearing this PG could be metalated and 
                                                 
54
 Shen, K.; Fu, Y.; Li, J.; Liu, L.; Guo, Q. Tetrahedron 2007, 63, 1568. 
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functionalized at position 8. Nevertheless, deprotonation at position 6 was not achieved due to 
the higher acidity of the benzylic protons. Therefore, the copper intermediate 4 reacts with 
allylbromide providing 5 in 55% yield (Scheme 31). 
 
Table 1: Stability and reactivity of different protection groups (PGs). 
Entry PG acidic cleavage reactivity towards TMP-bases 
1 Mbs HBr reflux no deprotonation at position 8 
2 Bn HBr reflux benzylic protons too acidic 
3 MOM 1N HCl deprotonation 
4 THP HOAc/ NaOAc deprotonation 
Mbs=4-methoxybenzenesulfonyl, Bn=benzyl, MOM=methoxymethyl, THP=2,2,3,3-tetrahydropyranyl. 
 
Scheme 31: Deprotonation of the benzylic protons of the purine derivative 3. 
 
Methoxymethyl (MOM) as PG is still quite stable, can be removed more easily than before 
mentioned PGs by using 1N HCl or Lewis acids and the deprotonation and functionalization 
was readily achieved at positions 8 and 6 (entry 3).55 The 2,2,3,3-tetrahydropyranyl group 
(THP) is even more labile and therefore easy to cleave (entry 4). The deprotonation is equally 
achieved but the yield concerning a reaction with iodine was much lower and a cross-coupling 
product could not be isolated due to the cleavage of the PG.56 In summary, the MOM-PG was 
chosen because of its concerted stability and reactivity. 
 
                                                 
55
 For deprotonation and functionalization compare: Chapters B.1.2. and B.1.4. 
56
 Compare therefor: Chapter B.1.2. Table 2, entries 1-3 and Table 3, entry 3 
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1.2. Successive deprotonation of purine derivatives at positions 8 and 6 
 
 
Scheme 32: General reaction scheme for the zincation of purine derivatives of type 6 at position 8 and 
subsequent reaction with an electrophile. 
 
The most acidic proton of the purine scaffold at position 8 can be abstracted with 
TMPMgCl·LiCl at -60 °C or with each TMP derived zinc base at 25 °C within 15 to 30 min 
(Scheme 32). The mildest possible method by using TMPZnCl·LiCl for the deprotonation and 
subsequent reaction with iodine provides the iodinated compounds 8a-c in 60 to 98% yield 
(Table 2, entries 1-3). If TMPMgCl·LiCl is used at low temperature the yield is only slightly 
affected (entry 2). This displays an alternative for reactions that require magnesiated 
intermediates but is restricted to substrates which have a good solubility at low temperature 
and bear stable functional groups. The bromination with 1,2-dibromo-1,1,2,2-
tetrachloroethane proceeds under Barbier-conditions57 at 25 °C using TMP2Zn·2LiCl 
(entries 4-5) or after deprotonation with the more reactive bisamide zinc base 
TMP2Zn·2MgCl2·2LiCl and subsequent reaction with the brominating agent mentioned above 
(entry 6). The 8-brominated compounds 8d-f are obtained in 75% to 87% yield. Similarly, 6b 
reacts with S-phenyl benzenesulfonothioate under Barbier-conditions at 0 °C providing 3 in 
60% yield (entry 7). In contrast, the zincated intermediate of 6e does not react with S-phenyl 
benzenesulfonothioate. To attach the thioether to the MOM-protected derivative the 8-
lithiated intermediate was reacted with the electrophile giving product 8g in 40% yield 
(entry 8). A copper(I)-catalyzed allylation8 (10 mol% CuCN·2LiCl) with allyl bromide (-50 to 
25 °C, 10 h) leads to the 8-allylated purine (8h) in 84% yield (entry 9). 
 
 
 
                                                 
57
 Blomberg, C.; Hartog, F. Synthesis 1977, 18. 
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Table 2: Reaction of the zincated purine 7 with some electrophiles. 
Entry starting material electrophile product yield, %a 
1 
 
6a 
I2 
 
8a 
98b 
2 
 
6b 
I2 
 
8b 
80 (84)b 
3 
N
N
N
N
THP
Cl
 
6c 
I2 
N
N
N
N
THP
Cl
I
 
8c 
60b 
4 
N
N
N
N
Bn
 
6b 
(CCl2Br)2 
N
N
N
N
Bn
Br
 
8d 
82c 
5 
N
N
N
N
Bn
Cl
 
6d 
(CCl2Br)2 
N
N
N
N
Bn
Cl
Br
 
8e 
75c 
6 
 
6e 
(CCl2Br)2 
 
8f 
87d 
7 
N
N
N
N
Bn
 
6b 
PhSO2SPh 
 
3 
60e 
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Table 2 continued 
8 
 
6f 
PhSO2SPh 
 
8g 
40f 
9 
 
6e 
 
 
8h 
84g 
a
 Isolated, analytically pure product; the yields in parentheses were obtained after deprotonation with 
TMPMgCl·LiCl (1.1 equiv) at -60 °C. b 1) TMPZnCl·LiCl (1.1 equiv), 25 °C, 1 h; 2) I2 (1.2 equiv), 25 °C, 1 h. c 
1) electrophile (1.0 equiv); 2) TMP2Zn·2LiCl (0.6 equiv), 25 °C, 10 min. d 1) TMP2Zn·2MgCl2·2LiCl (1.1 
equiv), 0 °C to 25 °C, 15 min; 2) electrophile (1.4 equiv). e 1) electrophile (1.0 equiv); 2) TMP2Zn·2LiCl (1.2 
equiv), 0 °C, 10 min. f 1) nBuLi (1.05 equiv), -78 °C, 30 min; 2) PhSO2SPh (1.3 equiv), to 25°C in 14 h; g 1) 
TMPZnCl·MgCl2·LiCl (1.05 equiv), -50 °C, 30 min; 2) CuCN·2LiCl (10 mol%), 10 min; 3) electrophile (1.4 
equiv). 
 
Bisarylzinc reagents, which are obtained via deprotonation with TMP2Zn bases58 or with 
TMPMgCl·LiCl and transmetalation with 0.5 equivalents of ZnCl2, react very slow in Pd-
catalyzed Negishi cross-couplings,7,59 even at 50 °C (Scheme 33). Due to the long reaction 
times a lot of starting material decomposes and the yield drops to 35% for the example of 8i. 
Under microwave irradiation the product is obtained in traces only. 
 
 
Scheme 33: Preparation of a bispurinylzinc reagent and subsequent cross-coupling reaction with iodobenzene. 
 
The 8-zincated intermediates of type 7 undergo Pd-catalyzed Negishi cross-coupling reactions 
with Pd(dba)2, P(o-furyl)360 and aryl iodides within a few hours at 25 °C to give the 8-arylated 
compounds of type 8’ (Scheme 34).  
                                                 
58
 Prepared in the presence or absence of MgCl2. 
59
 (a) Negishi, E. Acc. Chem. Res. 1982, 15, 340; (b) Negishi, E.; Valente, L. F.; Kobayashi, M. J. Am. Chem. 
Soc. 1980, 102, 3298. 
60
 Farina, V.; Baker, S. R.; Benigni, D. A.; Sapino, C. Tetrahedron Lett. 1988, 29, 5739. 
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Scheme 34: General reaction scheme for a Negishi cross-coupling at position 8 with an aryl iodide. 
 
If ethyl 4-iodobenzoate is used in this cross-coupling reaction, the yield crucially depends on 
the substituents B and C. If both positions bear a proton, the cross-coupling product 8j is 
isolated in 97% yield (Table 3, entry 1). Similarly, the reaction of the 6-chloropurine 
derivative 6a provides 8k in 91% yield (entry 2). If a THP protection group is attached to the 
6-chloropurine, the corresponding product 8l is detected in traces, because of the deprotection 
of this more labile protective group (entry 3). The 2-chloropurine derivative 6g reacts within 
40 h to produce the 8-arylated compound 8m in 58% yield (entry 4), as the chloro-substituent 
is partially substituted by TMP. At higher temperatures this substitution reaction proceeds 
faster than the cross-coupling reaction. Therefore, only electrophiles which react at low 
temperatures, as for example allylating agents, provide high yielding reaction pathways. The 
cross-coupling reaction of the 2,6-dichloropurine derivative 6h furnishes the corresponding 
product 8n in 62% yield within 20 h (entry 5). The cross-coupling reaction of the 2-TMS-
purine derivative 6i provides the purine 8o in 52% yield, even though the starting material is 
consumed within 3 h (entry 6). If, additionally, a chloro-substituent is attached at position 6 
the corresponding product 8p is isolated in 91% yield (entry 7). In summary, as long as the 
substituent at position 6 (B) is a chloro atom, the substituent at position 2 (C) can be either a 
proton or a TMS-group without affecting the yield of the cross-coupling reaction. 
 
Table 3: Negishi cross-coupling with ethyl 4-iodobenzoate. 
Entry starting material product yield, %a 
1 
N
N
N
N
MOM
 
6e 
 
8j 
97b 
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Table 3 continued 
2 
N
N
N
N
MOM
Cl
 
6a 
 
8k 
91b 
3 
N
N
N
N
THP
Cl
 
6c 
 
8l 
tracesc 
4 
N
N
N
N
MOM
Cl
 
6g 
 
8m 
58b 
5 
 
6h 
 
8n 
62b 
6 
 
6i 
 
8o 
52b 
7 
 
6j 
 
8p 
91b 
a
 Isolated, analytically pure product. b Obtained by Pd-catalyzed cross-coupling reaction using Pd(dba)2 
(2 mol%) and P(o-furyl)3 (4 mol%) as catalyst. c Deprotected product is isolated in 75% yield. 
 
Similar results are obtained when 4-iodoanisole is used for the Negishi cross-coupling 
(Table 4). The main difference is observed when the purine 6e without any substituents at 
positions 2 and 6 is used as a substrate. Thereby, the corresponding cross-coupling product 8q 
is isolated in 61% yield (Table 4, entry 1). Compared to the cross-coupling with ethyl 4-
iodobenzoate, almost the same results are achieved, when the 6-chloropurine (6a) and the 2,6-
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dichloropurine derivative (6h) are deprotonated and cross-coupled with 4-iodoanisole. The 8-
arylated compounds 8r and 8s are produced in 95% and 71% yield, respectively (entries 2-3). 
Functional groups like thioethers are tolerated in both positions, 2 and 6, during deprotonation 
and cross-coupling reactions. Thereby, the reaction of 6k provides the corresponding product 
8t in 85% yield (entry 4). 
 
Table 4: Negishi cross-coupling with iodo-4-methoxybenzene. 
Entry starting material product yield, %a 
1 
N
N
N
N
MOM
 
6e 
 
8q 
61b 
2 
N
N
N
N
MOM
Cl
 
6a 
 
8r 
95b 
3 
 
6h 
 
8s 
71b 
4 
 
6k 
 
8t 
85b 
a
 Isolated, analytically pure product. b Obtained by Pd-catalyzed cross-coupling reaction using Pd(dba)2 
(2 mol%) and P(o-furyl)3 (4 mol%) as catalyst. 
 
Further attempts with arylbromides or heteroarylhalides as electrophiles for this cross-
coupling reaction failed. 
 
 
B. Results and Discussion 
 
32 
The deprotonation at position 6 of the purine scaffold is achieved with TMPZnCl·LiCl at 
25 °C or with TMPMgCl·LiCl at -20 °C, depending on the substrate (Scheme 35). Subsequent 
reaction with iodine provides the 6-iodinated compounds 10a-c in 50% to 70% yield (Table 5, 
entries 1-3). Negishi cross-coupling reactions with iodobenzene or ethyl 4-iodobenzoate give 
the 6,8-bisarylated products 10d-f in 53% to 63% yield (entries 4-6). 
 
N
N N
N
8
MOM
TMPZnClLiCl
(1.3 equiv) or
TMPMgClLiCl
(1.3 equiv)
N
N N
N
9
MetX
MOM
R
E+
N
N N
N
10
E
MOM
RR
8
6
2
 
Scheme 35: Deprotonation of purine derivatives of type 8 at position 6 and subsequent reaction with 
electrophiles. 
 
Table 5: Deprotonation and functionalization at position 6 of type 8 purines. 
Entry starting material electrophile product yield, %a 
1 
 
8g 
I2 
 
10a 
50b 
2 
 
8j 
I2 
 
10b 
70c 
3 
 
8q 
I2 
 
10c 
60c 
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Table 5 continued 
4 
 
8j  
 
10d 
63c, d 
5 
 
8q I
CO2Et
 
N
N
N
N
MOM
OMe
CO2Et
 
10e 
55c, d 
6 
 
8u I
CO2Et
 
 
10f 
53c, d 
a
 Isolated, analytically pure product. b TMPZnCl·LiCl (1.3 equiv), 25 °C, 2 h. c TMPMgCl·LiCl (1.3 equiv)         
-20 °C, 20 min. d 1) ZnCl2 (1.5 equiv), -20 °C to 25 °C, 15 min; 2) Pd(dba)2 (2 mol%), P(o-furyl)3 (4 mol%), aryl 
iodide (1.2 equiv). 
 
The deprotonation at postition 2 of different 6,8-disubstituted purine derivatives failed using 
TMPZnCl bases, TMP2Zn bases, TMPMgCl·LiCl, TMP2Mg·2LiCl and 
TMP2Mn·2MgCl2·4LiCl as base at -20 to 25 °C. If no decomposition was observed the 
reaction mixture was heated to 50 °C or was exposed to microwave irradiation. 
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1.3. Selection of the masked function at position 2 
 
 
Scheme 36: Different 2-substituted purine derivatives under consideration for the full functionalization pathway. 
 
The 2-chloropurine derivatives have been reported in the literatur and can be synthesized via 
2,6-dichloropurine which is commercially available.61 The limitation has been already shown 
in the chapter above (B.1.2. Successive deprotonation of purine derivatives at positions 8 and 
6) as the cross-coupling reaction with 2-chloro-9-MOM-9H-purine (6g) is not as high yielding 
as with other substrates. Moreover, the deprotonation of the 8-arylated compound 8m with 
TMP2Zn·2MgCl2·2LiCl is not possible, because of the almost quantitative substitution of the 
chlorine substituent which provides compound 12a in 2 h at 25 °C in 89% yield (Scheme 37). 
If a less sterically hindered base like a bispiperidide is used, the reaction is less efficient and 
proceeds at higher temperature under formation of the corresponding amine 12b in 35% yield. 
 
 
Scheme 37: Substitution of the 2-chloro substituent with bisamides. 
 
A high yielding procedure for the synthesis of 6-chloro-9-THP-2-(tributylstannyl)-9H-purine 
is known in the literature.62 The conversion of the tributylstannyl group to an iodo-substituent 
is easily achieved with iodine and known as well (Scheme 38). On the one hand, this method 
is easily adopted to synthesize 6-chloro-9-MOM-2-(tributylstannyl)-9H-purine (13a) in 82% 
                                                 
61
 Unciti-Broceta, A.; Pineda de las Infantas, M.; Gallo, M.; Espinosa, A. Chem. Eur. J. 2007, 13, 1754. 
62
 (a) Brun, V.; Legraverend, M.; Grierson, D. Tetrahedron Lett. 2001, 42, 8161; (b) Taddei, D.; Kilian, P.; 
Slawin, A.; Woollins, J. D. Org. Biomol. Chem. 2004, 2, 665. 
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yield and the corresponding iodinated compound (6e) in 90% yield. On the other hand, the 
chloro-substituent cannot be reduced without cleaving the carbon-tin bond. Therefore, the 
only possible functionalization pathway is the Stille cross-coupling at position 2, first. Thus, 
cross-coupling reactions would be the only possibility for functionalization at this position, 
which is no improvement in comparison to the already known methods. 
 
 
Scheme 38: Synthesis of 6-chloro-9-MOM-2-(tributylstannyl)-9H-purine and further functionalizations at 
position 2. 
 
The synthesis of 6-chloro-9-Rf-2-(trimethylsilyl)-9H-purine is known63 and can be adapted to 
synthesize 6-chloro-9-MOM-2-(trimethylsilyl)-9H-purine (6j) in 60% yield (Scheme 39). The 
selective reduction of the 6-chloro-substituent is possible before or after the cross-coupling 
reaction at position 8. If the first step is the Negishi cross-coupling and the second step is the 
reduction, the overall yield amounts to 86% for the final product 8o, whereas the other 
pathway provides the same product in an overall yield of 47%. Due to these results, we have 
chosen the first described pathway for the following full functionalization of the purine 
scaffold. Preliminary results for the iodination at position 2 of the purine derivative 8u with 
silver salts were successful. The iodinated compound 16 was obtained in 77% yield. 
                                                 
63
 Kato, K.; Hayakawa, H.; Tanaka, H.; Kumamoto, H.; Miyasaka, T. Tetrahedron Lett. 1995, 36, 6507. 
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N
N N
N
6a: R=MOM
6m: R=Rf
R
Cl
N
N N
N
6j: R=MOM, 60%
15: R=Rf, Lit: 83%
TMS
R
Cl
N
N N
N
6i: 90%
TMS
MOM
N
N N
N
8o
TMS
MOM
CO2Et
N
N N
N
TMS
MOM
CO2Et
Cl
i)
8p: 91%
Pd/C (20 wt%)
HCO2NH4 (2 equiv)
MeOH:THF (1:1)
45 °C, 30 min
95%
N
N N
N
TMS
MOM CF3
N
N N
H
N
I
CF3
1) AgOTf (2.4 equiv)
CHCl3, 25 °C, 30 min
2) I2 (2.4 equiv)
THF, 25 °C, 1.5 h
8u 16: 77%
1) TMPLi (5 equiv)
hexane:THF (1:1)
-78 °C, 1 h
2) TMSCl (2-5 equiv)
-78 °C, 1 h
to 25 °C in 14 h
Pd/ C (40 wt%)
HCO2NH4 (exc)
MeOH
25 °C, 1 h
i)
52%
 
Scheme 39: Synthesis of 6-chloro-9-MOM-2-(trimethylsilyl)-9H-purine (6j) and further functionalizations. i) 
TMPZnCl·LiCl (1.1 equiv), 25 °C, 15 min; Pd(dba)2 (2 mol%), P(o-furyl)3 (4 mol%), ethyl 4-iodobenzoate (1.2 
equiv), 25 °C, 3-14 h. 
 
 
1.4. Full functionalization of the purine scaffold 
 
Starting from an appropriate 6-chloro-9-MOM-2-TMS-purine derivative (6j), a regioselective 
functionalization of the purine scaffold was achieved successively at position 8, 6 and 2 via 
zinc and magnesium intermediates which were generated either by a direct zincation with 
TMPZnCl·LiCl31,32 or by an I/ Mg exchange using iPrMgCl. 
Starting from 6-chloropurine, 6-chloro-9-methoxymethyl-2-trimethylsilyl-9H-purine (6j) is 
prepared as described above (B.1.3. Selection of the masked function at position 2). Thus, this 
purine is readily metalated at position 8 using TMPZnCl·LiCl  within 15 min at 25 °C leading 
to the zincated purine 17 (Scheme 40). Iodolysis of 17 produces the expected 8-iodopurine 
(18a) in 77% yield (Table 6, entry 1). Copper(I)-catalyzed allylation8 (5 mol% CuCN·2LiCl) 
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with 3-bromocyclohexene (-30 °C to 25 °C, 10 h) leads to the 8-allylated purine (18b) in 91% 
yield (entry 2). Pd-catalyzed acylations (Pd(PPh3)4 (2 mol%))64 with 2-furoyl chloride or 3-
chlorobenzoyl chloride (0 to 25 °C, 6 h) provide the ketones 18c-d in 46% and 55% yield, 
respectively (entries 3-4). Negishi cross-coupling reactions7,59 with various aryl iodides using 
Pd(dba)2 (2 mol%) and P(o-furyl)3 (4 mol%) afford the 8-arylated purines 18e-g and 8p in 72-
91% yield (entries 4-9). An alkynyl group can also be introduced via Sonogashira65 coupling 
by preparing the iodide 18a in situ. Its reaction with p-anisylacetylene (NEt3 (1.2 equiv), CuI 
(4 mol%), Pd(dba)2 (2 mol%), P(o-furyl)3 (4 mol%), 25 °C, 3 h) leads to the 8-alkynylated 
purine 18h in 75% yield.  
 
N
N
N
N
MOM
Cl
Me3Si
TMPZnClLiCl
(1.2 equiv)
THF
25 °C, 15 min
N
N
N
N
MOM
Cl
Me3Si
ZnCl
6j 17 18a-h, 8p
N
N
N
N
MOM
Cl
Me3Si
E1
N
N
N
N
MOM
Me3Si
E1
E1
19a: E1 = m-C6H4OMe: 90%
19b: E1 = p-C6H4CO2Et: 95%
TMPZnClLiCl
(1.5 equiv)
THF, 90 °C,
1-2 h
N
N
N
N
MOM
ZnCl
Me3Si
E1
20a: E1 = m-C6H4OMe
20b: E1 = p-C6H4CO2Et
E2N
N
N
N
MOM
E2
Me3Si
E1
21a-j
I2
CsF
CH3CN/THF
130 °C, 12 h
N
N
N
N
MOM
E2
I
E1
iPrMgCl
(1.5 equiv)
THF
-78 °C, 1 h
N
N
N
N
MOM
E2
ClMg
E1
N
N
N
N
MOM
E2
E3
E1
E3
22a: E1 = m-C6H4OMe
E2 = p-C6H4CO2Et: 80%
22b: E1 = p-C6H4CO2Et
E2 = p-C6H4Cl: 49%
23a: E1 = m-C6H4OMe
E2 = p-C6H4CO2Et
23b: E1 = p-C6H4CO2Et
E2 = p-C6H4Cl
24a-h
HCO2NH4
Pd/C, MeOH
45 °C, 30 min
 
Scheme 40: General reaction scheme for the full functionalization of the purine scaffold. 
                                                 
64
 Negishi, E.; Bagheri, V.; Chatterjee, S.; Luo, F.; Miller, J. A.; Stoll, A. T. Tetrahedron Lett. 1983, 24, 5181. 
65
 Sonogashira, K.; Thoda, Y.; Hagihara, N. Tetrahedron Lett. 1975, 4467. 
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Table 6: Functionalization of position 8 via zincated purine 17. 
Entry electrophile product yield, %a 
1 I2 
 
18a 
77 
2 
 
 
18b 
91b 
3 
 
 
18c 
55c 
4 
 
 
18d 
46c 
5 
 
 
18e 
72d 
6 
 
 
8p 
91d 
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Table 6 continued 
7 
 
 
18f 
89d 
8 
 
 
18g 
74d 
9 
 
 
18h 
75e 
a
 Isolated, analytically pure product. b Obtained after addition of CuCN·2LiCl (5 mol%). c Obtained by Pd-
catalyzed acylation reaction using Pd(PPh3)4 (2 mol%). d Obtained by Pd-catalyzed cross-coupling reaction using 
Pd(dba)2 (2 mol%) and P(o-furyl)3 (4 mol%) as catalyst. e Obtained from 18a by Pd-catalyzed coupling reaction 
using NEt3 (1.2 equiv), CuI (4 mol%), Pd(dba)2 (2 mol%) and P(o-furyl)3 (4 mol%). 
 
The chloro-substituent at position 6 is then removed using a Pd-catalyzed reduction with 
HCO2NH4 (20 wt% Pd/ C, MeOH/ EtOH or MeOH/ THF, 45 °C, 15-30 min). Under these 
conditions, the 6-chloropurines 18e and 8p led to the dechlorinated products 19a-b in 90-95% 
yield (Scheme 40). Purines of type 19 are readily metalated at position 6. Thus, treatment of 
19a with TMPZnCl·MgCl2·LiCl (1.5 equiv) leads to a complete zincation under microwave 
irradiation30 (sealed vessel, 90 °C, 1 h) providing the 6-zincated purine 20a (E1=3-
methoxyphenyl). The purine 19b, which proved to be more acidic at position 6 than 19a 
reacts with TMPZnCl·LiCl (prepared in the absence of MgCl2)66 leading to 20b (E1=4-
carbethoxyphenyl, 90 °C, 2 h). The resulting zinc reagents (20a-b) react with a range of 
electrophiles (Table 7). Thus, iodolysis produces the 6-iodopurines 21a-b in 64-76% yield 
(Table 7, entries 1-2). The copper-catalyzed allylation of 20b with ethyl (2-
bromomethyl)acrylate67 leads to purine 21c in 68% yield (entry 3). A range of aryl iodides 
                                                 
66
 The kinetic basicity of TMPZnCl·LiCl can be increased by adding MgCl2 (1 equiv), see: Wunderlich, S. H.; 
Knochel, P. Angew. Chem. Int. Ed. 2007, 46, 7685. 
67
 (a) Rambaud, M.; Villiéras, J. Synthesis 1984, 406; (b) Villiéras, J.; Rambaud, M. Org. Synth. 1988, 66, 220. 
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bearing either electron-withdrawing substituents (CO2Et, CF3, Cl), electron-donating 
substituents (NBu2) or a heterocyclic backbone (2-thienyl) undergo Negishi cross-coupling 
reactions7,59 with 20a-b (25 °C, 8-40 h) affording the 2,6-bis-arylated purines 21d-i in 43-
64% yield (entries 4-9). In situ generation of iodide 21b followed by a Pd-catalyzed cross-
coupling with N-allyl-4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide68 affords the 6-
alkynylated purine 21j in 75% yield (entry 10). 
 
Table 7: Functionalization of position 6 via zincated purines 20a-b. 
entry electrophile product yield, %a 
1 I2 
 
21a 
64 
2 I2 
 
21b 
76 
3 
 
 
21c 
68b 
4 
 
 
21d 
64c 
 
                                                 
68
 Patel, M. C.; Livinghouse, T.; Pagenkopf, B. L. Org. Synth. 2003, 80, 93. 
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Table 7 continued 
5 
 
 
21e 
53c 
6 
 
 
21f 
55c 
7 
 
 
21g 
62c 
8 
 
 
21h 
55c 
9 
 
 
21i 
43c 
 
B. Results and Discussion 
 
42 
Table 7 continued 
10 
 
 
21j 
75d 
a
 Isolated, analytically pure product. b Obtained after addition of CuCN·2LiCl (25 mol%). c Obtained by Pd-
catalyzed cross-coupling reaction using Pd(dba)2 (2 mol%) and P(o-furyl)3 (4 mol%) as catalyst. d Obtained from 
22b by Pd-catalyzed coupling reaction using NEt3 (1.5 equiv), CuI (4 mol%), Pd(dba)2 (2 mol%) and P(o-furyl)3 
(4 mol%). 
 
After having functionalized positions 8 and 6, we have converted the 2-TMS-substituent of 
21d and 21g by treatment with I2 (1.4 equiv, 1:1 CH3CN:THF, microwave irradiation, sealed 
vessel, 110 - 130 °C, 12 h) in the presence of CsF (2 equiv) to achieve the corresponding 2-
iodopurines (22a-b) in 49-80% yield.69 Under these reaction conditions, the PG is not 
cleaved, as observed for the reaction with silver trifluoromethanesulfonate (Scheme 39). 
I/ Mg exchange of 22a-b with iPrMgCl (1.5 equiv, THF, -78 °C, 1 h) furnishes the Mg-
reagents 23a-b. Their reaction with various electrophiles such as allyl bromides (Table 8, 
entry 1), aldehydes (entry 2), immonium reagents70 (entry 3) or a range of functionalized aryl 
and heteroaryl iodides (entries 4-7) and the Sonogashira cross-coupling of 22a (entry 8) 
provides the fully 2,6,8-substituted purines in 55-94% yield. 
 
                                                 
69
 (a) Latouche, R.; Texier-Boullet, F.; Hamelin, J. Tetrahedron Lett. 1991, 32, 1179; (b) Furin, G. G.; 
Vyazankina, O. A.; Gostevsky, B. A.; Vyazankin, N. S. Tetrahedron 1988, 44, 2675; (c) Clark, J. H. Chem. Rev. 
1980, 80, 429. 
70
 Kinast, G.; Tietze, L. F. Angew. Chem. Int. Ed. 1976, 15, 239; Angew. Chem. 1976, 88, 261. 
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Table 8: Functionalization of position 2 via magnesiated purines 23a-b. 
entry electrophile product yield, %a 
1 
Br
 
N
N
N
N
MOM
OMe
CO2Et
 
24a 
68b 
2 
 
 
24b 
94 
3 CF3CO2- CH2NMe2+ 
 
24c 
86 
4 
 
 
24d 
65c 
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Table 8 contiunued 
5 
 
 
24e 
63c 
6 
 
 
24f 
58c 
7 
 
 
24g 
55c 
8 
 
 
24h 
76d 
a
 Isolated, analytically pure product. b Obtained after addition of CuCN·2LiCl (25 mol%). c Obtained after 
transmetallation with ZnCl2 (1.6 equiv) by Pd-catalyzed cross-coupling reaction using Pd(dba)2 (2 mol%) and 
P(o-furyl)3 (4 mol%) as catalyst d Obtained from 22a by Pd-catalyzed coupling reaction using NEt3 (1.5 equiv), 
CuI (4 mol%), Pd(dba)2 (2 mol%) and P(o-furyl)3 (4 mol%). 
 
 
B. Results and Discussion 
 
45 
2. Functionalization of the benzo[c][1,2,5]thiadiazole and the 
benzo[c][1,2,5]oxadiazole scaffold 
 
2.1. Functionalization of the benzo[c][1,2,5]thiadiazole scaffold via Zn-, 
Mg- and Mn-Intermediates 
 
The direct access to unsymmetrically substituted benzo[c][1,2,5]thiadiazole derivatives is 
demanding and can be achieved via organometallic intermediates. Benzo[c][1,2,5]thiadiazole 
(25)71 was readily magnesiated at position 4 with TMP2Mg·2LiCl25 at -40 °C to give the 
magnesiated intermediate within 14 h (Scheme 41).72 Transmetalation with ZnCl2 and Pd-
mediated Negishi cross-coupling reactions7,59 with various aryl halides and iodothiophenes 
provide the fluorescent compounds 26a-h in 61 to 98% yield (Table 9, entries 1-8). Iodination 
gives the corresponding 4-halogenated compound 26i in 85% yield (entry 9). 
 
 
Scheme 41: Successive deprotonation and functionalization at positions 4 and 7. 
 
Also, a second metalation at position 7 is achieved with TMP2Mg·2LiCl (Scheme 41). The 
organometallic reagent derived from 26c reacts with 1,2-dibromo-1,1,2,2-tetrachloroethane to 
give the 7-brominated compound (27a) in 55% yield. Deprotonation of precursor 26d and 
                                                 
71
 (a) Michaelis, A.; Storbeck, O. Liebigs Ann. Chem. 1893, 274, 263. (b) Michaelis, A.; Erdmann, G. Chem. 
Ber. 1895, 28, 2192. 
72
 Those results are mentioned for the sake of completeness and have already been reported: Zimdars, S.; 
Diploma Thesis, Ludwig-Maximilians-Universität München, München, 2007. 
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subsequent transmetalation with ZnCl2 followed by Negishi cross-coupling reactions7,59 with 
aryl iodides provides the 4,7-bis-aryl compounds 27b,c in 74 and 84% yield, respectively. 
Interestingly, all compounds which bear a phenol subunit (26e,f, 27c) display a large Stokes 
shift of 122 to 123 nm. 
 
Table 9: Functionalization of benzo[c][1,2,5]thiadiazole at position 4. 
entry electrophile product yield, %a 
1 
 
 
26a 
61b 
2 
 
 
26b 
98b,c 
3 
 
 
26c 
83b 
4 
 
 
26d 
72b 
5 
 
 
26e 
74b 
6 
 
 
26f 
82b 
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Table 9 continued 
7 
 
 
26g 
63b 
8 
 
 
26h 
61b 
9 I2 
N
S
N
I
 
26i 
85d 
a
 Isolated, analytically pure product. b Obtained by Pd-catalyzed cross-coupling reaction with Pd(dba)2 (2 mol%) 
and P(o-furyl)3 (4 mol%) as catalyst. c Obtained by cross-coupling reaction with 0.4 equiv of the electrophile. d 
Obtained by the reaction with I2 (3.0 equiv). 
 
5,6-Dibromobenzo[c][1,2,5]thiadiazole (28)50 is magnesiated with TMPMgCl·LiCl24 at -
20 °C within 10 min followed by an iodolysis to provide compound 29 in 48% yield 
(Scheme 42). Alternatively, a Pd-catalyzed cross-coupling of 28 with 
trimethylsilylmethylzinc chloride73 proceeds almost quantitative to give the benzothiadiazole 
derivative 30 in 92% yield. 
 
 
Scheme 42: Functionalization of 5,6-dibromobenzo[c][1,2,5]thiadiazole (28). 
 
Metalation at position 4 of the benzothiadiazole scaffold can also be achieved by an oxidative 
Mg-insertion11 when 4,7-dibromobenzo[c][1,2,5]thiadiazole (31)50 is used as substrate 
                                                 
73
 Hosomi, A.; Shirahata, A.; Araki, Y.; Sakurai, H. J. Org. Chem. 1981, 46, 4631. 
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(Scheme 43). After in situ transmetalation with ZnCl2 and a cross-coupling reaction with 4-
iodoanisole the 4,7-di-substituted compound 32 is obtained in 58% yield.  
 
 
Scheme 43: Functionalization of 4,7-dibromobenzo[c][1,2,5]thiadiazole (31) via Mg-insertion. 
 
Deprotonation of 31 at position 5 is achieved with TMP2Mn·2MgCl2·4LiCl.52c The resulting 
organomanganese reagent reacts with 1,2-dibromo-1,1,2,2-tetrachloroethane to give the 4,5,7-
tribromo compound (33) in 70% yield. This 4,5,7-tribromobenzo[c][1,2,5]thiadiazole (33) is 
readily metalated with TMP2Zn·2MgCl2·2LiCl (1.0 equiv, 25 °C, 3 h) and a Cu-catalyzed 
acylation reaction8 with 3-chlorobenzoyl chloride furnishes the tetrasubstituted 
benzothiadiazole derivative 35 in 46% yield. The ketone 34 was synthesized according to a 
reported method,52c and further reaction with hydrazine gives the fused thiadiazoloindazole 
(36) in 65% yield. 
 
 
Scheme 44: Deprotonation of 4,7-dibromobenzo[c][1,2,5]thiadiazole (31). 
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2.2. Synthesis of a new covalent organic framework 
 
2.2.1. Introduction 
 
The first porous, crystalline, covalent organic framework (COF) derived from 1,4-
benzenediboronic acid (37) by selfcondensation was published in 2005 by Yaghi.74 The 
layered, hexagonal framework (COF-1) has a pore diameter of about 1.5 nm and forms a 
graphite like structure (Scheme 45). These porous materials are under consideration for 
applications like gas storage75and optics76 as they have an exceptional thermal stability, a low 
density and a high, permanent porosity. 
 
 
Scheme 45: Self condensation of BDBA and the resulting structure published by Yaghi. 
 
Recently, Bein characterized a COF structure with 4 nm open pores which was obtained by 
the co-condensation of a trigonal boronic acid (38) and a linear polyol (39) as described in 
                                                 
74
 Côté, A. P.; Benin, A. I.; Ockwig, N. W.; O’Keeffe, M.; Matzger, A. J.; Yaghi, O. M. Science 2005, 310, 
1166. 
75
 Li, J.-R.; Kuppler, R. J.; Zhou, H.-C. Chem. Soc. Rev 2009, 38, 1477. 
76
 Kobler, J.; Lotsch, B. V.; Ozin, G. A.; Bein, T. ACS Nano 2009, 3, 1669. 
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Scheme 46.77 
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Scheme 46: Condensation reaction for the BTP-COF described by Bein. 
 
                                                 
77
 Dogru, M.; Sonnauer, A.; Gavryushin, A.; Knochel, P.; Bein, T. Chem. Commun. 2011, 47, 1707. 
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In order to build up a COF with potential new electronical or optical properties, the synthesis 
of a linear linker (40) based on the benzo[c][1,2,5]thiadiazole scaffold was made up. The 
connection via co-condensation with the trigonal polyol (41) should form a COF as described 
in Scheme 47. 
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Scheme 47: General reaction scheme for the condensation reaction to form a COF with the 
benzo[c][1,2,5]thiadiazole derived linker (40). 
 
The formed honeycomb shaped (Scheme 48) layers of this COF could either stack in an AB-
fashion like graphite or an AA-fashion like boron nitride. Thus, either cavities or channels 
with a pore diameter of about 3.5 nm would be build up. 
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Scheme 48: Honeycomb-like structure of the BTD-COF. 
 
 
2.2.2. Synthesis of 4,7-bis(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)benzo[c][1,2,5]thiadiazole as precursor for a COF 
 
The Negishi cross-coupling of 4,7-dibromobenzo[c][1,2,5]thiadiazole (31) with (4-
(trimethylsilyl)phenyl)zinc(II) chloride·MgBrCl using PdCl2(dppf) as catalyst has been 
reported to afford the product (42) in 55% yield.78 We found a combination of a similar zinc 
reagent which was prepared in the presence of LiCl with a more efficient Pd-catalyst 
furnishing the desired compound within 3 h at 50 °C in 75% yield (Scheme 49). 
4,7-Bis(4-(trimethylsilyl)phenyl)benzo[c][1,2,5]thiadiazole (42) reacts almost quantitative 
with ICl to give the corresponding bis-iodinated compound 43 in 93% yield. This step was 
                                                 
78
 Ito, Y.; Kjima, Y; Suginome, M.; Murakami, M. Heterocycles 1996, 42, 597. 
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neccessary because the direct conversion to a boronic acid was not successful as the 
benzo[c][1,2,5]thiadiazole subunit was not stable when it was exposed to BBr3 or BCl3. A 
Suzuki cross-coupling with bis(pinacolato)diboron furnishes the final product (40) in 74% 
yield. 
 
 
Scheme 49: Synthesis of the benzo[c][1,2,5]thiadiazole derived linker (40). 
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2.3. New benzo[c][1,2,5]thiadiazole and benzo[c][1,2,5]oxadiazole based 
perylene dyes 
 
2.3.1. Introduction 
Organic functional materials with electronic and optical properties are of increasing interest in 
science and technology,79 especially in cases where the variability and the saving of resources 
are important features. Organic light emitting diodes (OLEDs) or organic photovoltaic 
devices based on extended pi-systems of polycyclic aromatic or heteroaromatic compounds 
are of great interest, especially perylene monoimides and bisimides80 because of their high 
chemical and photochemical stability.81 However, such systems exhibit strong tendencies for 
crystallization which is problematic for functional materials since the molecular packing, 
which invariably determines the crystal lattice, can be hardly predicted. Moreover, there are 
interfering border effects between the crystallites. The availability of amorphous organic 
materials82 would solve these problems.  
 
2.3.2. Preparation of precursors for new benzo[c][1,2,5]thiadiazole and 
benzo[c][1,2,5]oxadiazole based perylene dyes 
To attach a benzo[c][1,2,5]thiadiazole or benzo[c][1,2,5]oxadiazole unit to a perylene core 
with or without a spacer in between there are two pathways which can be followed 
(Scheme 50). The first possibility is the metalation of the heterocycle and subsequent cross-
coupling reaction with a halogenated perylene. The second one is the condensation of a 
                                                 
79
 (a) Brabec, C. J.; Sariciftci, N. S.; Hummelen, J. C. Adv. Funct. Mater. 2001, 11, 15; (b) Günes, S.; 
Neugebauer, H.; Sariciftci, N. S. Chem. Rev. 2007, 107, 1324; (c) Grätzel, M. Nature 2001, 414, 338; (d) Choi, 
H.; Kim, S.; Kang, S. O.; Ko, J.; Kang, M.-S.; Clifford, J. N.; Forneli, A.; Palomares, E.; Nazeeruddin, M. K.; 
Grätzel, M. Angew. Chem. Int. Ed. 2008, 47, 8259. 
80
 (a) Langhals, H. Heterocycles, 1995, 40, 477; (b) Langhals, H. Helv. Chim. Acta. 2005, 88, 1309; (c) Li, C.; 
Schöneboom, J.; Liu, Z.; Pschirer, N. G.; Erk, P.; Herrmann, A.; Müllen, K. Chem. Eur. J. 2009, 15, 878. 
81
 (a) Langhals, H.; Demmig, S.; Huber, H. Spectrochim. Acta 1988, 44A, 1189; (b) Langhals, H; Kollefrath, R.; 
Lindner, J. Macromol. Rep. 1995, A32, 415; (c) Langhals, H.; Gold, J. J. Prakt. Chem. 1996, 338, 654; (d) 
Langhals, H.; Jona, W. Angew. Chem. Int. Ed. 1998, 37, 952. 
82
 (a) Saragi, T. P. I.; Spehr, T.; Siebert, A.; Fuhrmann-Lieker, T.; Salbeck, J. Chem. Rev. 2007, 107, 1011; (b) 
Silaghi, S. D.; Spehr, T.; Cobet, C.; Saragi, T. P. I.; Werner, C.; Salbeck, J.; Esser, N. J. Appl. Phys. 2008, 103, 
043503/1. 
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aminated heterocycle and an perylene anhydride.83 A spacer unit can be attached to the 
heterocycle and/ or to the perylene. 
 
 
Scheme 50: Possible pathways for the attachment of the benzo[c][1,2,5]thiadiazole or the 
benzo[c][1,2,5]oxadiazole scaffold to perylenes via cross-coupling reaction or condensation. 
 
For the direct cross-coupling with a halogenated perylene or benzoperylene the 
benzo[c][1,2,5]thiadiazole derived zinc reagents 44 and 47 are prepared as shown in 
Scheme 51. Therefore, benzo[c][1,2,5]thiadiazole (25) is metalated according to a procedure 
described in a previous chapter (2.1. Functionalization of the benzo[c][1,2,5]thiadiazole 
scaffold via Zn-, Mg- and Mn-Intermediates) and furnishes the zinc reagent 44 with a 
concentration of 0.2 M in THF. The cross-coupling of 44 with (4-iodophenyl)trimethylsilane 
provides compound 45 in 38% yield. The reaction of this compound with ICl occurs almost 
quantitative and gives the iodinated product 46 in 93% yield. The complete metalation via Mg 
insertion in the presence of ZnCl2 is achieved in 2 h at 25 °C and leads to the zinc reagent 47 
with a concentration of 0.25 M in THF. The cross-coupling reactions were performed at 25 °C 
                                                 
83
 (a) Kaiser, H.; Lindner, J.; Langhals, H. Chem. Ber. 1991, 124, 529; (b) Langhals, H.; Demmig, S.; Fotrawa, 
T. J. Prakt. Chem. 1991, 333, 733. 
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under Pd catalysis with either Pd(dba)2 (2 mol%) and P(o-furyl)3 (4 mol%) for iodinated 
perylenes or Pd(OAc)2 (2 mol%) and SPhos (4 mol%) for brominated perylenes.84 
 
 
Scheme 51: Preparation of benzo[c][1,2,5]thiadiazol derived zinc reagents. i) TMP2Mg·2LiCl (1.3 equiv),  
-40 °C, 14 h; ZnCl2 (1.4 equiv), -40 to 25 °C, 30 min, Pd(OAc)2 (2 mol%), SPhos (4 mol%), (4-
iodophenyl)trimethylsilane (1.2 equiv), 25 °C, 10 h. 
 
The direct Negishi cross-coupling reaction of the zinc reagent 44 with halogenated perylenes 
(R=1-hexylheptyl) is shown in Scheme 52. 
 
                                                 
84
 Purification and characterization of these cross-coupling products were performed by Andreas Walter and 
Andreas Esterbauer. 
B. Results and Discussion 
 
57 
N OO
R
N OO
R
N
S
N
ZnCl
48
44
49: 47%
Pd(dba)2 (2 mol%)
P(o-furyl)3 (4 mol%)
NO O
I
N
S
N
NO O
N OO
R
Br
N OO
R
N
S
N
50
51: 47%
N
S
N
ZnCl
44
Pd(OAc)2 (2 mol%)
SPhos (4 mol%)
 
Scheme 52: Direct cross-coupling of the zinc reagent 44 with perylene dyes. 
 
When we found, that the obtained materials had an amorphous morphology, a quantum yield 
close to 100% and a quantitative Förster type energy transfer85 from the benzothiadiazole unit 
to the perylene chromophore, we synthesized a small library of heterocyclic compounds 
bearing an amine as functional group (Scheme 53, Table 10). Those compounds can be 
condensed with different perylene anhydrides to find out if and how the properties are 
tuneable.  
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The zinc reagent 44 which is derived from 25 reacts with 4-iodoaniline, 3-iodoaniline and 5-
iodopyridin-2-amine to give the compounds 52a-c in 45 to 52% yield (Table 10, entries 1-3). 
Similarly, benzo[c][1,2,5]oxadiazole (53) is metalated with TMPMgCl·LiCl (-5 °C, 14 h), and 
funishes after transmetalation with ZnCl2 and cross-coupling reaction the compounds 54a-c in 
43 to 47% yield (entries 4-6). 
 
 
Scheme 53: Preparation of heterocyclic compounds bearing an amine as functional group for further 
transformation. 
 
Table 10: Heterocyclic compounds bearing an amine as functional group derived from 25 and 53. 
entry electrophile product yield, %a 
1 
 
 
52a 
61b 
2 
 
 
52b 
61b 
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Table 10 continued 
3 
 
 
52c 
53b 
4 
 
 
54a 
59b 
5 
 
 
54b 
55b 
6 
 
 
54c 
54b 
a
 Isolated, analytically pure product. b Obtained by Pd-catalyzed cross-coupling reaction with Pd(OAc)2 
(2 mol%) and SPhos (4 mol%) as catalyst. 
 
In addition, we synthesized 5-aminated benzo[c][1,2,5]thiadiazoles to see if and how the 
connection of perylenes in this position affects the properties of these new materials 
(Scheme 54). Therefore, the readily available 4,7-dibromobenzo[c][1,2,5]thiadiazol-5-amine 
(55) was reacted with (4-trimethylsilyl)phenylzinc(II) chloride in the presence of a Pd catalyst 
and provided the compound 56 in 49% yield. Afterwards, compound 56 can be used for the 
already described condensation reaction. Moreover, we found that the Negishi cross-coupling 
is even possible, when the perylene is already connected to the 4,7-
dibromobenzo[c][1,2,5]thiadiazol derivative (57).86 
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 Purification and characterization were performed by Andreas Walter. 
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Scheme 54: Connection of the perylene core to position 5 of benzo[c][1,2,5]thiadiazole. 
 
 
3. Summary and Outlook 
 
3.1. Functionalization of the purine scaffold 
 
In summary, we have described a novel triple functionalization sequence of the purine 
scaffold starting from the readily available 6-chloropurine 6j via 8-zincated, 6-zincated and 2-
magnesiated intermediates using either a selective zincation with TMPZnCl·LiCl or an I/ Mg-
exchange triggered by iPrMgCl. Our new functionalization approach of the purine skeleton 
allows besides cross-coupling reactions, the performance of novel functionalizations such as 
allylations, acylations and aminomethylations. In conclusion, this new method offers a 
general access to a large variety of highly functionalized purine derivatives (Scheme 55). 
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Scheme 55: Full functionalization of the purine scaffold. 
 
 
3.2. Functionalization of the benzothiadiazole and benzofurazan scaffold 
 
The metalation of all positions of the benzo[c][1,2,5]thiadiazole scaffold using LiCl-
solubilized TMP-bases is demonstrated on various substrates. Thus, unsymmetrically 
substituted benzothiadiazole derivatives and a new fused thiadiazoloindazole have been 
prepared. 
 
 
Scheme 56: Examples for the synthesis of unsymmetrically functionalized benzo[c][1,2,5]thiadiazole 
derivatives. 
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Furthermore, the synthesis of a benzothiadiazole derived linker for the formation of a new 
COF was accomplished in a 3 step synthesis with an overall yield of 52%.  
 
 
 
Scheme 57: Synthesis of the benzothiadiazole derived linker and resulting TEM pictures of the formed COF. 
 
Benzo[c][1,2,5]thiadiazole and benzo[c][1,2,5]oxadiazole were magnesiated with 
TMP2Mg·2LiCl and TMPMgCl·LiCl and efficiently attached to perylene and benzoperylene 
building blocks by using a Pd-catalyzed cross-coupling reactions. The resulting 
bichromophores exhibit efficient FRET as indicated by high fluorescence quantum yields. 
These new materials were obtained as amorphous solids and are therefore of interest for 
material science. 
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Scheme 58: One example of an amorphous, fluorescent benzothiadiazoloperylene dye. 
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1. General Considerations 
 
All reactions were carried out with magnetic stirring under argon atmosphere in flame-dried 
glassware if not indicated otherwise. Syringes which were used to transfer anhydrous solvents 
or reagents were purged with argon prior to use.  
 
Solvents were dried according to standard procedures by distillation from drying agents and 
stored under argon. 
CH2Cl2 was continuously refluxed and freshly distilled from P2O5. 
DME was heated to reflux over and freshly distilled from sodium benzophenone ketyl. 
DMF was heated to reflux for 14 h over CaH2 and distilled from CaH2.  
Et2O was predried over CaH2 and dried with the solvent purification system SPS-400-2 from 
INNOVATIVE TECHNOLOGIES INC. 
EtOH was treated with phthalic anhydride (25 g/L) and sodium, heated to reflux for 6 h and 
distilled. 
THF was continuously refluxed and freshly distilled from sodium benzophenone ketyl under 
nitrogen. 
 
Solvents for column chromatography were distilled prior to use.  
 
Reagents 
 
Acid chlorides, liquid aldehydes, TMPH and NEt3 were distilled prior to use. All compounds 
which were purchased from commercial sources were used without further purification. Pd/ C 
(10% Pd, 50% wet with water) was purchased from Acros Organics. 
Following compounds were prepared according to literature procedures: 
6-Chloro-9-(methoxymethyl)-9H-purine (6a),87 9-benzyl-9H-purine (6b),88 6-chloro-9-
(tetrahydro-2-pyranyl)-9H-purine (6c),89 6-chloro-9-benzyl-9H-purine (6d),90 9-
                                                 
87
 Maurer, H. K. Ph.D. Dissertation, Universität Heidelberg, Heidelberg, Germany, 1963. 
88
 Montgomery, J.; Temple, C. J. Am. Chem. Soc. 1961, 83, 630. 
89
 Robins, R.; Godefroi, E.; Taylor, E.; Lewis, L.; Jackson, A. J. Am. Chem. Soc. 1961, 83, 2574. 
90
 Tromp, R.; Spanjersberg, R.; von Frijtag Drabbe Künzel, J.; IJzermann, A. J. Med. Chem. 2005, 48, 321. 
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(methoxymethyl)-9H-purin-6-amine, 91 2-chloropurine,61 MOMCl solution in toluene,92 
benzo[c][1,2,5]thiadiazole (25),93 5,6-dibromobenzo[c][1,2,5]thiadiazole (28),50 4,7-
dibromobenzo[c][1,2,5]thiadiazole (31),50 (4-bromophenyl)trimethylsilane,94 4,7-
dibromobenzo[c][1,2,5]thiadiazol-5-amine (51).95 
 
Reactions were monitored by gas chromatography (GC, GC-MS) or thin layer 
chromatography (TLC). The completion of deprotonations was determined via quenching of 
reaction aliquots with iodine. Microwave reactions were performed in sealed reaction vessels 
under argon atmosphere with a high powered, focused microwave (Biotage initiator™ 2.5). 
 
iPrMgCl·LiCl and iPrMgCl solutions in THF were purchased from Chemetall (Frankfurt/ 
Main, Germany). 
nBuLi solution in hexane was purchased from Chemetall. 
TMP2Mg·2LiCl25 solution (0.6 M in THF) was prepared by the slow addition of nBuLi 
(4.26 mL, 2.35 M in hexane, 10 mmol) to a solution of TMPH (1.41 g, 10 mmol) in THF 
(10 mL) at -40 °C. After stirring for 30 min the mixture was warmed up to 0 °C and 
TMPMgCl·LiCl (8.3 mL, 1.2 M in THF, 10 mmol) was added dropwise. The resulting 
mixture was stirred for 30 min, warmed up to 25 °C and the solvent was evaporated under 
vacuum (10-3 mbar). THF was then added slowly under vigorous stirring until the salts were 
completely dissolved. 
TMPMgCl·LiCl24 solution (1.2 M in THF) was prepared by the slow addition of TMPH 
(17.8 g, 126 mmol) to a iPrMgCl·LiCl solution (100 mL, 1.2 M in THF, 120 mmol) and 
stirring of the resulting mixture at 25 °C for 3 days. 
TMP2Zn·2LiCl solution (1.3 M in THF) was prepared by the slow addition of nBuLi 
(4.26 mL, 2.35 M in hexane, 10 mmol) to a solution of TMPH (1.41 g, 10 mmol) in THF 
(10 mL) at -40 °C. After stirring for 30 min the mixture was warmed up to 0 °C and ZnCl2 
(5.0 mL, 1.0 M in THF, 5.0 mmol) was added dropwise. The solution was warmed up to 
25 °C, the solvent was evaporated under vacuum (10-3 mbar) and THF was added slowly 
under vigorous stirring until the salts were completely dissolved. 
                                                 
91
 Fuji, T.; Saito, T.; Fujisawa, T. Heterocycles 1988, 27, 1163. 
92
 Berliner, M.; Belecki, K. Org. Synth. 2007, 84, 102. 
93
 Tsubata, Y.; Suzuki, T.; Miyashi, T. J. Org. Chem. 1992, 57, 6749. 
94
 Itami, K.; Terakawa, K.; Yoshida, J.; Kajimoto, O. J. Am. Chem. Soc. 2003, 125, 6058. 
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TMP2Zn·2MgCl2·2LiCl29 solution (0.9 M in THF) was prepared by the slow addition of 
ZnCl2 (5 mL, 1.0 M in THF, 5 mmol) to a solution of TMPMgCl·LiCl (8.3 mL, 1.2 M in THF, 
10 mmol) and stirring for 30 min at 25 °C. 
PIP2Zn·2MgCl2·2LiCl solution (0.4 M in THF) was prepared similar to the 
TMP2Zn·2MgCl2·2LiCl solution by the slow addition of iPrMgCl·LiCl (7.3 mL, 1.31 M in 
THF, 9.5 mmol) to a solution of piperidine (0.85 g, 10 mmol) in THF (10 mL). After stirring 
for 7 h at 25 °C, ZnCl2 (5.0 mL, 1.0 M in THF, 5.0 mmol) was added and the resulting 
solution was stirred for 30 min. 
TMPZnCl·MgCl2·LiCl solution (0.5 M in THF) was prepared by the slow addition of ZnCl2 
(10 mL, 1.0 M in THF, 10 mmol) to a solution of TMPMgCl·LiCl (8.3 mL, 1.2 M in THF, 
10 mmol) and stirring for 30 min at 25 °C. 
TMPZnCl·LiCl31 solution (1.2 M in THF) was prepared by the slow addition of nBuLi 
(25 mL of a 2.4 M in hexane, 60 mmol) to a solution of TMPH (8.48 g, 60 mmol) in THF 
(60 mL) at -40 °C. The reaction mixture was allowed to warm up slowly to -10 °C within 1 h. 
ZnCl2 (66 mL, 1.0 M in THF, 66 mmol) was added dropwise and the resulting solution was 
stirred for 30 min at -10 °C and then for 30 min at 25 °C. The solvent was removed under 
vacuum affording a yellowish solid. THF was then added slowly under vigorous stirring until 
the salts were completely dissolved (ca 1 h). 
CuCN·2LiCl solution (1.0 M in THF) was prepared by drying CuCN (7.17 g, 80 mmol) and 
LiCl (6.77 g, 160 mmol) in a Schlenk-tube under vacuum (10-3 mbar) at 140 °C for 6 h. After 
cooling, dry THF (80 mL) was added and stirring was continued until all the salts were 
dissolved (approx. 24 h). The slightly yellow solution was stored under argon. 
ZnCl2 solution (1.0 M in THF) was prepared by drying ZnCl2 (137 g, 100 mmol) in a 
Schlenk-flask under vacuum (10-3 mbar) at 140 °C for 6 h. After cooling, dry THF (100 mL) 
was added and stirring was continued until all salts were dissolved (approx. 5 h). The 
colorless solution was stored under argon over molecular sieves (4 Å). 
(4-Trimethylsilylphenyl)zinc(II) chloride·MgBrCl·LiCl96 solution (0.35 M in THF) was 
prepared by drying LiCl (212 mg, 5 mmol) under vacuum (10-3 mbar) at 140 °C. After 
cooling Mg (146 mg, 6.0 mmol), THF (5 mL) and (4-bromophenyl)trimethylsilane (917 mg, 
4.0 mmol) were successively added. The mixture was stirred for 2 h at 25 °C, was canulate to 
a solution of ZnCl2 (5 mL, 1.0 M in THF, 5.0 mmol) and was stirred for 15 min at 25 °C. 
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 Rahman, M. J.; Yamakawa, J.; Matsumoto, A.; Enozawa, H.; Nishinaga, T.; Kamada, K.; Iyoda, M. J. Org. 
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Diphenylzinc(II)·MgClI·LiCl solution (0.5 M in THF) was prepared by drying LiCl 
(318 mg, 7.5 mmol) under vacuum (10-3 mbar) at 140 °C. After cooling Mg (182 mg, 
7.5 mmol), THF (5 mL) and iodobenzene (1.02 g, 5.0 mmol) were successively added. The 
mixture was stirred for 2 h at 25 °C, was canulate to a solution of ZnCl2 (2.25 mL, 1.0 M in 
THF, 2.25 mmol) and was stirred for 30 min at 25 °C. 
 
Content Determination of Organometallic Reagents 
 
Organzinc and organomagnesium reagents were titrated against I2 in a 0.5 M LiCl solution 
in THF.97 
Organolithium reagents were titrated against menthol using 1,10-phenanthroline as indicator 
in THF.98  
TMP derived Mg and Zn bases were titrated against benzoic acid using 4-
(phenylazo)diphenylamine as indicator in THF.99 
 
Chromatography 
 
Flash column chromatography (FCC) was performed using silica gel 60 (0.040-0.063 mm) 
from Merck. 
Thin layer chromatography (TLC) was performed using SiO2 pre-coated aluminium plates 
(Merck 60, F-254). The chromatograms were examined under UV light at 254 nm. 
 
Analytical Data 
 
NMR spectra were recorded on VARIAN Mercury 200, BRUKER AXR 300, VARIAN VXR 
400 S and BRUKER AMX 600 instruments. Chemical shifts are reported as δ-values in ppm 
relative to the residual solvent peak of CHCl3 (δH : 7.25, δC : 77.0). For the characterization of 
the observed signal multiplicities the following appreviations were used: s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet) as well as br (broad). 
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 Krasovskiy, A.; Knochel, P. Synthesis 2006, 890. 
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 Lin, H.-S.; Paquette, A. Synth. Commun. 1994, 24, 2503. 
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Mass spectroscopy: High resolution (HR-MS) and low resolution (MS) spectra were 
recorded on a FINNIGAN MAT 95Q instrument. Electron impact ionization (EI) was 
conducted with an electron energy of 70 eV.  
For the combination of gas chromatography with mass spectroscopic detection, a GC/MS 
from HEWLETT-PACKARD HP 6890 / MSD 5973 was used.  
Infrared spectra (IR) were recorded from 4500 cm-1 to 650 cm-1 on a PERKIN ELMER 
Spectrum BX-59343 instrument. For detection a SMITHS DETECTION DuraSamplIR II 
Diamond ATR sensor was used. The absorption bands are reported in wavenumbers (cm-1). 
Melting points (mp) were determined on a BÜCHI B-540 apparatus and are uncorrected. 
 
 
2. Functionalization of the purine scaffold 
 
2.1. Synthesis of compounds 3-16 
 
Synthesis of 9-benzyl-8-(phenylthio)-9H-purine (3) 
 
 
In a Schlenk-tube TMP2Zn·2MgCl2·2LiCl (2.6 mL, 0.95 M in THF, 2.4 mmol) was added 
within 1.5 h to a solution of 9-benzyl-9H-purine (6d, 410 mg, 2.0 mmol) and PhSO2SPh 
(500 mg, 2.0 mmol) in THF (4 mL) at 0 °C and the resulting reaction mixture was stirred for 
10 min. After addition of NH3(conc)/ NH4Cl(sat) (1:3, 10 mL) the reaction mixture was warmed 
up to 25 °C, the aqueous layer was extracted with CH2Cl2 (4 x 50 mL), the combined organic 
layers were dried (MgSO4) and the solvent was evaporated in vacuo. Purification via column 
chromatography (silicagel, CH2Cl2/ MeOH gradient = 400:1, 400:2, 400:3, 400:4) yielded 9-
benzyl-8-(phenylthio)-9H-purine (3, 380 mg, 60%) as a colorless solid. 
 
mp (°C): 134-135. 
IR (ATR) ν~  (cm-1): 3056 (w), 3030 (w), 3010 (w), 2970 (vw), 2474 (vw), 2360 (m), 2342 
(w), 1948 (vw), 1892 (w), 1806 (vw), 1738 (w), 1578 (s), 1496 (w), 1468 (s), 1458 (m), 1444 
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(m), 1424 (s), 1374 (s), 1354 (m), 1344 (s), 1312 (w), 1298 (vs), 1230 (s), 1222 (s), 1180 (m), 
1130 (w), 1094 (m), 1074 (m), 1020 (w), 1000 (w), 988 (w), 924 (m), 914 (w), 892 (w), 826 
(w), 792 (w), 776 (w), 748 (m), 726 (s), 708 (m), 696 (s), 688 (s), 676 (m), 624 (w). 
1H-NMR (300 MHz, CDCl3): δ = 8.94 (s, 1H), 8.93 (s, 1H), 7.61-7.57 (m, 2H), 7.46-7.41 
(m, 3H), 7.40-7.31 (m, 5H), 5.50 ppm (s, 2H). 
13C-NMR (75 MHz, CDCl3): δ = 155.6, 153.5, 151.7, 145.7, 134.9, 134.3, 134.2, 129.9, 
129.8, 129.0, 128.4, 128.0, 127.2, 46.5 ppm. 
MS (70 eV, EI): m/z (%) = 319 (17), 318 (83), 317 (54), 227 (7), 209 (30), 167 (39), 92 (7), 
91 (100), 65 (12). 
HRMS (EI): m/z calc. for [C18H14N4S] 318.0939; found: 318.0935. 
 
Synthesis of 9-(1-phenylbut-3-en-1-yl)-8-(phenylthio)-9H-purine (5) 
 
 
In a Schlenk-tube TMP2Zn·2MgCl2·2LiCl (1.3 mL, 0.95 M in THF, 1.2 mmol) was added 
dropwise to a solution of 9-benzyl-8-(phenylthio)-9H-purine (3, 318 mg, 1.0 mmol) in THF 
(3.5 mL) and the resulting reaction mixture was stirred for 15 min. At -20 °C CuCN·2LiCl 
(1.0 mL, 1.0 M in THF, 1.0 mmol) was added dropwise and after 10 min allyl bromide 
(0.26 mL, 3 mmol) was added. After warming up to 25 °C and further stirring for 30 min, a 
mixture of NH3(conc)/ NH4Cl(sat) (1:3, 10 mL) was added, the aqueous layer was extracted with 
CH2Cl2 (3 x 30 mL), the combined organic layers were dried (Na2SO4) and the solvent was 
evaporated in vacuo. Purification via column chromatography (silicagel, CH2Cl2/ MeOH 
gradient = 400:0.5, 400:1, 400:2, 400:4) yielded 9-(1-phenylbut-3-en-1-yl)-8-(phenylthio)-
9H-purine (5, 196 mg, 55%) as a slightly yellow oil. 
 
IR (ATR) ν~  (cm-1): 3058 (w), 3030 (w), 3008 (w), 2980 (w), 2920 (w), 1952 (vw), 1874 
(vw), 1642 (w), 1582 (s), 1496 (w), 1454 (s), 1428 (s), 1372 (m), 1330 (s), 1302 (s), 1278 (s), 
1234 (s), 1190 (m), 1180 (m), 1158 (w), 1116 (w), 1092 (m), 1024 (m), 1000 (m), 992 (m), 
960 (m), 912 (s), 846 (w), 832 (w), 790 (m), 770 (w), 746 (s), 714 (m), 696 (vs), 686 (vs), 652 
(m), 616 (m). 
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1H-NMR (600 MHz, CDCl3): δ = 8.90 (s, 1H), 8.89 (s, 1H), 7.59-7.55 (m, 4H), 7.45-7.41 
(m, 3H), 7.37-7.34 (m, 2H), 7.33-7.30 (m, 1H), 5.88 (dd, J = 10.5, 5.7 Hz, 1H), 5.69-5.62 (m, 
1H), 5.06-5.03 (m, 1H), 4.96-4.94 (m, 1H), 3.84-3.79 (m, 1H), 3.27-3.22 ppm (m 1H). 
13C-NMR (150 MHz, CDCl3): δ = 155.6, 153.6, 151.1, 145.7, 138.1, 134.2, 134.0, 133.4, 
129.7, 129.7, 128.8, 128.4, 127.8, 127.7, 118.9, 60.5, 36.3 ppm. 
MS (70 eV, EI): m/z (%) = 358 (62), 357 (44), 317 (39), 249 (21), 239 (21), 228 (40), 227 
(100), 131 (35), 130 (37), 129 (29), 91 (37). 
HRMS (EI): m/z calc. for [C21H18N4S] 358.1252; found: 358.1252. 
 
Synthesis of 6-chloro-2-iodo-9-(methoxymethyl)-9H-purine (6e) 
 
 
In a Schlenk-flask I2 (950 mg, 3.75 mmol) dissolved in THF (4 mL) was added dropwise to a 
solution of 6-chloro-9-MOM-2-(tributylstannyl)-9H-purine (13a, 1.22 g, 2.5 mmol) in THF 
(12 mL). After stirring the resulting reaction mixture for 1 h, Na2S2O3 solution (10 mL) and 
EtOAc (50 mL) were added. The organic layer was washed with H2O (30 mL) and NaCl(sat) 
solution, was dried (Na2SO4) and the solvent was evaporated in vacuo. Purification via 
trituration with pentane yielded 6-chloro-2-iodo-9-(methoxymethyl)-9H-purine (6e, 730 mg, 
90%) as a pale yellow solid. 
 
1H-NMR (300 MHz, CDCl3): δ = 8.17 (s, 1H), 5.60 (s, 2H), 3.42 ppm (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 152.9, 150.8, 145.0, 131.5, 117.2, 74.8, 57.7 ppm. 
MS (70 eV, EI): m/z (%) = 325 (9), 324 (28), 296 (33), 294 (100), 197 (7), 45 (16). 
HRMS (EI): m/z calc. for [C7H6ClIN4O] 323.9275; found: 323.9252. 
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Synthesis of 9-(methoxymethyl)-9H-purine (6f) 
 
 
In a round bottom flask with reflux condenser tBuONO (0.5 mL, 4 mmol) was added to a 
solution of 9-(methoxymethyl)-9H-purin-6-amine (558 mg, 2 mmol) in THF (10 mL). The 
reaction mixture was refluxed for 3 h, tert-butyl nitrite (0.5 mL, 4 mmol) was added and the 
mixture was refluxed for further 3 h. The solvents were evaporated in vacuo. Purification via 
column chromatography (silicagel, CH2Cl2/ MeOH gradient = 100:0, 100:1 to 30:1) yielded 
9-(methoxymethyl)-9H-purine (6f, 230 mg, 70%) as a pale yellow solid. 
 
mp (°C): 87-88. 
IR (ATR) ν~  (cm-1): 3102 (vw), 3044 (w), 2992 (w), 2948 (w), 2834 (vw), 1860 (vw), 1692 
(w), 1596 (m), 1580 (s), 1504 (m), 1470 (w), 1456 (w), 1418 (w), 1394 (m), 1356 (m), 1342 
(m), 1304 (m), 1292 (m), 1256 (w), 1230 (m), 1218 (m), 1200 (m), 1178 (m), 1126 (m), 1088 
(vs), 1018 (m), 936 (w), 922 (w), 908 (m), 892 (m), 794 (m), 754 (s), 658 (m), 636 (s), 606 
(vw). 
1H-NMR (300 MHz, CDCl3): δ = 9.17 (s, 1H), 9.01 (s, 1H), 8.24 (s, 1H), 5.64 (s, 2H), 3.38 
ppm (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 153.1, 148.8, 145.2, 133.8, 73.9, 57.3 ppm. 
MS (70 eV, EI): m/z (%) = 164 (8), 135 (11), 134 (100), 133 (38), 79 (5), 52 (7), 45 (86). 
HRMS (EI): m/z calc. for [C7H8N4O] 164.0698; found: 164.0697. 
 
Synthesis of 2-chloro-9-(methoxymethyl)-9H-purine (6g) 
 
 
In a round bottom flask NEt3 (7.2 mL, 52 mmol) was added to a solution of 2-chloropurine 
(4 g, 26 mmol) in DME (300 mL). MOMCl (30 mL, 2.0 M in toluene, 60 mmol) was added 
dropwise. The reaction mixture was stirred until the starting material was completely 
consumed. K2CO3 (10 g) and H2O (200 mL) were added. The solvents were evaporated in 
vacuo, the crude solid triturated with EtOAc and the solvent evaporated. Purification via 
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column chromatography (silicagel, CH2Cl2/ EtOH 20:1) yielded 2-chloro-9-(methoxymethyl)-
9H-purine (6g, 3.0 g, 58%) as a colorless solid. 
 
mp (°C): 113-115. 
IR (ATR) ν~  (cm-1): 3078 (w), 3058 (w), 2950 (w), 2838 (w), 2362 (w), 2340 (vw), 2280 
(vw), 1736 (w), 1696 (w), 1664 (w), 1594 (m), 1570 (s), 1502 (m), 1444 (w), 1430 (m), 1402 
(m), 1358 (s), 1342 (s), 1298 (m), 1234 (m), 1218 (m), 1204 (s), 1180 (s), 1150 (s), 1110 (s), 
1086 (vs), 1020 (s), 946 (w), 910 (s), 790 (m), 770 (s), 702 (m), 682 (m), 636 (m), 610 (vw). 
1H-NMR (600 MHz, CDCl3): δ = 9.01 (s, 1H), 8.24 (s, 1H), 5.61 (s, 2H), 3.41 ppm (s, 3H). 
13C-NMR (150 MHz, CDCl3): δ = 155.0, 153.5, 150.4, 145.9, 132.9, 74.1, 57.5 ppm. 
MS (70 eV, EI): m/z (%) = 200 (7), 198 (20), 170 (24), 169 (15), 168 (84), 167 (36), 52 (5), 
45 (100). 
HRMS (EI): m/z calc. for [C7H7ClN4O] 198.0308; found: 198.0309. 
 
Synthesis of 2,6-dichloro-9-(methoxymethyl)-9H-purine (6h) 
 
N
N
N
N
MOM
Cl
Cl
 
In a round bottom flask K2CO3 (6.2 g, 45 mmol) was added to a solution of 2,6-
dichloropurine (1.89 g, 10 mmol) in DMF (20 mL). MOMCl (7.5 mL, 2.0 M in toluene, 
15 mmol) was added dropwise. The reaction mixture was stirred until the starting material 
was completely consumed. H2O (20 mL) was added. The solvents were evaporated in vacuo, 
the crude solid triturated with EtOAc and the solvent evaporated. Purification via column 
chromatography (silicagel, CH2Cl2/ EtOH gradient = 100:0, 500:1 to 100:1) yielded 2,6-
dichloro-9-(methoxymethyl)-9H-purine (6h, 860 mg, 37%) as a colorless solid. 
 
mp (°C): 126-127. 
IR (ATR) ν~  (cm-1): 3106 (w), 3084 (vw), 3014 (vw), 2970 (vw), 2946 (w), 2846 (vw), 2836 
(vw), 1834 (vw), 1696 (vw), 1596 (m), 1556 (s), 1496 (m), 1456 (w), 1442 (w), 1418 (w), 
1396 (w), 1386 (w), 1360 (m), 1342 (m), 1310 (m), 1272 (m), 1254 (w), 1222 (s), 1182 (m), 
1170 (s), 1138 (s), 1100 (vs), 1046 (w), 1024 (m), 956 (m), 936 (w), 912 (s), 880 (s), 786 (s), 
720 (m), 682 (w), 658 (w), 626 (m). 
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1H-NMR (300 MHz, CDCl3): δ = 8.27 (s, 1H), 5.61 (s, 2H), 3.41 ppm (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 153.6, 152.1, 145.7, 130.6, 74.7, 57.6 ppm. 
MS (70 eV, EI): m/z (%) = 232 (9), 212 (9), 211 (12), 204 (40), 203 (20), 202 (62), 201 (21), 
196 (12), 45 (100). 
HRMS (EI): m/z calc. for [C7H6Cl2N4O] 231.9919; found: 231.9919. 
 
Synthesis of 9-(methoxymethyl)-2-(trimethylsilyl)-9H-purine (6i) 
 
 
In a round bottom flask Pd/ C (40 wt%) and HCO2NH4 (1.25 g, 35 mmol) were added to a 
solution of the 6-chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purine (6j, 2.5 mmol) in 
MeOH (5 mL) at 45 °C. When the reaction started proceeding (intensive bubbling) the 
mixture was stirred for further 30 min until the starting material was completely consumed as 
monitored by TLC. The solution was filtered through celite®. After washing the cake with 
EtOH (400 mL) and concentration via rotary evaporation, the crude material was redissolved 
in CH2Cl2 (100 mL) and the undissolved HCO2NH4 was filtered off. The solvents were 
evaporated in vacuo. Purification via column chromatography (silicagel, EtOAc) yielded 9-
(methoxymethyl)-2-(trimethylsilyl)-9H-purine (6i, 550 mg, 90%) as a pale yellow oil. 
 
IR (ATR) ν~  (cm-1): 3418 (brw), 2956 (w), 2900 (vw), 2830 (vw), 1740 (vw), 1588 (m), 
1562 (m), 1498 (w), 1442 (w), 1426 (w), 1396 (w), 1364 (m), 1350 (m), 1330 (w), 1290 (w), 
1246 (m), 1180 (m), 1092 (s), 1024 (w), 918 (m), 898 (w), 838 (vs), 756 (s), 696 (w), 670 (w), 
658 (vw), 636 (m), 622 (w). 
1H-NMR (300 MHz, CDCl3): δ = 9.12 (s, 1H), 8.14 (s, 1H), 5.58 (s, 2H), 3.32 (s, 3H), 0.30 
ppm (s. 9H). 
13C-NMR (75 MHz, CDCl3): δ = 174.6, 150.9, 147.1, 144.7, 132.3, 73.6, 57.5, -1.9 ppm. 
HRMS (ESI): m/z calc. for [C10H16N4OSi+H+] 237.1166; found: 237.1166. 
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Synthesis of 6-chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purine (6j) 
 
 
In a 1L Schlenk-flask equipped with a large stirring bar and septum nBuLi (76.6 mL, 2.61 M 
in hexane, 200 mmol) was added to a solution of TMPH (28.25 g, 200 mmol) in THF 
(100 mL) at -78 °C and the reaction mixture was stirred for 1 h. Subsequently, a solution of 6-
chloro-9-(methoxymethyl)-9H-purine (7.94 g, 40 mmol) in THF (80 mL) was added dropwise 
within 1 h and the reaction mixture was stirred for 2 h. Then, TMSCl (21.7 g, 200 mmol) was 
added dropwise within 20 min and stirred for 1 h. After addition of NaHCO3(sat) (20 mL) and 
NaCl(sat) (20 mL) the mixture was slowly warmed up to 25 °C. After addition of NH4Cl(sat) 
(500 mL) the aqueous layer was extracted with CH2Cl2 (3 x 200 mL). The combined organic 
layers were dried (MgSO4) and the solvent was evaporated in vacuo. Purification via column 
chromatography (silicagel, pentane/ EtOAc gradient = 5:1, 4:1, 3:1) yielded 6-chloro-9-
(methoxymethyl)-2-(trimethylsilyl)-9H-purine (6j, 6.50 g, 60%) as a bright yellow oil. 
 
IR (ATR) ν~  (cm-1): 2957 (w), 1708 (w), 1586 (m), 1540 (m), 1492 (w), 1462 (w), 1360 (m), 
1350 (m), 1307 (w), 1247 (m), 1183 (m), 1133 (m), 1101 (s), 1027 (w), 950 (w), 917 (w), 874 
(m), 838 (vs), 776 (m), 759 (m), 650 (w). 
1H-NMR (300 MHz, CDCl3): δ = 8.19 (s, 1H), 5.63 (s, 2H), 3.39 (s, 3H), 0.37 ppm (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 175.6, 151.5, 150.1, 144.4, 130.1, 74.4, 57.7, -1.9 ppm. 
MS (70 eV, EI): m/z (%) = 270 (20), 257 (24), 255 (71), 240 (22), 235 (41), 225 (28), 95 
(32), 93 (100), 73 (88), 45 (99). 
HRMS (EI): m/z calc. for [C10H15ClN4OSi] 270.0704; found: 270.0691. 
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Synthesis of 9-(methoxymethyl)-2-((4-methoxyphenyl)thio)-9H-purine (6k) 
 
 
4-Methoxy thiophenol (168 mg, 1.2 mmol) was added to a solution of tBuOK (224 mg, 
2.0 mmol) in NMP (2 mL). After the mixture was stirred for 5 min at 110 °C, 2-chloro-9-
(methoxymethyl)-9H-purine (6g, 193 mg, 1.0 mmol) was added and the resulting mixture was 
heated for 1 h. After cooling to 25 °C, EtOAc (30 mL) was added, the organic layer was 
washed with H2O (3 x 15 mL) and NaCl(sat) (15 mL). The organic layer was dried (Na2SO4) 
and the solvent was evaporated in vacuo. Purification via column chromatography (silicagel, 
EtOAc) yielded 9-(methoxymethyl)-2-((4-methoxyphenyl)thio)-9H-purine (6k, 160 mg, 53%) 
as a yellow oil. 
 
1H-NMR (300 MHz, CDCl3): δ = 8.87 (s, 1H), 8.03 (s, 1H), 7.55-7.50 (m, 2H), 6.95-6.90 
(m, 2H), 5.37 (s, 2H), 3.82 (s, 3H), 3.23 ppm (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 167.2, 160.6, 152.8, 149.1, 144.2, 137.2, 131.1, 120.7, 
114.6, 73.7, 57.7, 55.4 ppm. 
MS (70 eV, EI): m/z (%) = 304 (5), 303 (17), 302 (100), 301 (88), 272 (6), 271 (19), 259 (7), 
257 (23), 139 (7), 45 (27). 
HRMS (EI): m/z calc. for [C14H14N4O2S] 302.0837; found: 302.0829. 
 
Synthesis of 6-chloro-8-iodo-9-(methoxymethyl)-9H-purine (8a) 
 
 
TMPZnCl·LiCl (0.92 mL, 1.2 M in THF, 1.1 mmol) was added dropwise to a solution of 6-
chloro-9-(methoxymethyl)-9H-purine (6a, 199 mg, 1.0 mmol) in THF (1.5 mL). After stirring 
for 30 min, a solution of I2 (305 mg, 1.2 mmol) in THF (4 mL) was added dropwise and the 
reaction mixture stirred for 1 h. Then, a mixture of Na2S2O3(sat)/ NH4Cl(sat) (1:2, 10 mL) was 
added, the aqueous layer was extracted with Et2O (3 x 30 mL), the combined organic layers 
were washed with NaCl(sat) solution (10 mL) and dried (Na2SO4). The solvent was evaporated 
C. Experimental Section 
 
77 
in vacuo. Purification via column chromatography (silicagel, pentane/ EtOAc = 1:2) yielded 
6-chloro-8-iodo-9-(methoxymethyl)-9H-purine (8a, 317 mg, 98%) as a beige solid. 
 
1H-NMR (300 MHz, CDCl3): δ = 8.71 (s, 1H), 5.61 (s, 2H), 3.42 ppm (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 153.5, 152.3, 149.6, 133.7, 107.4, 76.0, 57.6 ppm. 
MS (70 eV, EI): m/z (%) = 323 (20), 296 (28), 295 (9), 294 (94), 292 (8), 197 (7), 169 (29), 
168 (9), 167 (100), 77 (7), 45 (66). 
HRMS (EI): m/z calc. for [C7H6ClIN4O] 323.9275; found: 323.9266. 
 
Synthesis of 9-benzyl-8-iodo-9H-purine (8b) 
 
 
Method A: TMPZnCl·LiCl (0.92 mL, 1.2 M in THF, 1.1 mmol) was added dropwise to a 
solution of 9-benzyl-9H-purine (6b, 210 mg, 1.0 mmol) in THF (1.5 mL). After stirring for 
30 min, a solution of I2 (305 mg, 1.2 mmol) in THF (2 mL) was added dropwise and the 
reaction mixture stirred for 1 h. Then, a mixture of Na2S2O3(sat)/ NH4Cl(sat) (1:2, 10 mL) was 
added, the aqueous layer was extracted with CH2Cl2 (3 x 30 mL), the combined organic layers 
were dried (MgSO4) and the solvent was evaporated in vacuo. Purification via column 
chromatography (silicagel, pentane/ Et2O = 1:9) yielded 8-iodo-9-benzyl-9H-purine (8b, 
270 mg, 80%) as a colorless solid. 
Method B: TMPMgCl·LiCl (0.95 mL, 1.16 M in THF, 1.1 mmol) was added very slow to a 
solution of 9-benzyl-9H-purine (6b, 210 mg, 1.0 mmol) in THF (4 mL) at -60 °C. After 
15 min of stirring, a solution of I2 (380 mg, 1.5 mmol) in THF (3 mL) was added dropwise 
and the reaction mixture stirred for 2.5 h. After work-up and purification as described above 
8-iodo-9-benzyl-9H-purine is obtained (8b, 284 mg, 84%) as a colorless solid. 
 
mp (°C): 211-213. 
IR (ATR) ν~  (cm-1): 3066 (w), 3026 (w), 2360 (m), 2340 (m), 1894 (w), 1738 (m), 1578 (s), 
1494 (m), 1468 (m), 1448 (m), 1436 (m), 1420 (s), 1398 (s), 1364 (m), 1342 (s), 1328 (s), 
1302 (s), 1294 (s), 1244 (s), 1218 (m), 1196 (m), 1164 (s), 1132 (m), 1094 (m), 1072 (m), 
1028 (m), 1002 (w), 984 (m), 922 (m), 908 (m), 888 (m), 858 (w), 812 (m), 790 (m), 772 (m), 
724 (vs), 692 (s), 672 (m), 648 (m), 622 (w). 
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1H-NMR (300 MHz, CDCl3): δ = 9.08 (s, 1H), 8.95 (s, 1H), 7.35-7.31 (m, 5H), 5.48 ppm (s, 
2H). 
13C-NMR (75 MHz, CDCl3): δ = 152.8, 147.1, 136.4, 134.7, 128.9, 128.5, 127.9, 108.3, 49.0 
ppm. 
MS (70 eV, EI): m/z (%) = 337 (5), 336 (41), 335 (18), 210 (16), 209 (100), 208 (9), 104 (6), 
92 (7), 91 (84), 65 (16). 
HRMS (EI): m/z calc. for [C12H8IN4] 335.9872; found: 335.9859. 
 
Synthesis of 6-chloro-8-iodo-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (8c) 
 
 
TMPZnCl·LiCl (1.0 mL, 1.1 M in THF, 1.1 mmol) was added dropwise to a solution of 6-
chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (6c, 239 mg, 1.0 mmol) in THF (1.5 mL). 
After stirring for 30 min, a solution of I2 (305 mg, 1.2 mmol) in THF (2 mL) was added 
dropwise and the reaction mixture stirred for 1 h. Then, a mixture of Na2S2O3/NH4Cl(sat) (1:2, 
10 mL) was added, the aqueous layer was extracted with CH2Cl2 (3 x 30 mL), the combined 
organic layers were dried (MgSO4) and the solvent was evaporated in vacuo. Purification via 
column chromatography (silicagel, CH2Cl2) yielded 6-chloro-8-iodo-9-(tetrahydro-2H-pyran-
2-yl)-9H-purine (8c, 220 mg, 60%) as a colorless solid. 
 
mp (°C): 143-145. 
IR (ATR) ν~  (cm-1): 3068 (w), 2970 (w), 2954 (w), 2938 (w), 2918 (w), 2840 (w), 2728 (w), 
2594 (w), 2362 (vw), 2340 (vw), 1736 (vw), 1592 (vs), 1568 (s), 1554 (s), 1444 (s), 1432 (s), 
1406 (m), 1384 (s), 1352 (m), 1334 (m), 1314 (s), 1280 (m), 1250 (s), 1224 (s), 1194 (m), 
1174 (m), 1152 (s), 1124 (m), 1082 (s), 1062 (m), 1040 (vs), 1008 (s), 998 (s), 960 (m), 930 
(s), 912 (s), 864 (s), 822 (m), 788 (m), 702 (w), 694 (vw), 660 (w), 626 (m), 618 (m). 
1H-NMR (300 MHz, CDCl3): δ = 8.68 (s, 1H), 5.67 (dd, J = 11.4, 2.4 Hz, 1H), 4.25-4.19 (m, 
1H), 3.79-3.71 (m, 1H), 3.20-3.07 (m, 1H), 2.20-2.13 (m, 1H), 1.94-1.63 ppm (m, 4H). 
13C-NMR (75 MHz, CDCl3): δ = 152.5, 151.6, 149.5, 134.3, 106.6, 87.4, 69.3, 28.8, 24.6, 
23.3 ppm. 
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MS (70 eV, EI): m/z (%) = 282 (27), 281 (6), 280 (100), 245 (27), 127 (6), 118 (7), 99 (7), 91 
(6), 85 (6). 
HRMS (EI): m/z calc. for [C10H10ClIN4O] 363.9588; found: 363.9580. 
 
Synthesis of 9-benzyl-8-bromo-9H-purine (8d) 
 
 
TMP2Zn·2MgCl2·2LiCl (1.7 mL, 0.76 M in THF, 1.3 mmol) was added dropwise to a solution 
of 9-benzyl-9H-purine (6b, 210 mg, 1.0 mmol) and 1,2-dibromo-1,1,2,2-tetrachloroethane 
(326 mg, 1.0 mmol) in THF (2 mL). After 15 min of stirring, a mixture of NH3(conc)/ NH4Cl(sat) 
(1:3, 10 mL) was added, the aqueous layer was extracted with Et2O (3 x 30 mL), the 
combined organic layers were dried (MgSO4) and the solvent was evaporated in vacuo. 
Purification via column chromatography (silicagel, CH2Cl2/ MeOH gradient = 200:0, 200:1 to 
100:1) yielded 9-benzyl-8-bromo-9H-purine (8d, 238 mg, 82%) as a colorless solid. 
 
mp (°C): 130-131. 
IR (ATR) ν~  (cm-1): 3028 (w), 2964 (vw), 2358 (vw), 2342 (vw), 1948 (vw), 1892 (vw), 
1738 (w), 1582 (s), 1494 (w), 1472 (s), 1448 (m), 1432 (s), 1410 (m), 1372 (m), 1348 (s), 
1330 (m), 1304 (s), 1242 (s), 1178 (s), 1134 (w), 1098 (m), 1074 (w), 1026 (w), 992 (w), 978 
(w), 920 (w), 910 (m), 888 (w), 820 (w), 790 (w), 774 (w), 724 (vs), 692 (m), 676 (m), 624 
(w), 604 (w). 
1H-NMR (400 MHz, CDCl3): δ = 9.05 (s, 1H), 8.99 (s, 1H), 7.37-7.31 (m, 5H), 5.49 ppm (s, 
2H). 
13C-NMR (100 MHz, CDCl3): δ = 152.9, 152.5, 147.2, 134.5, 134.3, 134.2, 129.0, 128.5, 
127.9, 47.6 ppm. 
MS (70 eV, EI): m/z (%) = 290 (36), 289 (20), 288 (37), 287 (16), 209 (100),92 (13), 91 (87), 
65 (28). 
HRMS (EI): m/z calc. for [C12H9BrN4] 288.0011; found: 287.9994. 
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Synthesis of 9-benzyl-8-bromo-6-chloro-9H-purine (8e) 
 
 
TMP2Zn·2MgCl2·2LiCl (1.3 mL, 0.95 M in THF, 1.2 mmol) was added dropwise to a solution 
of 9-benzyl-6-chloro-9H-purine (6d, 245 mg, 1.0 mmol) and 1,2-dibromo-1,1,2,2-
tetrachloroethane (326 mg, 1.0 mmol) in THF (2 mL). After 15 min of stirring, a mixture of 
NH3(conc)/ NH4Cl(sat) (1:3, 10 mL) was added, the aqueous layer was extracted with Et2O (3 x 
30 mL), the combined organic layers were dried (MgSO4) and the solvent was evaporated in 
vacuo. Purification via column chromatography (silicagel, pentane/ CH2Cl2 gradient = 1:5 to 
1:7) yielded 9-benzyl-8-bromo-6-chloro-9H-purine (8e, 240 mg, 75%) as a colorless solid. 
 
mp (°C): 87-88. 
IR (ATR) ν~  (cm-1): 3028 (w), 2960 (w), 2942 (w), 2360 (m), 2342 (w), 2216 (w), 1890 
(vw), 1736 (m), 1696 (m), 1586 (s), 1556 (s), 1494 (m), 1464 (m), 1452 (s), 1434 (s), 1408 
(m), 1374 (m), 1350 (m), 1326 (vs), 1242 (s), 1200 (s), 1192 (s), 1158 (m), 1144 (s), 1076 
(m), 1024 (w), 1000 (m), 966 (vw), 940 (m), 892 (m), 868 (m), 814 (w), 788 (w), 772 (w), 
724 (s), 704 (s), 692 (s), 674 (m), 638 (w). 
1H-NMR (300 MHz, CDCl3): δ = 8.75 (s, 1H), 7.36-7.31 (m, 5H), 5.49 ppm (s, 2H). 
13C-NMR (75 MHz, CDCl3): δ = 152.2, 152.1, 149.5, 134.3, 134.1, 134.0, 129.0, 128.7, 
128.0, 48.3 ppm. 
MS (70 eV, EI): m/z (%) = 324 (15), 323 (7), 322 (11), 245 (14), 244 (6), 243 (45), 92 (6), 91 
(100), 65 (9). 
HRMS (EI): m/z calc. for [C12H8BrClN4] 321.9621; found: 321.9617. 
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Synthesis of 8-bromo-6-chloro-2-iodo-9-(methoxymethyl)-9H-purine (8f) 
 
 
TMP2Zn·2MgCl2·2LiCl (1.3 mL, 0.95 M in THF, 1.2 mmol) was added dropwise to a solution 
of 6-chloro-2-iodo-9-(methoxymethyl)-9H-purine (6e, 325 mg, 1.0 mmol) and 1,2-dibromo-
1,1,2,2-tetrachloroethane (456 mg, 1.4 mmol) in THF (2 mL). After stirring for 1 h, a mixture 
of NH3(conc)/ NH4Cl(sat) (1:3, 10 mL) was added, the aqueous layer was extracted with Et2O (3 
x 30 mL), the combined organic layers were dried (MgSO4) and the solvent was evaporated in 
vacuo. Purification via column chromatography (silicagel, pentane/ EtOAc gradient = 3:1 to 
2:1) yielded 8-bromo-6-chloro-2-iodo-9-(methoxymethyl)-9H-purine (8f, 348 mg, 87%) as a 
colorless solid. 
 
1H-NMR (300 MHz, CDCl3): δ = 5.60 (s, 2H), 3.44 ppm (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 153.8, 149.0, 134.3, 131.6, 11.1, 74.9, 57.8 ppm. 
MS (70 eV, EI): m/z (%) = 404 (16), 402 (13), 376 (12), 374 (48), 372 (35), 323 (15), 295 
(13), 293 (40), 45 (100). 
HRMS (EI): m/z calc. for [C7H5BrClIN4O] 401.8380; found: 401.8376. 
 
Synthesis of 9-methoxymethyl-8-(phenylthio)-9H-purine (8g) 
 
 
nBuLi (0.86 mL, 2.44 M in hexane, 2.1 mmol) was added dropwise to a solution of 9-
(methoxymethyl)-9H-purine (6f, 328 mg, 2.0 mmol) in THF (10 mL) at -78 °C. After 15 min 
of stirring, a solution of PhSO2SPh (651 mg, 2.6 mmol) in THF (2.6 mL) was added and the 
reaction mixture was slowly warmed up to 25 °C overnight. After addition of NH4Cl(sat) 
(20 mL), the aqueous layer was extracted with CH2Cl2 (3 x 40 mL), the combined organic 
layers were dried (MgSO4) and the solvent was evaporated in vacuo. Purification via column 
chromatography (silicagel, Et2O) yielded 9-methoxymethyl-8-(phenylthio)-9H-purine (8g, 
216 mg, 40%) as a colorless solid. 
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mp (°C): 79-80. 
IR (ATR) ν~  (cm-1): 2956 (w), 2936 (w), 2832 (w), 1704 (w), 1582 (m), 1562 (s), 1462 (m), 
1450 (s), 1440 (s), 1410 (m), 1392 (m), 1348 (m), 1322 (s), 1286 (m), 1246 (s), 1232 (m), 
1188 (m), 1140 (s), 1114 (vs), 1088 (m), 1060 (vs), 1024 (m), 1000 (w), 954 (w), 942 (w), 
918 (s), 864 (w), 850 (w), 788 (w), 772 (m), 756 (vs), 720 (m), 704 (m), 690 (m), 682 (m), 
638 (w), 622 (w), 606 (vw). 
1H-NMR (300 MHz, CDCl3): δ = 8.67 (s, 1H), 7.70-7.64 (m, 2H), 7.47-7.42 (m, 3H), 5.64 
(s, 2H), 3.40 ppm (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 155.6, 154.0, 151.4, 148.5, 133.7, 131.6, 129.7, 129.6, 
127.1, 73.7, 57.4 ppm. 
MS (70 eV, EI): m/z (%) = 308 (18), 307 (16), 306 (47), 277 (15), 276 (20), 275 (38), 265 
(30), 263 (100), 45 (96). 
HRMS (EI): m/z calc. for [C13H11ClN4OS] 306.0342; found: 306.0336. 
 
Synthesis of 6-chloro-8-(cyclohex-2-en-1-yl)-2-iodo-9-(methoxymethyl)-9H-purine (8h) 
 
 
TMPMgCl·LiCl (1 mL, 1.13 M in THF, 1.13 mmol) was added dropwise to a premixed 
solution of 6-chloro-2-iodo-9-(methoxymethyl)-9H-purine (6e, 325 mg, 1.0 mmol) in THF 
(1 mL) and ZnCl2 (1.0 mL, 1.0 M in THF, 1.0 mmol) at -65 °C. After stirring for 30 min, 
CuCN·2LiCl (0.1 mL, 1.0 M in THF, 0.1 mmol) and 3-bromocyclohexene were added 
successive and the reaction mixture warmed up to 25 °C in 2 h. Then, a mixture of 
NH3(conc)/ NH4Cl(sat) (1:3, 10 mL) was added, the aqueous layer was extracted with Et2O (3 x 
30 mL), the combined organic layers were dried (MgSO4) and the solvent was evaporated in 
vacuo. Purification via column chromatography (silicagel, pentane/ Et2O = 3:1) yielded 6-
chloro-8-(cyclohex-2-en-1-yl)-2-iodo-9-(methoxymethyl)-9H-purine (8h, 340 mg, 84%) as a 
colorless solid. 
 
1H-NMR (300 MHz, CDCl3): δ = 6.06-5.99 (m, 1H), 5.79-5.73 (m, 1H), 5.60 (s, 2H), 3.97-
3.88 (m, 1H), 3.40 (s, 3H), 2.24-2.10 (m, 3H), 2.08-1.94 (m, 2H), 1.79-1.64 ppm (m, 1H). 
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13C-NMR (75 MHz, CDCl3): δ = 161.8, 154.5, 149.0, 130.8, 130.8, 124.3, 115.7, 73.2, 57.4, 
35.5, 28.1, 24.5, 21.2 ppm. 
MS (70 eV, EI): m/z (%) = 406 (13), 404 (39), 375 (13), 374 (28), 373 (19), 361 (28), 359 
(23), 345 (14), 308 (15), 81 (14), 79 (14), 45 (100). 
HRMS (EI): m/z calc. for [C13H14ClIN4O] 403.9901; found: 403.9892. 
 
Synthesis of 9-benzyl-8-phenyl-9H-purine (8i) 
 
 
TMP2Zn·2MgCl2·2LiCl (2.2 mL, 0.9 M in THF, 2 mmol) was added dropwise to a solution of 
9-benzyl-9H-purine (6d, 210 mg, 1.0 mmol) in THF (2 mL). After stirring for 1 h, the 
resulting solution was treated with Pd(dba)2 (38 mg, 5 mol%, 0.05 mmol), P(o-furyl)3 (23 mg, 
10 mol%, 0.1 mmol) and iodobenzene (225 mg, 1.1 mmol). The reaction mixture was stirred 
at 45 °C for 14 h, NH4Cl(sat) (10 mL) was added and the aqueous layer was extracted with 
CH2Cl2 (3 x 30 mL). The combined organic layers were dried (MgSO4) and the solvent was 
evaporated in vacuo. Purification via column chromatography (silicagel, CH2Cl2) yielded 9-
benzyl-8-phenyl-9H-purine (8i, 100 mg, 35%) as a colorless solid. 
 
mp (°C): 119-120. 
IR (ATR) ν~  (cm-1): 3034 (w), 2970 (vw), 2956 (vw), 2360 (w), 2342 (w), 1738 (w), 1608 
(m), 1586 (s), 1520 (vw), 1496 (w), 1480 (m), 1454 (m), 1442 (m), 1422 (m), 1376 (m), 1364 
(m), 1352 (s), 1298 (s), 1262 (m), 1250 (m), 1234 (m), 1152 (w), 1100 (w), 1076 (w), 1026 
(w), 1004 (w), 990 (w), 930 (w), 918 (m), 910 (m), 888 (w), 856 (w), 830 (w), 798 (m), 780 
(s), 718 (vs), 694 (vs), 650 (w), 622 (w), 606 (vw). 
1H-NMR (600 MHz, CDCl3): δ = 9.19 (s, 1H), 9.03 (s, 1H), 7.69-7.68 (m, 2H), 7.57-7.55 
(m, 1H), 7.51-7.49 (m, 2H), 7.31-7.26 (m, 3H), 7.09-7.07 (m, 2H), 5.59 ppm (s, 2H). 
13C-NMR (150 MHz, CDCl3): δ = 156.5, 153.6, 152.3, 147.5, 135.8, 131.0, 129.3, 129.0, 
128.9, 128.1, 126.7, 126.7, 47.0 ppm. 
MS (70 eV, EI): m/z (%) = 287 (14), 286 (82), 285 (70), 272 (13), 209 (24), 182 (18), 91 
(100), 65 (10). 
HRMS (EI): m/z calc. for [C18H14N4] 286.1218; found: 286.1217. 
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Synthesis of ethyl 4-(9-(methoxymethyl)-9H-purin-8-yl)benzoate (8j) 
 
 
TMPZnCl·LiCl (4.6 mL, 1.2 M in THF, 5.5 mmol) was added dropwise to a solution of 9-
(methoxymethyl)-9H-purine (6e, 820 mg, 5.0 mmol) in THF (7 mL). After stirring for 1 h, the 
resulting solution was treated with Pd(dba)2 (58 mg, 2 mol%, 0.1 mmol), P(o-furyl)3 (46 mg, 
4 mol%, 0.2 mmol) and ethyl 4-iodobenzoate (1.66 g, 6.0 mmol). The reaction mixture was 
stirred for 14 h, NH4Cl(sat) (50 mL) was added, the aqueous layer was extracted with CH2Cl2 
(3 x 100 mL). The combined organic layers were dried (MgSO4) and the solvent was 
evaporated in vacuo. Purification via column chromatography (silicagel, EtOAc) yielded ethyl 
4-(9-(methoxymethyl)-9H-purin-8-yl)benzoate (8j, 1.51 g, 97%) as a colorless solid. 
 
mp (°C): 117-119. 
IR (ATR) ν~  (cm-1): 2978 (vw), 2932 (vw), 2830 (vw), 2362 (vw), 2340 (vw), 1712 (s), 1654 
(vw), 1608 (w), 1594 (w), 1586 (w), 1570 (w), 1522 (vw), 1484 (w), 1466 (w), 1436 (w), 
1410 (w), 1392 (w), 1370 (m), 1350 (m), 1314 (m), 1282 (vs), 1256 (s), 1218 (w), 1172 (w), 
1156 (m), 1126 (m), 1112 (s), 1088 (s), 1034 (w), 1016 (m), 964 (w), 936 (w), 926 (w), 914 
(w), 906 (w), 886 (w), 868 (m), 854 (w), 828 (vw), 792 (w), 778 (m), 764 (m), 718 (s), 696 
(w), 656 (vw), 618 (vw), 608 (vw). 
1H-NMR (600 MHz, CDCl3): δ = 9.34 (s, 1H), 9.18 (s, 1H), 8.24-8.19 (m, 4H), 5.66 (s, 2H), 
4.43 (q, J = 7.2 Hz, 2H), 3.60 (s, 3H), 1.43 ppm (t, J = 7.2 Hz, 3H). 
13C-NMR (150 MHz, CDCl3): δ = 165.7, 156.8, 154.4, 152.8, 147.7, 133.3, 133.1, 132.0, 
130.1, 129.8, 73.5, 61.5, 57.9, 14.3 ppm. 
MS (70 eV, EI): m/z (%) = 312 (18), 283 (13), 282 (64), 281 (77), 267 (17), 253 (13), 209 
(17), 133 (11), 45 (100). 
HRMS (EI): m/z calc. for [C16H16N4O3] 312.1222; found: 312.1216. 
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Synthesis of ethyl 4-(6-chloro-9-(methoxymethyl)-9H-purin-8-yl)benzoate (8k) 
 
 
TMPZnCl·LiCl (1.1 mL, 1.0 M in THF, 1.1 mmol) was added dropwise to a solution of 6-
chloro-9-(methoxymethyl)-9H-purine (6a, 199 mg, 1.0 mmol) in THF (2 mL). After 15 min 
of stirring, the resulting solution was treated with Pd(dba)2 (8 mg, 1 mol%, 0.01 mmol), P(o-
furyl)3 (5 mg, 2 mol%, 0.02 mmol) and ethyl 4-iodobenzoate (348 mg, 1.2 mmol). The 
reaction mixture was stirred for 5 h, NH4Cl(sat) (20 mL) was added, the aqueous layer was 
extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were dried (MgSO4) and the 
solvent was evaporated in vacuo. Purification via column chromatography (silicagel, 
pentane/ EtOAc = 5:1) yielded ethyl 4-(6-chloro-9-(methoxymethyl)-9H-purin-8-yl)benzoate 
(8k, 317 mg, 91%) as a colorless solid. 
 
mp (°C): 142-144. 
IR (ATR) ν~  (cm-1): 2940 (vw), 2830 (vw), 1714 (s), 1612 (vw), 1592 (m), 1566 (m), 1524 
(vw), 1468 (w), 1448 (w), 1410 (w), 1388 (w), 1366 (w), 1342 (m), 1294 (m), 1266 (s), 1254 
(s), 1238 (m), 1186 (w), 1176 (w), 1142 (s), 1090 (vs), 1032 (m), 1014 (m), 948 (m), 916 (m), 
868 (m), 852 (w), 794 (w), 770 (m), 738 (m), 718 (m), 694 (w), 636 (vw), 620 (vw), 608 (w). 
1H-NMR (600 MHz, CDCl3): δ = 8.77 (s, 1H), 8.21-8.18 (m, 4H), 5.63 (s, 2H), 4.42 (q, 
J = 7.3 Hz, 2H), 3.58 (s, 3H), 1.42 ppm (t, J = 7.3 Hz, 3H). 
13C-NMR (150 MHz, CDCl3): δ = 165.7, 155.7, 154.2, 152.2, 150.6, 132.9, 132.0, 131.1, 
130.0, 129.8, 73.9, 61.5, 57.8, 14.3 ppm. 
MS (70 eV, EI): m/z (%) = 348 (15), 346 (39), 317 (34), 316 (50), 315 (92), 314 (97), 300 
(20), 286 (10), 271 (12), 243 (14), 45 (100). 
HRMS (EI): m/z calc. for [C16H15ClN4O3] 346.0833; found: 346.0823. 
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Synthesis of ethyl 4-(2-chloro-9-(methoxymethyl)-9H-purin-8-yl)benzoate (8m) 
 
 
TMPZnCl·LiCl (1.1 mL, 1.0 M in THF, 1.1 mmol) was added dropwise to a solution of 2-
chloro-9-(methoxymethyl)-9H-purine (6g, 199 mg, 1.0 mmol) in THF (1 mL). After 15 min 
of stirring, the resulting solution was treated with Pd(dba)2 (12 mg, 2 mol%, 0.02 mmol), P(o-
furyl)3 (9 mg, 4 mol%, 0.04 mmol) and ethyl 4-iodobenzoate (348 mg, 1.2 mmol). The 
reaction mixture was stirred for 24 h, NH4Cl(sat) (20 mL) was added, the aqueous layer was 
extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were dried (MgSO4) and the 
solvent was evaporated in vacuo. Purification via column chromatography (silicagel, 
pentane/ EtOAc =  4:1) yielded ethyl 4-(2-chloro-9-(methoxymethyl)-9H-purin-8-yl)benzoate 
(8m, 200 mg, 91%) as a colorless solid. 
 
mp (°C): 142-143. 
IR (ATR) ν~  (cm-1): 2986 (vw), 2946 (vw), 2362 (vw), 1716 (s), 1594 (m), 1578 (m), 1522 
(vw), 1482 (w), 1464 (w), 1452 (w), 1412 (m), 1396 (w), 1364 (m), 1346 (s), 1312 (m), 1274 
(s), 1252 (s), 1182 (w), 1168 (w), 1142 (s), 1124 (m), 1104 (s), 1082 (vs), 1034 (w), 1016 (s), 
970 (vw), 932 (w), 910 (m), 874 (m), 856 (w), 794 (w), 776 (s), 732 (m), 720 (m), 704 (m), 
690 (w), 676 (w), 636 (w), 612 (m). 
1H-NMR (600 MHz, CDCl3): δ = 9.02 (s, 1H), 8.25-8.23 (m, 2H), 8.20-8.18 (m, 2H, 5.62 (s, 
2H), 4.44 (q, J = 7.2 Hz, 2H), 3.61 (s, 3H), 1.44 ppm (t, J = 7.2 Hz, 3H). 
13C-NMR (150 MHz, CDCl3): δ = 165.7, 156.4, 155.6, 154.7, 149.8, 133.1, 132.4, 132.0, 
130.2, 129.7, 73.4, 61.5, 57.8, 14.3 ppm. 
MS (70 eV, EI): m/z (%) = 348 (17), 346 (48), 318 (24), 317 (41), 316 (59), 315 (79), 301 
(16), 287 (13), 271 (14), 243 (21), 45 (100). 
HRMS (EI): m/z calc. for [C16H15ClN4O3] 346.0833; found: 346.0824. 
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Synthesis of ethyl 4-(2,6-dichloro-9-(methoxymethyl)-9H-purin-8-yl)benzoate (8n) 
 
 
TMPZnCl·LiCl (6.6 mL, 1.0 M in THF, 6.6 mmol) was added dropwise to a solution of 2,6-
dichloro-9-(methoxymethyl)-9H-purine (6h, 1.4 g, 6.0 mmol) in THF (9 mL). After 15 min of 
stirring, the resulting solution was treated with Pd(dba)2 (69 mg, 2 mol%, 0.12 mmol), P(o-
furyl)3 (56 mg, 4 mol%, 0.24 mmol) and ethyl 4-iodobenzoate (2.0 g, 7.2 mmol). The reaction 
mixture was stirred for 14 h, NH4Cl(sat) (50 mL) was added, the aqueous layer was extracted 
with CH2Cl2 (3 x 100 mL). The combined organic layers were dried (MgSO4) and the solvent 
was evaporated in vacuo. Purification via column chromatography (silicagel, 
pentane/ EtOAc = 2:1) yielded ethyl 4-(2,6-dichloro-9-(methoxymethyl)-9H-purin-8-
yl)benzoate (8n, 1.4 g, 62%) as a beige solid. 
 
1H-NMR (300 MHz, CDCl3): δ = 8.25-818 (m, 4H), 5.61 (s, 2H), 4.44 (q, J = 7.0 Hz, 2H), 
3.61 (s, 3H), 1.44 ppm (t, J = 7.2 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 165.7, 156.4, 155.5, 153.1, 151.4, 133.3, 131.6, 130.3, 
130.1, 129.9, 74.0, 61.5, 58.0, 14.3 ppm. 
MS (70 eV, EI): m/z (%) = 382 (13), 380 (19), 352 (13), 351 (20), 350 (21), 349 (26), 335 
(6), 274 (5), 45 (100). 
HRMS (EI): m/z calc. for [C16H14Cl2N4O3] 380.0443; found: 380.0437. 
 
Synthesis of ethyl 4-(9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate (8o) 
 
 
TMPZnCl·LiCl (1.0 mL, 1.18 M in THF, 1.2 mmol) was added dropwise to a solution of 9-
(methoxymethyl)-2-(trimethylsily)-9H-purine (6i, 236 mg, 1.0 mmol) in THF (2 mL). After 
15 min of stirring, the resulting solution was treated with Pd(dba)2 (12 mg, 2 mol%, 
0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.04 mmol) and ethyl 4-iodobenzoate (348 mg, 
1.2 mmol). The reaction mixture was stirred for 3 h, NH4Cl(sat) (20 mL) was added, the 
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aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were 
dried (MgSO4) and the solvent was evaporated in vacuo. Purification via column 
chromatography (silicagel, pentane/ EtOAc = 9:1) yielded ethyl 4-(9-(methoxymethyl)-2-
(trimethylsilyl)-9H-purin-8-yl)benzoate (8o, 200 mg, 52%) as a beige solid. 
 
The analytical data match those of compound 20b. 
 
Synthesis of ethyl 4-(6-chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-
yl)benzoate (8p) 
 
 
TMPZnCl·LiCl (1.0 mL, 1.18 M in THF, 1.2 mmol) was added dropwise to a solution of 6-
chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purine (6j, 271 mg, 1.0 mmol) in THF 
(2 mL). After 15 min of stirring, the resulting solution was treated with Pd(dba)2 (12 mg, 
2 mol%, 0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.04 mmol) and ethyl 4-iodobenzoate 
(348 mg, 1.2 mmol). The reaction mixture was stirred at 45 °C for 14 h, NH4Cl(sat) (20 mL) 
was added, the aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The combined organic 
layers were dried (MgSO4) and the solvent was evaporated in vacuo. Purification via column 
chromatography (silicagel, isohexane/ EtOAc = 10:1) yielded ethyl 4-(6-chloro-9-
(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate (8p, 380 mg, 91%) as a colorless 
solid. The reaction was done also on 20 and 30 mmol scale furnishing the desired compound 
in 70% and 85% yield, respectively. 
 
mp (°C): 121-122. 
IR (ATR) ν~  (cm-1): 2958 (w), 2902 (w), 1721 (m), 1552 (w), 1462 (w), 1365 (w), 1346 (w), 
1274 (m), 1242 (m), 1111 (m), 1090 (s), 1022 (w), 1016 (w), 961 (w), 912 (w), 869 (w), 840 
(vs), 775 (m), 759 (m), 718 (m), 620 (w). 
1H-NMR (400 MHz, CDCl3): δ = 8.20 (s, 4H), 5.65 (s, 2H), 4.41 (q, J=7.1 Hz, 2H), 3.60 (s, 
3H), 1.41 (t, J=7.1 Hz, 3H) 0.40 ppm (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 175.3, 165.8, 154.9, 153.5, 149.5, 132.8, 132.3, 130.0, 
129.9, 129.8, 73.8, 61.4, 58.0, 14.3, -1.9 ppm. 
C. Experimental Section 
 
89 
MS (70 eV, EI): m/z (%) = 418 (55), 404 (100), 389 (64), 388 (51), 384 (100), 374 (72), 93 
(57), 57 (46), 45 (83), 43 (56). 
HRMS (EI): m/z calc. for [C19H23ClN4O3Si] 418.1228; found: 418.1225. 
 
Synthesis of 9-(methoxymethyl)-8-(4-methoxyphenyl)-9H-purine (8q) 
 
 
TMPZnCl·LiCl (1.0 mL, 1.18 M in THF, 1.2 mmol) was added dropwise to a solution of 9-
(methoxymethyl)-9H-purine (6e, 164 mg, 1.0 mmol) in THF (2 mL). After 45 min of stirring, 
the resulting solution was treated with Pd(dba)2 (12 mg, 2 mol%, 0.02 mmol), P(o-furyl)3 
(9 mg, 4 mol%, 0.04 mmol) and 4-iodoanisole (281 mg, 1.2 mmol). The reaction mixture was 
stirred for 14 h, NH4Cl(sat) (20 mL) was added, the aqueous layer was extracted with CH2Cl2 
(3 x 50 mL). The combined organic layers were dried (MgSO4) and the solvent was 
evaporated in vacuo. Purification via column chromatography (silicagel, Et2O) yielded 9-
(methoxymethyl)-8-(4-methoxyphenyl)-9H-purine (8q, 165 mg, 61%) as a colorless solid. 
 
mp (°C): 164-166. 
IR (ATR) ν~  (cm-1): 3002 (vw), 2942 (w), 2842 (vw), 1610 (m), 1594 (m), 1572 (m), 1526 
(w), 1474 (s), 1444 (m), 1420 (m), 1350 (s), 1318 (m), 1302 (m), 1290 (m), 1252 (s), 1228 
(m), 1212 (m), 1184 (s), 1156 (m), 1128 (m), 1092 (vs), 1036 (s), 1016 (m), 978 (w), 920 (m), 
906 (m), 854 (s), 826 (m), 796 (m), 766 (s), 742 (m), 704 (m), 664 (w), 644 (w), 636 (w). 
1H-NMR (300 MHz, CDCl3): δ = 9.10 (s, 1H), 8.97 (s, 1H), 8.09-8.04 (m, 2H), 7.09-7.04 
(m, 2H), 5.62 (s, 2H), 3.89 (s, 3H), 3.59 ppm (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 162.1, 156.8, 154.1, 152.3, 147.2, 133.6, 131.4, 120.9, 
114.5, 73.2, 57.6, 55.5 ppm. 
MS (70 eV, EI): m/z (%) = 270 (100), 240 (61), 239 (94), 227 (18), 226 (11), 225 (25), 209 
(10), 134 (11), 133 (12), 45 (81). 
HRMS (EI): m/z calc. for [C14H14N4O2] 270.1117; found: 270.1109. 
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Synthesis of 6-chloro-9-(methoxymethyl)-8-(4-methoxyphenyl)-9H-purine (8r) 
 
 
TMPZnCl·LiCl (5.6 mL, 1.18 M in THF, 6.6 mmol) was added dropwise to a solution of 6-
chloro-9-(methoxymethyl)-9H-purine (6a, 1.19 g, 6.0 mmol) in THF (9 mL). After 45 min of 
stirring, the resulting solution was treated with Pd(dba)2 (69 mg, 2 mol%, 0.12 mmol), P(o-
furyl)3 (56 mg, 4 mol%, 0.24 mmol) and 4-iodoanisole (1.69 g, 7.2 mmol). The reaction 
mixture was stirred for 2 h, NH4Cl(sat) (50 mL) was added, the aqueous layer was extracted 
with CH2Cl2 (3 x 100 mL). The combined organic layers were dried (Na2SO4) and the solvent 
was evaporated in vacuo. Purification via column chromatography (silicagel, CH2Cl2, then 
pentane/ EtOAc gradient = 1:1 to 1:2) yielded 6-chloro-9-(methoxymethyl)-8-(4-
methoxyphenyl)-9H-purine (8r, 1.74 g, 95%) as a colorless solid. 
 
mp (°C): 157-159. 
IR (ATR) ν~  (cm-1): 2816 (w), 1614 (s), 1568 (s), 1530 (m), 1480 (s), 1440 (m), 1420 (m), 
1400 (m), 1364 (m), 1348 (s), 1306 (m), 1252 (s), 1240 (s), 1206 (m), 1180 (s), 1160 (s), 
1140 (s), 1086 (vs), 1046 (s), 1024 (s), 962 (s), 946 (s), 870 (m), 844 (s), 814 (m), 784 (m), 
744 (m), 718 (m), 704 (s), 646 (m), 618 (m). 
1H-NMR (600 MHz, CDCl3): δ = 8.74 (s, 1H), 8.10 (d, J = 8.6 Hz, 2H), 7.07 (d, J = 9.1 Hz, 
2H), 5.63 (s, 2H), 3.91 (s, 3H), 3.59 ppm (s, 3H). 
13C-NMR (150 MHz, CDCl3): δ = 162.3, 157.0, 154.4, 151.5, 149.6, 131.6, 131.1, 120.3, 
114.5, 73.9, 57.7, 55.5 ppm. 
MS (70 eV, EI): m/z (%) = 306 (29), 305 (16), 304 (100), 276 (11), 275 (16), 274 (35), 273 
(39), 261 (13), 259 (12), 45 (65). 
HRMS (EI): m/z calc. for [C14H13ClN4O2] 304.0727; found: 304.0721. 
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Synthesis of 2,6-dichloro-9-(methoxymethyl)-8-(4-methoxyphenyl)-9H-purine (8s) 
 
 
TMPZnCl·LiCl (8.8 mL, 1.25 M in THF, 11 mmol) was added dropwise to a solution of 2,6-
dichloro-9-(methoxymethyl)-9H-purine (6h, 2.33 g, 10 mmol) in THF (10 mL). After 15 min 
of stirring, the resulting solution was treated with Pd(dba)2 (58 mg, 1 mol%, 0.1 mmol), P(o-
furyl)3 (46 mg, 2 mol%, 0.2 mmol) and 4-iodoanisole (2.81 g, 12 mmol). The reaction mixture 
was stirred for 6 h, NH4Cl(sat) (100 mL) was added, the aqueous layer was extracted with 
CH2Cl2 (3 x 200 mL). The combined organic layers were dried (MgSO4) and the solvent was 
evaporated in vacuo. Purification via column chromatography (silicagel, CH2Cl2) yielded 2,6-
dichloro-9-(methoxymethyl)-8-(4-methoxyphenyl)-9H-purine (8s, 2.4 g, 71%) as a colorless 
solid. 
 
mp (°C): 179-181. 
IR (ATR) ν~  (cm-1): 2362 (m), 2340 (m), 1740 (vs), 1610 (w), 1560 (m), 1478 (w), 1458 (w), 
1436 (w), 1424 (w), 1398 (w), 1366 (s), 1354 (s), 1314 (w), 1296 (w), 1262 (m), 1228 (m), 
1218 (s), 1180 (m), 1158 (m), 1118 (w), 1082 (m), 1042 (w), 1020 (w), 964 (m), 882 (w), 840 
(m), 802 (w), 742 (w), 666 (w). 
1H-NMR (300 MHz, CDCl3): δ = 8.08-8.03 (m, 2H), 7.06-7.02 (m, 2H), 5.57 (s, 2H), 3.89 
(s, 3H), 3.59 ppm (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 162.4, 157.6, 155.7, 152.2, 150.1, 131.6, 130.3, 120.0, 
114.6, 74.0, 57.8, 55.5 ppm. 
MS (70 eV, EI): m/z (%) = 340 (22), 338 (34), 310 (11), 309 (10), 308 (17), 307 (12), 295 
(6), 293 (6), 133 (11), 45 (100). 
HRMS (EI): m/z calc. for [C14H12Cl2N4O2] 338.0337; found: 338.0327. 
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Synthesis of 9-(methoxymethyl)-8-(4-methoxyphenyl)-2-((4-methoxyphenyl)thio)-9H-
purine (8t) 
 
 
TMPZnCl·LiCl (1.5 mL, 0.72 M in THF, 1.1 mmol) was added dropwise to a solution of 9-
(methoxymethyl)-2-((4-methoxyphenyl)thio)-9H-purine (6k, 302 mg, 1.0 mmol) in THF 
(2 mL). After 45 min of stirring the resulting solution was treated with Pd(dba)2 (12 mg, 
2 mol%, 0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.04 mmol) and 4-iodoanisole (281 mg, 
1.2 mmol). The reaction mixture was stirred for 14 h, NH4Cl(sat) (20 mL) was added, the 
aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were 
dried (Na2SO4) and the solvent was evaporated in vacuo. Purification via column 
chromatography (silicagel, pentane/ EtOAc gradient = 1:1 to 0:1) yielded 9-(methoxymethyl)-
8-(4-methoxyphenyl)-2-((4-methoxyphenyl)thio)-9H-purine (8t, 345 mg, 85%) as an orange 
solid. 
 
1H-NMR (600 MHz, CDCl3): δ = 8.86 (s, 1H), 7.99 (d, J = 8.6 Hz, 2H), 7.57 (d, J = 8.6 Hz, 
2H), 7.02 (d, J = 9.1 Hz, 2H), 6.96 (d, J = 8.6 Hz, 2H), 5.35 (s, 2H), 3.86-3.85 (m, 6H), 3.35 
ppm (s, 3H). 
13C-NMR (150 MHz, CDCl3): δ = 166.0, 161.8, 160.4, 155.5, 154.9, 147.5, 137.2, 131.1, 
130.7, 121.0, 120.8, 114.5, 114.4, 73.2, 57.7, 55.3, 55.3 ppm. 
MS (70 eV, EI): m/z (%) = 409 (40), 408 (100), 407 (79), 363 (39), 69 (36), 57 (52), 55 (47), 
44 (48), 43 (35), 41 (44). 
HRMS (EI): m/z calc. for [C21H20N4O3S] 408.1256; found: 408.1252. 
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Synthesis of 9-(methoxymethyl)-8-(3-(trifluoromethyl)phenyl)-2-(trimethylsilyl)-9H-
purine (8u) 
 
 
TMPZnCl·LiCl (9.14 mL, 1.05 M in THF, 9.6 mmol) was added dropwise to a solution of 9-
(methoxymethyl)-2-(trimethylsily)-9H-purine (6i, 1.9 g, 8.0 mmol) in THF (8 mL). After 
15 min of stirring the resulting solution was treated with Pd(dba)2 (92 mg, 2 mol%, 
0.16 mmol), P(o-furyl)3 (74 mg, 4 mol%, 0.32 mmol) and 1-iodo-3-(trifluoromethyl)benzene 
(3.05 g, 11.2 mmol). The reaction mixture was stirred for 24 h, NH4Cl(sat) solution (50 mL) 
was added, the aqueous layer was extracted with CH2Cl2 (3 x 100 mL), the combined organic 
layers were dried (MgSO4) and the solvent was evaporated in vacuo. Purification via column 
chromatography (silicagel, pentane/ EtOAc = 3:1) yielded 9-(methoxymethyl)-8-(3-
(trifluoromethyl)phenyl)-2-(trimethylsilyl)-9H-purine (16, 1.45 g, 48%) as a colorless solid. 
 
mp (°C): 135-136. 
IR (ATR) ν~  (cm-1): 3076 (vw), 2958 (w), 2902 (vw), 2840 (vw), 1620 (vw), 1574 (w), 1490 
(vw), 1464 (w), 1434 (w), 1416 (m), 1368 (m), 1356 (m), 1322 (m), 1296 (w), 1280 (m), 1262 
(w), 1250 (m), 1216 (w), 1180 (m), 1166 (m), 1154 (m), 1124 (s), 1110 (s), 1088 (s), 1034 
(m), 928 (w), 912 (w), 840 (vs), 804 (s), 766 (m), 726 (m), 714 (w), 698 (m), 686 (w), 666 
(vw), 652 (w), 624 (vw). 
1H-NMR (400 MHz, CDCl3): δ = 9.27 (s, 1H), 8.46 (br, 1H), 8.36-8.34 (m, 1H), 7.85-7.83 
(m, 1H), 7.73-7.69 (m, 1H), 5.69 (s, 2H), 3.64 (s, 3H), 0.44 ppm (s, 9H). 
13C-NMR (100 MHz, CDCl3): δ = 174.7, 154.4, 153.0, 146.7, 132.8 (q, 4JC-F=1 Hz), 132.1, 
131.7 (q, 2JC-F=33 Hz), 129.7, 129.6, 127.7 (q, 3JC-F=4 Hz), 126.7 (q, 3JC-F=4 Hz), 123.7 (q, 
1JC-F=272 Hz), 73.1, 57.9, -1.8 ppm. 
HRMS (ESI): m/z calc. for [C17H19F3N4OSi+H+] 381.1353; found: 381.1350. 
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Synthesis of 6-iodo-9-(methoxymethyl)-8-(phenylthio)-9H-purine (10a) 
 
 
TMPZnCl·LiCl (1.2 mL, 1.0 M in THF, 1.2 mmol) was added dropwise to a solution of 9-
(methoxymethyl)-8-(phenylthio)-9H-purine (8g, 272 mg, 1.0 mmol) in THF (10 mL). After 
stirring for 1 h, a solution of I2 (305 mg, 1.2 mmol) in THF (3 mL) was added dropwise and 
the reaction mixture stirred for 1 h. Then, a mixture of Na2S2O3(sat)/NH4Cl(sat) (1:2, 10 mL) 
was added, the aqueous layer was extracted with Et2O (3 x 30 mL), the combined organic 
layers were washed with NaCl(sat) solution (10 mL) and dried (MgSO4). The solvents were 
evaporated in vacuo. Purification via column chromatography (silicagel, pentane/ EtOAc 
gradient = 3:1 to 2:1) yielded 6-iodo-9-(methoxymethyl)-8-(phenylthio)-9H-purine (10a, 
200 mg, 50%) as a beige solid. 
 
mp (°C): 106-108. 
IR (ATR) ν~  (cm-1): 3042 (vw), 2994 (vw), 2932 (w), 2826 (vw), 1558 (s), 1444 (m), 1434 
(s), 1416 (m), 1332 (m), 1314 (s), 1276 (m), 1238 (s), 1220 (m), 1180 (m), 1160 (w), 1126 
(s), 1106 (vs), 1060 (s), 1026 (m), 974 (w), 932 (w), 908 (s), 854 (m), 786 (w), 764 (m), 752 
(vs), 702 (m), 688 (m), 638 (w), 620 (w). 
1H-NMR (300 MHz, CDCl3): δ = 8.55 (s, 1H), 7.70-7.67 (m, 2H), 7.46-7.43 (m, 3H), 5.60 
(s, 2H), 3.39 ppm (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 154.6, 151.6, 138.7, 134.7, 133.4, 129.6, 129.5, 127.6, 
119.3, 73.8, 57.4 ppm. 
MS (70 eV, EI): m/z (%) = 408 (24), 407 (16), 399 (13), 398 (96), 392 (11), 391 (100), 109 
(12), 91 (14), 77 (11), 45 (51). 
HRMS (EI): m/z calc. for [C13H11IN4OS] 397.9698; found: 397.9669. 
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Synthesis of ethyl 4-(6-iodo-9-(methoxymethyl)-9H-purin-8-yl)benzoate (10b) 
 
 
A solution of ethyl 4-(9-(methoxymethyl)-9H-purin-8-yl)benzoate (8j, 312 mg, 1.0 mmol) in 
THF (10 mL) was added dropwise to TMPMgCl·LiCl (1.3 mL, 0.94 M in THF, 1.2 mmol) at  
-20 °C. After stirring for 1 h, the resulting reaction mixture was added to a solution of I2 
(1.0 g, 3.9 mmol) in THF (2 mL) at 0 °C and the solution was stirred for 1 h. Then, a mixture 
of Na2S2O3(sat)/ NH4Cl(sat) (1:2, 20 mL) was added, the aqueous layer was extracted with 
EtOAc (3 x 50 mL), the combined organic layers were washed with NaCl(sat) solution (20 mL) 
and dried (MgSO4). The solvents were evaporated in vacuo. Purification via column 
chromatography (silicagel, pentane/ EtOAc = 1:1) yielded ethyl 4-(6-iodo-9-
(methoxymethyl)-9H-purin-8-yl)benzoate (10b, 306 mg, 70%) as a beige solid. 
 
mp (°C): 152-154. 
IR (ATR) ν~  (cm-1): 2936 (vw), 2832 (vw), 2362 (vw), 1716 (s), 1580 (w), 1556 (s), 1522 
(w), 1470 (m), 1434 (m), 1408 (w), 1386 (w), 1368 (w), 1338 (m), 1266 (s), 1254 (s), 1228 
(m), 1186 (w), 1168 (m), 1132 (m), 1088 (vs), 1034 (m), 1014 (m), 912 (m), 870 (m), 848 
(m), 792 (w), 776 (m), 768 (m), 732 (m), 716 (s), 696 (m), 634 (vw), 616 (vw). 
1H-NMR (600 MHz, CDCl3): δ = 8.68 (s, 1H), 8.24-8.20 (m, 4H), 5.61 (s, 2H), 4.44 (q, 
J = 7.3 Hz, 2H), 3.59 (s, 3H), 1.44 ppm (t, J = 7.1 Hz, 3H). 
13C-NMR (150 MHz, CDCl3): δ = 165.7, 155.1, 152.2, 150.5, 138.1, 133.0, 132.1, 130.1, 
129.9, 121.6, 73.8, 61.5, 57.8, 14.3 ppm. 
MS (70 eV, EI): m/z (%) = 439 (14), 438 (62), 409 (17), 408 (100), 407 (88), 393 (17), 239 
(11), 238 (14), 221 (11), 207 (16), 45 (70). 
HRMS (EI): m/z calc. for [C16H15IN4O3] 438.0189; found: 438.0182. 
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Synthesis of 6-iodo-9-(methoxymethyl)-8-(4-methoxyphenyl)-9H-purine (10c) 
 
 
A solution of 9-(methoxymethyl)-8-(4-methoxyphenyl)-9H-purine (8q, 270 mg, 1.0 mmol) in 
THF (10 mL) was added dropwise to TMPMgCl·LiCl (1.3 mL, 0.94 M in THF, 1.2 mmol) at  
-20 °C. After stirring for 1 h, the resulting reaction mixture was added to a solution of I2 
(1.0 g, 3.9 mmol) in THF (2 mL) at -20 °C and the solution was stirred for 3 h. Then, a 
mixture of Na2S2O3/ NH4Cl(sat) (1:2, 20 mL) was added, the aqueous layer was extracted with 
EtOAc (3 x 50 mL), the combined organic layers were washed with NaCl(sat) (20 mL) and 
dried (MgSO4). The solvents were evaporated in vacuo. Purification via column 
chromatography (silicagel, pentane/ Et2O = 1:1) yielded 6-iodo-9-(methoxymethyl)-8-(4-
methoxyphenyl)-9H-purine (10c, 238 mg, 60%) as a beige solid. 
 
mp (°C): 156-158. 
IR (ATR) ν~  (cm-1): 2956 (w), 2932 (w), 2832 (w), 1612 (m), 1562 (s), 1526 (m), 1466 (s), 
1418 (m), 1358 (m), 1338 (m), 1296 (m), 1256 (s), 1246 (s), 1230 (m), 1184 (s), 1166 (m), 
1138 (s), 1128 (s), 1090 (vs), 1038 (s), 1020 (m), 964 (w), 914 (s), 856 (m), 842 (s), 790 (m), 
768 (s), 742 (m), 694 (m), 644 (m), 610 (m). 
1H-NMR (600 MHz, CDCl3): δ = 8.63 (s, 1H), 8.10-8.08 (m, 2H), 7.08-7.06 (m, 2H), 5.59 
(s, 2H), 3.90 (s, 3H), 3.58 ppm (s, 3H). 
13C-NMR (150 MHz, CDCl3): δ = 162.3, 156.3, 151.6, 150.6, 138.1, 131.7, 120.3, 120.2, 
114.5, 73.9, 57.7, 55.5 ppm. 
MS (70 eV, EI): m/z (%) = 397 (15), 396 (100), 366 (21), 365 (23), 269 (12), 239 (11), 238 
(9), 197 (7), 133 (12), 45 (30). 
HRMS (EI): m/z calc. for [C14H13IN4O2] 396.0083; found: 396.0074. 
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Synthesis of ethyl 4-(9-(methoxymethyl)-6-phenyl-9H-purin-8-yl)benzoate (10d) 
 
 
A solution of ethyl 4-(9-(methoxymethyl)-9H-purin-8-yl)benzoate (8j, 312 mg, 1.0 mmol) in 
THF (10 mL) was added dropwise to TMPMgCl·LiCl (1.3 mL, 0.94 M in THF, 1.2 mmol) at  
-20 °C. After stirring for 1 h, ZnCl2 (1.3 mL, 1.0 M in THF, 1.3 mmol) was added, the 
resulting reaction mixture was stirred for 30 min and warmed up to 25 °C. Then, Pd(dba)2 
(12 mg, 2 mol%, 0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.04 mmol) and iodobenzene 
(265 mg, 1.3 mmol) were added. The reaction mixture was stirred for 14 h, NH4Cl(sat) (20 mL) 
was added, the aqueous layer was extracted with CH2Cl2 (3 x 50 mL), the combined organic 
layers were dried (MgSO4) and the solvent was evaporated in vacuo. Purification via column 
chromatography (silicagel, pentane/ EtOAc = 5:1) yielded ethyl 4-(9-(methoxymethyl)-6-
phenyl-9H-purin-8-yl)benzoate (10d, 245 mg, 63%) as a beige solid. 
 
mp (°C): 156-157. 
IR (ATR) ν~  (cm-1): 2954 (w), 2938 (w), 2908 (w), 2838 (vw), 1708 (s), 1588 (m), 1560 (m), 
1498 (w), 1466 (w), 1442 (w), 1428 (w), 1410 (w), 1368 (m), 1330 (m), 1282 (vs), 1254 (m), 
1210 (m), 1184 (m), 1142 (m), 1126 (m), 1102 (s), 1082 (s), 1036 (m), 1018 (s), 980 (w), 954 
(w), 934 (w), 914 (m), 874 (m), 864 (m), 854 (m), 770 (s), 752 (m), 718 (m), 694 (s), 686 (m), 
670 (m), 646 (w), 626 (w). 
1H-NMR (400 MHz, CDCl3): δ = 9.07 (s, 1H), 8.94-8.92 (m, 2H), 8.28-8.23 (m, 4H), 7.61-
7.53 (m, 3H), 5.68 (s, 2H), 4.45 (q, J = 7.0 Hz, 2H), 3.62 (s, 3H), 1.45 ppm (t, J = 7.1 Hz, 
3H). 
13C-NMR (100 MHz, CDCl3): δ = 165.8, 155.1, 154.7, 154.2, 152.4, 135.2, 132.8, 132.6, 
131.2, 130.5, 130.0, 129.9, 129.8, 128.7, 73.4, 61.4, 57.6, 14.3 ppm. 
MS (70 eV, EI): m/z (%) = 388 (26), 359 (9), 358 (46), 357 (100), 343 (10), 329 (13), 285 
(6), 209 (9), 45 (23). 
HRMS (EI): m/z calc. for [C22H20N4O3] 388.1535; found: 388.1529. 
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Synthesis of ethyl 4-(9-(methoxymethyl)-8-(4-methoxyphenyl)-9H-purin-6-yl)benzoate 
(10e) 
 
 
A solution of 9-(methoxymethyl)-8-(4-methoxyphenyl)-9H-purine (8q, 270 mg, 1.0 mmol) in 
THF (10 mL) was added dropwise to TMPMgCl·LiCl (1.3 mL, 0.94 M in THF, 1.2 mmol) at  
-20 °C. After stirring for 1 h, ZnCl2 (1.3 mL, 1.0 M in THF, 1.3 mmol) was added, the 
resulting reaction mixture stirred for 30 min and warmed up to 25 °C. Then, Pd(dba)2 (12 mg, 
2 mol%, 0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.04 mmol) and ethyl 4-iodobenzoate 
(359 mg, 1.3 mmol) were added. The reaction mixture was stirred for 14 h, NH4Cl(sat) (20 mL) 
was added, the aqueous layer was extracted with CH2Cl2 (3 x 50 mL), the combined organic 
layers were dried (MgSO4) and the solvent was evaporated in vacuo. Purification via column 
chromatography (silicagel, pentane/ EtOAc = 3:1) yielded ethyl 4-(9-(methoxymethyl)-8-(4-
methoxyphenyl)-9H-purin-6-yl)benzoate (10e, 230 mg, 55%) as a beige solid. 
 
mp (°C): 158-159. 
IR (ATR) ν~  (cm-1): 2996 (vw), 2940 (w), 2930 (w), 2846 (vw), 1712 (m), 1614 (m), 1580 
(m), 1558 (w), 1532 (w), 1476 (m), 1460 (m), 1448 (m), 1380 (w), 1364 (w), 1326 (m), 1294 
(m), 1274 (s), 1254 (vs), 1182 (m), 1170 (m), 1144 (m), 1098 (s), 1082 (m), 1038 (m), 1020 
(m), 914 (w), 878 (w), 838 (w), 770 (m), 744 (w), 706 (w), 642 (vw), 618 (vw). 
1H-NMR (400 MHz, CDCl3): δ = 9.05-9.01 (m, 3H), 8.24-8.22 (m, 2H), 8.18-8.14 (m, 2H), 
7.12-7.08 (m, 2H), 5.68 (s, 2H), 4.43 (q. J = 7.0 Hz, 2H), 3.92 (s, 3H), 3.62 (s, 3H), 1.44 ppm 
(t, J = 7.1 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 166.3, 162.1, 156.4, 155.6, 151.7, 151.7, 139.5, 132.1, 
131.5, 131.1, 129.8, 129.7, 121.0, 114.5, 73.4, 61.1, 57.5, 55.5, 14.3 ppm. 
MS (70 eV, EI): m/z (%) = 419 (21), 418 (86), 389 (9), 388 (43), 387 (100), 373 (17), 359 
(15), 315 (9), 300 (9), 159 (8), 45 (28). 
HRMS (EI): m/z calc. for [C23H22N4O4] 418.1641; found: 418.1640. 
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Synthesis of ethyl 4-(9-(methoxymethyl)-8-(3-(trifluoromethyl)phenyl)-2-(trimethylsilyl)-
9H-purin-6-yl)benzoate (10f) 
 
 
A solution of 9-(methoxymethyl)-8-(3-(trifluoromethyl)phenyl)-2-(trimethylsilyl)-9H-purine 
(8u, 380 mg, 1.0 mmol) in THF (1 mL) was added dropwise to TMPMgCl·LiCl (1.3 mL, 
0.94 M in THF, 1.2 mmol) at -20 °C. After stirring for 1 h, ZnCl2 (1.3 mL, 1.0 M in THF, 
1.3 mmol) was added, the resulting reaction mixture stirred for 30 min and warmed up to 
25 °C. Then, Pd(dba)2 (12 mg, 2 mol%, 0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.04 mmol) 
and ethyl 4-iodobenzoate (359 mg, 1.3 mmol) were added. The reaction mixture was stirred 
for 3h, NH4Cl(sat) (20 mL) was added, the aqueous layer was extracted with CH2Cl2 (3 x 
50 mL), the combined organic layers were dried (MgSO4) and the solvent was evaporated in 
vacuo. Purification via column chromatography (silicagel, pentane/ CH2Cl2 = 5:4) yielded 
ethyl 4-(9-(methoxymethyl)-8-(3-(trifluoromethyl)phenyl)-2-(trimethylsilyl)-9H-purin-6-yl)-
benzoate (10f, 280 mg, 53%) as a beige solid. 
 
mp (°C): 148-149. 
IR (ATR) ν~  (cm-1): 2958 (w), 2930 (vw), 2902 (vw), 2830 (vw), 1718 (s), 1598 (w), 1568 
(m), 1506 (vw), 1464 (m), 1424 (w), 1388 (w), 1368 (w), 1326 (s), 1296 (m), 1270 (vs), 1246 
(s), 1214 (w), 1190 (w), 1172 (m), 1156 (m), 1130 (s), 1102 (vs), 1088 (s), 1074 (s), 1042 
(w), 1020 (m), 918 (w), 910 (w), 882 (w), 844 (vs), 822 (s), 808 (m), 774 (m), 758 (m), 728 
(w), 694 (s), 670 (w), 652 (w). 
1H-NMR (300 MHz, CDCl3): δ = 9.10-9.06 (m, 2H), 8.52 (br s, 1H), 8.45-8.42 (m, 1H), 
8.27-8.23 (m, 2H), 7.87-7.84 (m, 1H), 7.76-7.71 (m, 1H), 5.72 (s, 2H), 4.44 (q, J = 7.2 Hz, 
2H), 3.66 (s, 3H), 1.45 (t, J = 7.2 Hz, 3H), 0.49 (s, 9H) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 174.0, 166.5, 154.6, 153.9, 150.8, 140.4, 133.0 (q,  
4JC-F=1 Hz), 131.9, 131.7 (q, 2JC-F=33 Hz), 130.0, 129.8, 129.7, 129.7, 129.6, 127.5 (q,  
3JC-F=4 Hz), 126.8 (q, 3JC-F=4 Hz), 123.8 (q, 1JC-F=272 Hz), 73.2, 61.1, 57.8, 14.3, -1.7 ppm. 
HRMS (ESI): m/z calc. for [C26H27F3N4O3Si+H+] 529.1877; found: 529.1872. 
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Synthesis of ethyl 4-(9-(methoxymethyl)-2-(2,2,6,6-tetramethylpiperidin-1-yl)-9H-purin-
8-yl)benzoate (12a) 
 
 
TMP2Zn·2MgCl2·2LiCl (0.8 mL, 0.8 M in THF, 0.6 mmol) was added dropwise to a solution 
of ethyl 4-(2-chloro-9-(methoxymethyl)-9H-purin-8-yl)benzoate (8m, 173 mg, 0.5 mmol) in 
THF (1 mL). After stirring for 2 h, NH4Cl(sat) (10 mL) was added, the aqueous layer was 
extracted with CH2Cl2 (3 x 30 mL), the combined organic layers were dried (MgSO4) and the 
solvent was evaporated in vacuo. Purification via column chromatography (silicagel, 
pentane/ EtOAc = 4:1) yielded ethyl 4-(9-(methoxymethyl)-2-(2,2,6,6-tetramethylpiperidin-1-
yl)-9H-purin-8-yl)benzoate (12a, 200 mg, 89%) as a yellow solid. 
 
mp (°C): 193-195. 
IR (ATR) ν~  (cm-1): 2968 (w), 2946 (w), 2872 (vw), 2362 (vw), 2340 (vw), 2148 (m), 1712 
(m), 1618 (w), 1600 (s), 1578 (w), 1546 (s), 1534 (s), 1508 (w), 1472 (w), 1456 (w), 1418 (s), 
1366 (m), 1336 (m), 1320 (w), 1278 (vs), 1254 (m), 1182 (w), 1158 (m), 1128 (m), 1106 (s), 
1094 (s), 1068 (w), 1042 (w), 1014 (m), 992 (w), 970 (w), 940 (w), 914 (m), 880 (w), 870 
(w), 856 (w), 788 (w), 776 (w), 738 (w), 710 (m), 684 (w). 
1H-NMR (300 MHz, CDCl3): δ =8.94 (s, 1H), 8.14-8.10 (m, 2H), 8.03-8.00 (m, 2H), 5.17 (s, 
2H), 4.40 (q, J=7.1 Hz, 2H), 3.56 (s, 3H), 1.90-1.70 (m, 18H), 1.41 ppm (t, J=7.2 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 166.0, 164.7, 148.3, 144.7, 133.5, 131.4, 129.8, 128.3, 
120.0, 118.5, 72.9, 61.2, 57.4, 57.0, 53.4, 27.7, 14.8, 14.3 ppm. 
MS (70 eV, EI): m/z (%) = 451 (40), 328 (27), 327 (100), 297 (27), 296 (45), 268 (38), 232 
(19), 171 (21), 69 (24), 45 (32). 
HRMS (EI): m/z calc. for [C25H33N5O3] 451.2583; found: 451.2582. 
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Synthesis of ethyl 4-(9-(methoxymethyl)-2-(piperidin-1-yl)-9H-purin-8-yl)benzoate (12b) 
 
 
PIP2Zn·2MgCl2·2LiCl (1.3 mL, 0.42 M in THF, 0.6 mmol) was added dropwise to a solution 
of ethyl 4-(2-chloro-9-(methoxymethyl)-9H-purin-8-yl)benzoate (8m, 173 mg, 0.5 mmol) in 
THF (1 mL). After stirring for 2 h, the reaction mixture was heated to 50 °C for 20 h. 
NH4Cl(sat) (10 mL) was added, the aqueous layer was extracted with CH2Cl2 (3 x 30 mL), the 
combined organic layers were dried (MgSO4) and the solvent was evaporated in vacuo. 
Purification via column chromatography (silicagel, pentane/ EtOAc = 4:1) yielded ethyl 4-(9-
(methoxymethyl)-2-(piperidin-1-yl)-9H-purin-8-yl)benzoate (12b, 70 mg, 35%) as a pale 
yellow solid. 
 
mp (°C): 206-207. 
IR (ATR) ν~  (cm-1): 2931 (m), 2863 (m), 2830 (w), 2149 (m), 1704 (s), 1636 (s), 1610 (m), 
1545 (vs), 1532 (s), 1474 (m), 1456 (m), 1443 (m), 1418 (m), 1398 (m), 1361 (m), 1320 (m), 
1280 (s), 1272 (s), 1238 (s), 1200 (m), 1177 (m), 1096 (vs), 1071 (m), 1059 (m), 1016 (m), 
1023 (m), 998 (m), 960 (w), 937 (w), 883 (w), 868 (m), 858 (m), 813 (w), 800 (w), 774 (s), 
729 (w), 706 (m), 684 (m), 658(w). 
1H-NMR (300 MHz, CDCl3): δ = 8.63 (s, 1H), 8.13-8.09 (m, 2H), 7.98-7.94 (m, 2H), 5.12 
(s, 2H), 4.62-4.59 (m, 2H), 4.40 (q, J=7.1 Hz, 2H), 3.68-3.65 (m, 2H), 3.52 (s, 3H), 1.85-1.73 
(br m, 6H), 1.40 ppm (t, J=7.1 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 165.9, 165.4, 162.7, 147.5, 145.0, 133.2, 131.5, 129.8, 
128.4, 117.8, 72.6, 61.2, 57.3, 49.6, 27.2, 25.9, 14.3 ppm. 
MS (70 eV, EI): m/z (%) = 396 (13), 395 (49), 380 (27), 364 (10), 352 (19), 351 (22), 350 
(100), 323 (12), 322 (21), 294 (11), 45 (27), 41 (14). 
HRMS (EI): m/z calc. for [C21H25N5O3] 395.1957; found: 395.1957. 
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Synthesis of 6-chloro-9-(methoxymethyl)-2-(tributylstannyl)-9H-purine (13a) 
 
 
nBuLi (4.2 mL, 2.5 M in hexane, 10.5 mmol) was added to a solution of TMPH (1.41 g, 
10 mmol) in THF (2.6 mL) and hexane (1.3 mL) at -78 °C and the reaction mixture was 
stirred for 1 h. Subsequently, a solution of 6-chloro-9-(methoxymethyl)-9H-purine (8a, 
397 mg, 2.0 mmol) in THF (3.5 mL) was added dropwise and the reaction mixture was stirred 
for 1 h. Then, nBu3SnCl (2.71 mL, 10 mmol) was added dropwise and stirred for 1 h. After 
addition of NH4Cl(sat) (4 mL) the mixture was slowly warmed up to 25 °C within 14 h. After 
addition of NaHCO3(sat) (4 mL) the aqueous layer was extracted with Et2O (3 x 20 mL). The 
combined organic layers were dried (MgSO4), filtered over celite® and the solvent was 
evaporated in vacuo. Purification via column chromatography (silicagel, pentane/ EtOAc 
gradient = 6:1 to 4:1) yielded 6-chloro-9-(methoxymethyl)-2-(tributylstannyl)-9H-purine 
(13a, 822 mg, 84%) as a bright yellow oil. 
 
IR (ATR) ν~  (cm-1): 2954 (m), 2922 (m), 2872 (w), 2852 (m), 1582 (m), 1536 (s), 1492 (w), 
1464 (m), 1410 (w), 1394 (w), 1376 (w), 1338 (s), 1304 (w), 1246 (m), 1178 (s), 1134 (s), 
1102 (vs), 1076 (m), 1046 (w), 1024 (m), 960 (w), 942 (m), 918 (m), 876 (w), 858 (m), 794 
(w), 764 (s), 694 (m), 668 (m), 650 (m). 
1H-NMR (600 MHz, CDCl3): δ = 8.15 (s, 1H), 5.64 (s, 2H), 3.40 (s, 3H), 1.64-1.59 (m, 6H), 
1.37-1.20 (m, 12H), 0.89 ppm (t, J=7.4 Hz, 9H). 
13C-NMR (150 MHz, CDCl3): δ = 182.6, 151.3, 149.5, 143.6, 129.9, 74.2, 57.6, 28.9  
(t, 3JC-Sn=11 Hz), 27.2 (t, 2JC-Sn=28 Hz), 13.7, 10.7 ppm (t, 1JC-Sn=173 Hz). 
HRMS (ESI): m/z calc. for [C19H33ClN4OSn+H+] 489.1438; found: 489.1443. 
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Synthesis of 6-chloro-9-(methoxymethyl)-2-(4-methoxyphenyl)-9H-purine (14b) 
 
 
Pd(dba)2 (12 mg, 2 mol%, 0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.04 mmol), 4-iodoanisole 
(280 mg, 1.2 mmol) and CuI (38 mg, 20 mol%, 0.20 mmol) were successively added to a 
solution of 6-chloro-9-(methoxymethyl)-2-(tributylstannyl)-9H-purine (13a, 488 mg, 
1.0 mmol) in DMF (4 mL) and the resulting reaction mixture was stirred at 80 °C for 12 h. 
After cooling to 25 °C, the solution was diluted with Et2O (50 mL). The organic layer was 
washed with H2O (3 x 20 mL), was dried (Na2SO4) and the solvent was evaporated in vacuo. 
Purification via column chromatography (silicagel, pentane/ EtOAc = 1:2) and trituration with 
pentane yielded 6-chloro-9-(methoxymethyl)-2-(4-methoxyphenyl)-9H-purine (14b, 185 mg, 
60%) as a white solid. 
 
1H-NMR (300 MHz, CDCl3): δ = 8.47-8.42 (m, 2H), 8.19 (s, 1H), 7.00-6.95 (m, 2H), 5.65 
(s, 2H), 3.88 (s, 3H), 3.44 ppm (s, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 162.0, 159.7, 152.9, 151.0, 145.3, 144.6, 130.1, 129.0, 
113.9, 74.4, 57.6, 55.4 ppm. 
MS (70 eV, EI): m/z (%) = 306 (27), 305 (14), 304 (85), 276 (17), 275 (36), 274 (49), 273 
(100), 239 (10), 225 (9), 45 (55). 
HRMS (EI): m/z calc. for [C14H13ClN4O2] 304.0727; found: 304.0722. 
 
Synthesis of 2-iodo-8-(3-(trifluoromethyl)phenyl)-purine (16) 
 
 
I2 (609 mg, 2.4 mmol) was added to a solution of 9-(methoxymethyl)-8-(3-
(trifluoromethyl)phenyl)-2-trimethylsilyl-9H-purine (8u, 380 mg, 1.0 mmol) and AgOTf 
(617 mg, 2.4 mmol) in CHCl3 (13 mL) and the resulting reaction mixture was stirred at 1.5 h. 
NaHCO3(sat) (20 mL) was added, the aqueous layer was extracted with CH2Cl2 (4 x 30 mL), 
the combined organic layers were dried (MgSO4) and were filtered over celite®. The solvent 
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was evaporated in vacuo. Purification via column chromatography (silicagel, 
pentane/ EtOAc = 3:1) yielded 2-iodo-8-(3-(trifluoromethyl)phenyl)-purine (16, 300 mg, 
77%) as a white solid. 
 
mp (°C): 249-254. 
IR (ATR) ν~  (cm-1): 3064 (vw), 2938 (w), 2830 (br) 2782 (w), 2700 (w), 2662 (w), 1616 (w), 
1586 (w), 1572 (m), 1520 (vw), 1464 (w), 1436 (vw), 1406 (w), 1338 (s), 1318 (s), 1274 (m), 
1244 (w), 1226 (m), 1168 (m), 1112 (vs), 1094 (s), 1070 (m), 998 (vw), 938 (m), 924 (m), 
862 (w), 846 (w), 808 (w), 788 (w), 728 (m), 704 (m), 690 (m), 666 (w), 652 (vw). 
1H-NMR (400 MHz, CD3OD/ CDCl3): δ = 8.74 (br s, 1H), 8.43 (br s, 1H), 8.36-8.34 (br m, 
1H), 7.80-7.78 (br m, 1H), 7.70-7.66 (br m, 1H). 
13C-NMR (100 MHz, CD3OD/ CDCl3): δ = 181.7, 132.2 (q, 2JC-F=33 Hz), 131.2 (br), 130.4, 
129.6, 128.7 (q, 3JC-F=4 Hz), 124.8 (q, 3JC-F=4 Hz), 124.7 (q, 1JC-F=272 Hz), 119.1 ppm. 
HRMS (ESI): m/z calc. for [C12H6F3IN4+H+] 390.9662; found: 390.9658. 
 
2.2. Full functionalization of the purine scaffold 
 
2.2.1. Typical procedures 1-5 
TP1: Typical procedure for the preparation of (6-chloro-9-(methoxymethyl)-2-
(trimethylsilyl)-9H-purin-8-yl)zinc(II) chloride (17) 
 
 
In a Schlenk-flask equipped with a stirring bar and septum TMPZnCl·LiCl (1.2 equiv, 1.0 M 
in THF) was added dropwise to a 1 M solution of 6-chloro-9-(methoxymethyl)-2-
(trimethylsilyl)-9H-purine (6j, 1-30 mmol) in THF at 25 °C and stirred for 15 min resulting in 
a reddish-brown solution. 
C. Experimental Section 
 
105 
TP2: Typical procedure for the reduction of the 6-chloropurine derivatives 18e and 8p 
 
 
To a solution of the 6-chloropurine derivative 18e or 8p (5-20 mmol) in EtOH/ MeOH (1:1) 
or EtOH/ THF (1:1) at 45 °C were added Pd/ C (20 wt%) and HCO2NH4 (2 equiv). The 
solution was slowly stirred at 45 °C. When the reaction started proceeding (intensive 
bubbling) the mixture was stirred for further 30-60 min until the starting material was 
completely consumed as monitored by TLC. The solution was filtered through celite®. After 
washing the cake with plenty of EtOAc (400-750 mL) and concentration via rotary 
evaporation, the crude material was redissolved in CH2Cl2 (100 mL) and the undissolved 
HCO2NH4 was filtered off. After concentration via rotary evaporation, the crude material was 
purified by flash column chromatography. 
 
TP3: Typical procedure for the preparation of (8-(4-(ethoxycarbonyl)phenyl)-9-
(methoxymethyl)-2-(trimethylsilyl)-9H-purin-6-yl)zinc(II) chloride (20b) 
 
 
In a microwave-vessel equipped with a stirring bar and septum, ethyl 4-(9-(methoxymethyl)-
2-(trimethylsilyl)-9H-purin-8-yl)benzoate (19b, 1-10 mmol) was added to TMPZnCl·LiCl 
(1.5 equiv, 1.0 M in THF). After sealing the vessel, the reaction mixture was stirred at 90 °C 
for 2 h under microwave irradiation furnishing a very dark blue solution. 
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TP4: Typical procedure for the preparation of 9-(methoxymethyl)-8-(3-methoxyphenyl)-
2-(trimethylsilyl)-9H-purin-6-yl)zinc(II) chloride (20a) 
 
 
In a microwave-vessel equipped with a stirring bar and septum, ZnCl2 (1.6 equiv, 1.0 M in 
THF) was added to TMPMgCl·LiCl (1.5 equiv, 1.0 M in THF) and stirred at 25 °C for 1.5 h. 
9-(Methoxymethyl)-8-(3-methoxyphenyl)-2-(trimethylsilyl)-9H-purine (19a, 1-5 mmol) was 
added. After sealing the vessel, the reaction mixture was stirred at 90 °C for 1 h under 
microwave irradiation furnishing a very dark green solution. 
 
TP5: Typical procedure for the I/ Mg-exchange at C2 of the purine derivatives 23a-b 
 
 
To a solution of the 2-iodopurine derivative 23a or 23b (1.0 mmol) in dry THF (10 mL), was 
added dropwise a solution of iPrMgCl (0.67 mL, 1.78 M in THF, 1.2 mmol) at -78 °C. The 
solution was stirred for 30 min at -78 °C prior to a second addition of iPrMgCl (0.3 mmol) 
and further stirring for 30 min. 
 
 
2.2.2. Synthesis of compounds 18a-24h 
Synthesis of 6-chloro-8-iodo-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purine (18a) 
 
 
6-Chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purine (6j, 271 mg, 1.0 mmol) was 
metalated according to TP1 and the resulting solution was added dropwise to a solution of I2 
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(330 mg, 1.3 mmol) in THF (1.5 mL) at 0 °C. After stirring the reaction mixture at 25 °C for 
1 h, Na2S2O3(sat) (10 mL) and NH4Cl(sat) (10 mL) were added, the aqueous layer was extracted 
with CH2Cl2 (3 x 30 mL). The combined organic layers were dried (MgSO4) and the solvent 
was evaporated in vacuo. Purification via column chromatography (silicagel, 
isohexane/ EtOAc = 7:1) yielded 6-chloro-8-iodo-9-(methoxymethyl)-2-(trimethylsilyl)-9H-
purine (18a, 300 mg, 77%) as a slightly yellow solid. 
 
mp (°C): 98-99. 
IR (ATR) ν~  (cm-1): 2955 (w), 2364 (w), 1741 (w), 1577 (w), 1547 (m), 1425 (w), 1398 (w), 
1361 (w), 1331 (w), 1290 (w), 1244 (m), 1201 (m), 1177 (w), 1136 (w), 1106 (m), 1045 (w), 
959 (w), 917 (w), 874 (m), 843 (vs), 777 (m), 758 (m). 
1H-NMR (400 MHz, CDCl3): δ = 5.60 (s, 2H), 3.39 (s, 3H), 0.37 ppm (s, 9H). 
13C-NMR (100 MHz, CDCl3): δ = 175.6, 152.9, 148.3, 132.4, 106.7, 75.7, 57.7, -2.0 ppm. 
MS (70 eV, EI): m/z (%) = 396 (8), 383 (16), 381 (47), 366 (17), 361 (35), 351 (17), 269 
(19), 95 (18), 93 (54), 73 (41), 45 (100). 
HRMS (EI): m/z calc. for [C10H14ClIN4OSi] 395.9670; found: 395.9664. 
 
Synthesis of 6-chloro-8-(cyclohex-2-en-1-yl)-9-(methoxymethyl)-2-(trimethylsilyl)-9H-
purine (18b) 
 
 
6-Chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purine (6j, 271 mg, 1.0 mmol) was 
metalated according to TP1 and the resulting solution was cooled to -30 °C, treated with 
CuCN·2LiCl (0.05 mL, 1.0 M in THF, 5 mol%, 0.05 mmol) and 3-bromocyclohexene 
(193 mg, 1.2 mmol) and slowly warmed up to 25 °C. After stirring at this temperature for 
12 h, NH4Cl(sat) (10 mL) and NH3(conc) (1 mL) were added, the aqueous layer was extracted 
with CH2Cl2 (3 x 25 mL). The combined organic layers were dried (MgSO4) and the solvent 
was evaporated in vacuo. Purification via column chromatography (silicagel, 
isohexane/ EtOAc = 15:1) yielded 6-chloro-8-(cyclohex-2-en-1-yl)-9-(methoxymethyl)-2-
(trimethylsilyl)-9H-purine (18b, 320 mg, 91%) as a colorless oil. 
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IR (ATR) ν~  (cm-1): 3029 (w), 2937 (w), 2837 (w), 2867 (w), 1740 (w), 1534 (m), 1495 (w), 
1461 (w), 1449 (w), 1431 (w), 1358 (m), 1246 (m), 1204 (w), 1182 (w), 1138 (m), 1128 (m), 
1084 (m), 968 (w), 917 (w), 896 (w), 874 (w), 837 (vs), 805 (w), 776 (m), 75 (m), 722 (w), 
702 (w), 624 (m), 637 (m). 
1H-NMR (300 MHz, CDCl3): δ = 5.98-5.91 (m, 1H), 5.76-5.71 (m, 1H), 5.65 (s, 2H), 3.94-
3.86 (m, 1H), 3.35 (s, 3H), 2.18-1.88 (m, 5H), 1.74-1.62 (m, 1H), 0.34 ppm (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 174.0, 160.7, 153.0, 148.4, 130.2, 129.4, 124.7, 72.8, 57.3, 
35.5, 28.1, 24.4, 21.3, -1.9 ppm. 
MS (70 eV, EI): m/z (%) = 352 (35), 351 (23), 350 (100), 335 (25), 320 (23), 307 (52), 305 
(27), 93 (67), 73 (45), 45 (71). 
HRMS (EI): m/z calc. for [C16H23ClN4OSi] 350.1330; found: 350.1328. 
 
Synthesis of (6-chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)(furan-2-
yl)methanone (18c) 
 
 
6-Chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purine (6j, 271 mg, 1.0 mmol) was 
metalated according to TP1 and the resulting solution was cooled to 0 °C, treated with 
Pd(PPh3)4 (25 mg, 2 mol%, 0.02 mmol), and furan-2-carbonyl chloride (170 mg, 1.3 mmol) 
and slowly warmed up to 25 °C. After stirring at this temperature for 6 h, NH4Cl(sat) (10 mL) 
was added and the aqueous layer was extracted with CH2Cl2 (3 x 25 mL). The combined 
organic layers were dried (MgSO4) and the solvent was evaporated in vacuo. Purification via 
column chromatography (silicagel, isohexane/ EtOAc = 9:1) yielded (6-chloro-9-
(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)(furan-2-yl)methanone (18c, 200 mg, 55%) 
as a yellowish solid. 
 
mp (°C): 119-120. 
IR (ATR) ν~  (cm-1): 3151 (w), 3121 (w), 2956 (w), 2899 (w), 1654 (m), 1577 (w), 1546 (m), 
1467 (m), 1447 (m), 1393 (m), 1375 (w), 1345 (w), 1257 (m), 1245 (m), 1189 (w), 1156 (w), 
1138 (m), 1119 (m), 1085 (m), 1033 (w), 1021 (w), 976 (w), 948 (w), 920 (w), 881 (m), 839 
(vs), 771 (s), 644 (w), 622 (w). 
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1H-NMR (400 MHz, CDCl3): δ = 8.23 (dd, J = 3.7, 0.8 Hz, 1H), 7.81 (dd, J = 1.7, 0.7 Hz, 
1H), 6.68 (dd, J = 3.7, 1.7 Hz, 1H), 6.12 (s, 2H), 3.40 (s, 3H), 0.41 ppm (s, 9H). 
13C-NMR (100 MHz, CDCl3): δ = 178.2, 171.0, 152.3, 152.2, 150.7, 149.3, 146.3, 129.1, 
126.0, 113.2, 74.6, 57.8, -2.0 ppm. 
MS (70 eV, EI): m/z (%) = 364 (33), 349 (42), 329 (30), 321 (32), 319 (28), 269 (69), 95 
(77), 93 (100), 81 (23), 73 (59), 45 (100). 
HRMS (EI): m/z calc. for [C15H17ClN4O3Si] 364.0758; found: 364.0758. 
 
Synthesis of (6-chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)(3-
chlorophenyl)methanone (18d) 
 
 
6-Chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purine (6j, 271 mg, 1.0 mmol) was 
metalated according to TP1 and the resulting solution cooled to 0 °C, treated with Pd(PPh3)4 
(25 mg, 2 mol%, 0.02 mmol), and 3-chlorobenzoyl chloride (228 mg, 1.3 mmol) and slowly 
warmed up to 25 °C. After stirring at this temperature for 6 h, NH4Cl(sat) (10 mL) was added 
and the aqueous layer was extracted with CH2Cl2 (3 x 25 mL). The combined organic layers 
were dried (MgSO4) and the solvent was evaporated in vacuo. Purification via column 
chromatography (silicagel, isohexane/ EtOAc = 20:1) yielded (6-chloro-9-(methoxymethyl)-
2-(trimethylsilyl)-9H-purin-8-yl)(3-chlorophenyl)methanone (18d, 187 mg, 46%) as a pale 
yellow oil. 
 
IR (ATR) ν~  (cm-1): 2957 (w), 1727 (w), 1665 (m), 1574 (m), 1544 (m), 1456 (m), 1430 (w), 
1371 (m), 1354 (w), 1235 (s), 1185 (m), 1140 (m), 1121 (m), 1081 (s), 982 (w), 848 (w), 934 
(w), 877 (m), 841 (vs), 760 (s), 725 (m), 694 (w), 684 (w). 
1H-NMR (400 MHz, CDCl3): δ = 8.34-8.33 (m, 1H), 8.32-8.29 (m, H), 7.65-7.62 (m, 1H), 
7.51-7.47 (m, 1H), 6.07 (s, 2H), 3.38 (s, 3H), 0.42 ppm (s, 9H). 
13C-NMR (100 MHz, CDCl3): δ = 183.7, 178.4, 152.6, 52.1, 146.7, 136.9, 134.9, 134.3, 
131.1, 129.9, 129.6, 129.0, 74.7, 57.8, -2.0 ppm. 
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MS (70 eV, EI): m/z (%) = 408 (25), 393 (45), 365 (35), 269 (48), 139 (62), 93 (67), 85 (38), 
73 (36), 71 (64), 57 (100), 56 (36), 45 (51), 43 (81), 41 (37). 
HRMS (EI): m/z calc. for [C17H18Cl2N4O2Si] 408.0576; found: 408.0569. 
 
Synthesis of 6-chloro-9-(methoxymethyl)-8-(3-methoxyphenyl)-2-(trimethylsilyl)-9H-
purine (18e) 
 
 
6-Chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purine (6j, 2.30 g, 8.5 mmol) was 
metalated according to TP1 and the resulting solution was treated with Pd(dba)2 (129 mg, 
2 mol%, 0.17 mmol), P(o-furyl)3 (79 mg, 4 mol%, 0.34 mmol) and iodo-3-methoxybenzene 
(2.59 g, 11.1 mmol). After stirring the reaction mixture at 45 °C for 14 h, NH4Cl(sat) (50 mL) 
was added and the aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The combined 
organic layers were dried (MgSO4) and the solvent was evaporated in vacuo. Purification via 
column chromatography (silicagel, pentane/ EtOAc gradient = 20:1, 10:1, 5:1) yielded 6-
chloro-9-(methoxymethyl)-8-(3-methoxyphenyl)-2-(trimethylsilyl)-9H-purine (18e, 2.3 g, 
72%) as a colorless solid. The reaction was also done on 20 and 25 mmol scale furnishing the 
desired compound in 67% and 65% yield, respectively. 
 
mp (°C): 169-170. 
IR (ATR) ν~  (cm-1): 2956 (w), 1739 (w), 1606 (w), 1581 (w), 1550 (w), 1486 (w), 1352 (w), 
1252 (m), 1138 (w), 1094 (m), 1079 (w), 1047 (m), 964 (w), 914 (w), 884 (w), 869 (m), 841 
(vs), 791 (m), 778 (m), 758 (w), 728 (w). 
1H-NMR (300 MHz, CDCl3): δ = 7.70-7.65 (m, 2H), 7.46-7.41 (m, 1H), 7.11-7.08 (m, 1H), 
5.65 (s, 2H), 3.88 (s, 3H), 3.60 (s, 3H), 0.40 ppm (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 174.8, 159.9, 156.1, 153.6, 149.1, 130.1, 129.9, 129.5, 
122.2, 117.7, 114.7, 73.8, 58.0, 55.5, -1.9 ppm. 
MS (70 eV, EI): m/z (%) = 378 (32), 376 (88), 361 (67), 346 (34), 345 (45), 341 (74), 331 
(58), 296 (36), 73 (50), 45 (100). 
HRMS (EI): m/z calc. for [C17H21ClN4O2Si] 376.1122; found: 376.1119. 
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Synthesis of 6-chloro-9-(methoxymethyl)-8-(3-(trifluoromethyl)phenyl)-2-
(trimethylsilyl)-9H-purine (18f) 
 
 
6-Chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purine (6j, 271 mg, 1.0 mmol) was 
metalated according to TP1 and the resulting solution was treated with Pd(dba)2 (12 mg, 
2 mol%, 0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.04 mmol) and iodo-3-
(trifluoromethyl)benzene (354 mg, 1.3 mmol). After stirring the reaction mixture at 45 °C for 
14 h, NH4Cl(sat) (10 mL) was added, the aqueous layer was extracted with CH2Cl2 (3 x 
25 mL), the combined organic layers were dried (MgSO4) and the solvent was evaporated in 
vacuo. Purification via column chromatography (silicagel, isohexane/ EtOAc = 10:1) yielded 
6-chloro-9-(methoxymethyl)-8-(3-(trifluoromethyl)phenyl)-2-(trimethylsilyl)-9H-purine (18f, 
370 mg, 89%) as a colorless solid. 
 
mp (°C): 123. 
IR (ATR) ν~  (cm-1): 2961 (w), 1602 (w), 1579 (w), 1544 (m), 1463 (w), 1368 (w), 1328 (m), 
1306 (m), 1263 (m), 1249 (m), 1128 (vs), 1106 (s), 1093 (s), 1079 (m), 914 (m), 877 (m), 845 
(s), 815 (s), 773 (m), 729 (w), 702 (m), 689 (m), 654 (w). 
1H-NMR (400 MHz, CDCl3): δ = 8.43 (s, 1H), 8.33 (d, J=7.87 Hz, 1H), 7.82 (d, J=7.87 Hz, 
1H), 7.69 (t, J=7.87 Hz, 1H), 5.65 (s, 2H), 3.61 (s, 3H), 0.41 ppm (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 175.4, 154.4, 153.4, 148.6, 133.0 (q, 4JC-F=1 Hz), 131.6 (q, 
2JC-F=33 Hz), 129.9, 129.6, 129.3, 127.8 (q, 3JC-F=4 Hz), 126.8 (q, 3JC-F=4 Hz), 123.6 (q,  
1JC-F=272 Hz), 73.7, 57.9, -1.9 ppm. 
MS (70 eV, EI): m/z (%) = 414 (13), 399 (40), 384 (22), 383 (18), 379 (38), 369 (25), 334 
(20), 93 (44), 73 (31), 45 (100). 
HRMS (EI): m/z calc. for [C17H18ClF3N4OSi] 414.0891; found: 414.0882. 
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Synthesis of N,N-dibutyl-3-(6-chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-
yl)aniline (18g) 
 
 
6-Chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purine (6j, 271 mg, 1.0 mmol) was 
metalated according to TP1 and the resulting solution was treated with Pd(dba)2 (12 mg, 
2 mol%, 0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.04 mmol) and N,N-dibutyl-3-iodoaniline 
(431 mg, 1.3 mmol). After stirring the reaction mixture at 45 °C for 3 h, NH4Cl(sat) (10 mL) 
was added, the aqueous layer was extracted with CH2Cl2 (3 x 25 mL), the combined organic 
layers were dried (MgSO4) and the solvent was evaporated in vacuo. Purification via column 
chromatography (silicagel, pentane/ EtOAc = 19:1) yielded N,N-dibutyl-3-(6-chloro-9-
(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)aniline (18g, 475 mg, 74%) as a yellow 
solid. 
 
mp (°C): 98-99. 
IR (ATR) ν~  (cm-1): 2954 (w), 2934 (w), 2872 (w), 2360 (w), 2342 (vw), 1736 (w), 1606 
(w), 1572 (m), 1548 (m), 1494 (m), 1464 (m), 1456 (m), 1398 (w), 1366 (m), 1348 (m), 1310 
(w), 1286 (w), 1258 (m), 1244 (m), 1214 (m), 1200 (w), 1158 (w), 1138 (m), 1098 (s), 1046 
(m), 1012 (vw), 992 (vw), 962 (w), 912 (w), 878 (w), 840 (vs), 830 (s), 776 (s), 756 (m), 728 
(m), 696 (m), 670 (w), 616 (w). 
1H-NMR (300 MHz, CDCl3): δ = 7.36-7.28 (m, 3H), 6.82-6.79 (m, 1H), 5.68 (s, 2H), 3.62 
(s, 3H), 3.36-3.31 (m, 4H), 1.65-1.55 (m, 4H), 1.43-1.31 (m, 4H), 0.99-0.94 (m, 6H), 0.42 
ppm (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 174.1, 157.4, 153.6, 148.8, 148.3, 130.0, 129.7, 129.1, 
116.5, 114.0, 112.6, 73.8, 57.9, 50.8, 29.3, 20.3, 13.9, -1.9 ppm. 
HRMS (ESI): m/z calc. for [C24H36ClN5OSi+H+] 474.2450; found: 474.2448. 
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Synthesis of 6-chloro-9-(methoxymethyl)-8-((4-methoxyphenyl)ethynyl)-2-
(trimethylsilyl)-9H-purine (18h) 
 
 
6-Chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purine (6j, 271 mg, 1.0 mmol) was 
metalated according to TP1 and the resulting solution was added dropwise to a solution of I2 
(300 mg, 1.2 mmol) in THF (1.0 mL) at 0 °C. After stirring the reaction mixture at 25 °C for 
1 h, NEt3 (121 mg, 1.2 mmol), CuI (8 mg, 4 mol%, 0.04 mmol), Pd(dba)2 (12 mg, 2 mol%, 
0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.02 mmol) and ethynyl-4-methoxybenzene (172 mg, 
1.3 mmol) were successively added. After stirring the resulting mixture at 25 °C for 3 h, 
NH4Cl(sat) (20 mL) was added, the aqueous layer was extracted with CH2Cl2 (3 x 30 mL), the 
combined organic layers were dried (MgSO4) and the solvent was evaporated in vacuo. 
Purification via column chromatography (silicagel, isohexane/ EtOAc = 7:1) yielded 6-
chloro-9-(methoxymethyl)-8-((4-methoxyphenyl)ethynyl)-2-(trimethylsilyl)-9H-purine (18h, 
300 g, 75%) as a colorless solid. 
 
mp (°C): 167-168. 
IR (ATR) ν~  (cm-1): 2968 (w), 2935 (w), 2896 (w), 2836 (w), 2218 (w), 1605 (w), 1579 (w), 
1544 (m), 1516 (m), 1456 (w), 1341 (w), 1296 (w), 1254 (m), 1244 (s), 1202 (w), 1170 (m), 
1133 (m), 1113 (s), 1079 (m), 1030 (m), 965 (w), 917 (w), 841 (s), 828 (vs), 769 (m), 700 
(m), 622 (m), 615 (m). 
1H-NMR (400 MHz, CDCl3): δ = 7.58 (d, J = 9.0 Hz, 2H), 6.91 (d, J = 9.0 Hz, 2H), 5.74 (s, 
2H), 3.84 (s, 3H), 3.46 (s, 3H), 0.39 ppm (s, 9H). 
13C-NMR (100 MHz, CDCl3): δ = 175.9, 161.4, 151.4, 149.3, 139.6, 134.2, 130.1, 114.4, 
112.0, 98.6, 77.0, 73.9, 57.9, 55.4, -1.9 ppm. 
MS (70 eV, EI): m/z (%) = 402 (38), 401 (32), 400 (96), 385 (45), 365 (65), 55 (35), 95 (34), 
93 (100), 73 (44), 45 (84). 
HRMS (EI): m/z calc. for [C19H21ClN4O2Si] 400.1122; found: 400.1114. 
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Synthesis of 9-(methoxymethyl)-8-(3-methoxyphenyl)-2-(trimethylsilyl)-9H-purine (19a) 
 
 
6-Chloro-9-(methoxymethyl)-8-(3-methoxyphenyl)-2-(trimethylsilyl)-9H-purine (18e, 5.87 g, 
15.6 mmol) dissolved in MeOH/ THF (70 mL/ 70 mL) was reduced according to TP2. 
Purification via column chromatography (silicagel, isohexane/ EtOAc = 3:1) afforded 9-
(methoxymethyl)-8-(3-methoxyphenyl)-2-(trimethylsilyl)-9H-purine (19a, 4.83 g, 90%) as a 
white solid. 
 
mp (°C): 116-117. 
IR (ATR) ν~  (cm-1): 2998 (vw), 2956 (vw), 2898 (vw), 2836 (vw), 1574 (m), 1506 (vw), 
1486 (w), 1464 (w), 1440 (w), 1426 (w), 1418 (vw), 1400 (vw), 1368 (w), 1354 (w), 1320 
(w), 1288 (w), 1256 (w), 1246 (m), 1240 (m), 1234 (m), 1212 (w), 1202 (w), 1182 (w), 1144 
(w), 1110 (w), 1086 (m), 1054 (m), 1030 (m), 932 (vw), 910 (vw), 902 (w), 880 (w), 840 (vs), 
794 (w), 782 (m), 768 (m), 754 (m), 726 (m), 690 (w), 672 (w), 662 (w), 620 (w). 
1H-NMR (300 MHz, CDCl3): δ = 9.21 (s, 1H), 7.69-7.65 (m, 2H), 7.44 (t, J = 7.9 Hz, 1H), 
7.11-7.07 (m, 1H), 5.66 (s, 2H), 3.87 (s, 3H), 3.61 (s, 3H), 0.41 ppm (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 174.0, 160.0, 156.1, 153.3, 146.1, 132.2, 130.1, 130.0, 
122.0, 117.6, 114.5, 73.2, 57.9, 55.5, -1.8 ppm. 
MS (70 eV, EI): m/z (%) = 343 (27), 342 (74), 341 (27), 327 (58), 312 (26), 311 (41), 297 
(100), 212 (41), 89 (46), 73 (30), 45 (52). 
HRMS (EI): m/z calc. for [C17H22N4O2Si] 342.1512; found: 342.1504. 
 
Synthesis of ethyl 4-(9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate (19b) 
 
 
Ethyl 4-(6-chloro-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate (8p, 8.0 g, 
19 mmol) dissolved in MeOH/ EtOH (50 mL/ 50 mL) was reduced according to TP2. 
Purification via column chromatography (silicagel, isohexane/ EtOAc = 3:1) yielded ethyl 4-
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(9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate (19b, 7.1 g, 95%) as a 
colorless solid. 
 
mp (°C): 179-180. 
IR (ATR) ν~  (cm-1): 2956 (w), 2937 (w), 2900 (w), 2832 (w), 1714 (m), 1586 (w), 1575 (w), 
1473 (w), 1461 (w), 1411 (w), 1361 (m), 13141 (w), 1298 (w), 1271 (m), 1245 (m), 1184 (m), 
1152 (m), 1105 (m), 1105 (m), 1084 (s), 1014 (w), 928 (w), 910 (w), 839 (vs), 776 (m), 756 
(m), 718 (m), 700 (w). 
1H-NMR (300 MHz, CDCl3): δ = 9.24 (s, 1H), 8.20 (s, 4H), 5.67 (s, 2H), 4.40 (q, J = 7.2 Hz, 
2H), 3.60 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H), 0.41 ppm (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 174.7, 165.8, 154.8, 153.0, 146.8, 132.9, 132.6, 132.2, 
130.0, 129.6, 73.1, 61.4, 57.9, 14.3, -1.8 ppm. 
MS (70 eV, EI): m/z (%) = 384 (79), 383 (25), 369 (61), 351 (30), 350 (30), 338 (25), 337 
(100), 89 (36), 73 (24), 45 (31). 
HRMS (EI): m/z calc. for [C19H24N4O3Si] 384.1618; found: 384.1620. 
 
Synthesis of 6-iodo-9-(methoxymethyl)-8-(3-methoxyphenyl)-2-(trimethylsilyl)-9H-
purine (21a) 
 
 
9-(Methoxymethyl)-8-(3-methoxyphenyl)-2-(trimethylsilyl)-9H-purine (19a, 685 mg, 
2.0 mmol) was metalated according to TP4 and the resulting solution was added dropwise to 
a solution of I2 (609 mg, 2.4 mmol) in THF (2 mL) at 0 °C. After stirring the reaction mixture 
at 25 °C for 1 h, Na2S2O3(sat) (10 mL) and NH4Cl(sat) (10 mL) were added, the aqueous layer 
was extracted with CH2Cl2 (3 x 30 mL), the combined organic layers were dried (MgSO4) and 
the solvent was evaporated in vacuo. Purification via column chromatography (silicagel, 
pentane/ EtOAc = 15:1) yielded 6-iodo-9-(methoxymethyl)-8-(3-methoxyphenyl)-2-
(trimethylsilyl)-9H-purine (21a, 600 mg, 64%) as a colorless solid. 
 
mp (°C): 164-166. 
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IR (ATR) ν~  (cm-1): 3000 (vw), 2952 (vw), 2938 (vw), 2894 (vw), 2836 (vw), 2364 (vw), 
2340 (vw), 1736 (vw), 1606 (vw), 1590 (vw), 1570 (w), 1538 (m), 1504 (w), 1484 (w), 1462 
(w), 1444 (w), 1428 (w), 1414 (w), 1388 (w), 1372 (w), 1352 (w), 1324 (w), 1314 (w), 1288 
(vw), 1246 (s), 1210 (m), 1188 (w), 1154 (w), 1148 (w), 1120 (w), 1092 (s), 1078 (m), 1048 
(m), 994 (vw), 952 (vw), 912 (w), 886 (m), 844 (vs), 830 (s), 794 (m), 768 (s), 758 (m), 730 
(m), 692 (w), 668 (w), 658 (w), 624 (vw). 
1H-NMR (300 MHz, CDCl3): δ = 7.69-7.64 (m, 2H), 7.44 (t, J = 8.1 Hz, 1H), 7.11-7.07 (m, 
1H), 5.61 (s, 2H), 3.88 (s, 3H), 3.59 (s, 3H), 0.39 ppm (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 175.3, 159.9, 155.2, 149.8, 136.8, 130.1, 129.7, 122.3, 
121.2, 117.5, 114.9, 73.8, 58.0, 55.5, -1.8 ppm. 
MS (70 eV, EI): m/z (%) = 468 (67), 453 (27), 438 (21), 423 (18), 342 (19), 341 (74), 185 
(30), 73 (91), 69 (21), 45 (100). 
HRMS (EI): m/z calc. for [C17H21IN4O2Si] 468.0478; found: 468.0480. 
 
Synthesis of ethyl 4-(6-iodo-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-
yl)benzoate (21b) 
 
 
Ethyl 4-(9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate (19b, 385 mg, 
1.0 mmol) was metalated according to TP3 and the resulting solution was added dropwise to 
a solution of I2 (440 mg, 1.7 mmol) in THF (1.5 mL) at 0 °C. After stirring the reaction 
mixture at 25 °C for 30 min, Na2S2O3(sat) (10 mL) and NH4Cl(sat) (10 mL) were added, the 
aqueous layer was extracted with CH2Cl2 (3 x 30 mL), the combined organic layers were 
dried (MgSO4) and the solvent was evaporated in vacuo. Purification via column 
chromatography (silicagel, isohexane/ EtOAc = 15:1) yielded ethyl 4-(6-iodo-9-
(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate (21b, 390 mg, 76%) as a 
colorless solid. 
 
mp (°C): 137-139. 
IR (ATR) ν~  (cm-1): 2984 (vw), 2954 (w), 2900 (w), 2840 (vw), 1718 (m), 1614 (vw), 1578 
(w), 1560 (w), 1540 (m), 1516 (w), 1460 (w), 1426 (w), 1408 (vw), 1386 (w), 1364 (w), 1354 
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(w), 1344 (m), 1296 (w), 1274 (s), 1252 (s), 1244 (s), 1210 (m), 1180 (w), 1154 (m), 1124 
(m), 1110 (m), 1090 (vs), 1034 (m), 1016 (m), 942 (w), 914 (w), 840 (vs), 798 (m), 774 (s), 
760 (m), 746 (m), 718 (m), 698 (m), 690 (m), 662 (vw), 642 (vw), 628 (w), 616 (m). 
1H-NMR (400 MHz, CDCl3): δ = 8.22 (s, 4H), 5.63 (s, 2H), 4.44 (q, J = 7.2 Hz, 2H), 3.61 (s, 
3H), 1.44 (t, J = 7.1 Hz, 3H), 0.41 ppm (s, 9H). 
13C-NMR (100 MHz, CDCl3): δ = 175.8, 165.8, 154.1, 149.7, 136.7, 132.7, 132.4, 130.0, 
129.9, 121.7, 73.7, 61.4, 58.0, 14.3, -1.9 ppm. 
HRMS (ESI): m/z calc. for [C19H23IN4O3Si+H+] 511.0657; found: 511.0652. 
 
Synthesis of ethyl 4-(6-(2-(ethoxycarbonyl)allyl)-9-(methoxymethyl)-2-(trimethylsilyl)-
9H-purin-8-yl)benzoate (21c) 
 
 
Ethyl 4-(9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate (19b, 385 mg, 
1.0 mmol) was metalated according to TP3 and the resulting solution cooled to -20 °C. After 
dropwise addition of CuCN·2LiCl (0.25 mL, 1.0 M in THF, 25 mol%, 0.25 mmol) the mixture 
was stirred for 15 min and ethyl 2-(bromomethyl)acrylate67 was added. The reaction mixture 
was slowly warmed to 25 °C (within 8 h) and quenched by the addition of NH4Cl(sat) (20 mL) 
and NH3(conc) (2 mL). The aqueous layer was extracted with CH2Cl2 (3 x 25 mL), the 
combined organic layers were dried (MgSO4) and the solvent was evaporated in vacuo. 
Purification via column chromatography (silicagel, isohexane/ EtOAc = 5:1) yielded ethyl 4-
(6-(2-(ethoxycarbonyl)allyl)-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate 
(21c, 220 mg, 68%) as a pale yellow oil. 
 
IR (ATR) ν~  (cm-1): 2980 (w), 2958 (w), 2904 (w), 1716 (s), 1636 (w), 1615 (w), 1587 (m), 
1566 (m), 1464 (w), 1369 (w), 1344 (w), 1272 (s), 1246 (m), 1152 (m), 1094 (s), 1016 (m), 
925 (m), 841 (vs), 778 (m), 722 (m), 700 (m), 693 (m), 622 (m). 
1H-NMR (300 MHz, CDCl3): δ = 8.16 (s, 4H), 6.29 (s, 1H), 5.61-5.60 (m, 3H), 4.41-4.34 
(m, 2H), 4.29 (s, 2H), 4.19-4.12 (m, 2H), 3.57 (s, 3H), 1.41-1.36 (m, 3H), 1.22-1.17 (m, 3H), 
0.32 ppm (s, 9H). 
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13C-NMR (75 MHz, CDCl3): δ = 174.0, 167.0, 165.9, 157.0, 153.5, 152.6, 137.5, 133.2, 
132.3, 130.8, 129.9, 129.7, 126.4, 73.2, 61.3, 60.6, 57.8, 35.4, 14.3, 14.1, -1.9 ppm. 
MS (70 eV, EI): m/z (%) = 496 (72), 467 (28), 452 (40), 451 (100), 424 (62), 423 (85), 379 
(34), 75 (31), 73 (94), 45 (70). 
HRMS (EI): m/z calc. for [C25H32N4O5Si] 496.2142; found: 496.2140. 
 
Synthesis of ethyl 4-(9-(methoxymethyl)-8-(3-methoxyphenyl)-2-(trimethylsilyl)-9H-
purin-6-yl)benzoate (21d) 
 
 
9-(Methoxymethyl)-8-(3-methoxyphenyl)-2-(trimethylsilyl)-9H-purine (19a, 1.71 g, 
5.0 mmol) was metalated according to TP4 and the resulting solution was added dropwise to 
a solution of Pd(dba)2 (57 mg, 2 mol%, 0.10 mmol), P(o-furyl)3 (46 mg, 4 mol%, 0.20 mmol) 
and ethyl 4-iodobenzoate (2.42 g, 8.5 mmol) in dry THF (8 mL) at 25 °C. The reaction 
mixture was stirred for 12 h, NH4Cl(sat) (10 mL) was added, the aqueous layer was extracted 
with EtOAc (2 x 20 mL), the combined organic layers were dried (Na2SO4) and the solvent 
was evaporated in vacuo. The crude material was purified by flash column chromatography 
(silicagel, isohexane/ CH2Cl2 gradient = 1:2, 1:3) to afford ethyl 4-(9-(methoxymethyl)-8-(3-
methoxyphenyl)-2-(trimethylsilyl)-9H-purin-6-yl)benzoate (21d, 1.56 g, 63%) as an off-white 
powder. 
 
mp (°C): 134-136. 
IR (ATR) ν~  (cm-1): 2992 (vw), 2948 (vw), 2934 (vw), 2898 (vw), 2832 (vw), 1714 (m), 
1572 (m), 1558 (m), 1484 (w), 1462 (w), 1412 (w), 1390 (w), 1362 (w), 1346 (w), 1282 (s), 
1252 (m), 1214 (m), 1202 (w), 1188 (w), 1150 (w), 1130 (m), 1104 (m), 1086 (m), 1052 (m), 
1026 (m), 964 (vw), 916 (w), 888 (w), 854 (s), 840 (vs), 790 (m), 780 (m), 762 (m), 728 (w), 
702 (w), 676 (w), 664 (w), 624 (vw). 
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1H-NMR (300 MHz, CDCl3): δ = 9.09-9.05 (m, 2H), 8.24-8.20 (m, 2H), 7.78-7.74 (m, 2H), 
7.47 (t, J = 8.1 Hz, 1H), 7.13-7.09 (m, 1H), 5.72 (s, 2H), 4.42 (q, J = 7.1 Hz, 2H), 3.90 (s 3H), 
3.63 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H), 0.47 ppm (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 173.4, 166.5, 160.0, 155.5, 154.8, 150.3, 140.5, 131.8, 
130.3, 130.1, 130.0, 129.8, 129.6, 122.2, 117.1, 115.0, 73.4, 61.1, 57.9, 55.5, 14.4, -1.7 ppm. 
MS (70 eV, EI): m/z (%) = 491 (26), 490 (86), 489 (100), 476 (18), 475 (52), 460 (22), 459 
(31), 446 (20), 445 (63), 45 (20). 
HRMS (EI): m/z calc. for [C26H30N4O4Si] 490.2036; found: 490.2021. 
 
Synthesis of diethyl 4,4'-(9-(methoxymethyl)-2-(trimethylsilyl)-9H-purine-6,8-
diyl)dibenzoate (21e) 
 
 
 
Ethyl 4-(9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate (19b, 385 mg, 
1.0 mmol) was metalated according to TP3 and the resulting solution added dropwise to a 
mixture of Pd(dba)2 (12 mg, 2 mol%, 0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.04 mmol) 
and ethyl 4-iodobenzoate (470 mg, 1.7 mmol) in THF (1 mL). After stirring the reaction 
mixture for 20 h, NH4Cl(sat) (20 mL) was added, the aqueous layer was extracted with CH2Cl2 
(3 x 25 mL), the combined organic layers were dried (MgSO4) and the solvent was evaporated 
in vacuo. Purification via column chromatography (silicagel, isohexane/ EtOAc = 15:1) 
yielded diethyl 4,4'-(9-(methoxymethyl)-2-(trimethylsilyl)-9H-purine-6,8-diyl)dibenzoate 
(21e, 280 mg, 53%) as a colorless solid. 
 
mp (°C): 184-186. 
IR (ATR) ν~  (cm-1): 2982 (w), 2958 (w), 2903 (w), 1717 (s), 1584 (w), 1572 (m), 1464 (w), 
1366 (w), 1342 (w), 1256 (s), 1247 (s), 1195 (m), 1183 (m), 1159 (m), 1099 (s), 1087 (s), 
1019 (m), 914 (w), 873 (m), 842 (vs), 817 (m), 787 (m), 777 (m), 757 (m), 727 (m), 705 (m), 
618 (w). 
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1H-NMR (300 MHz, CDCl3): δ = 9.08-9.04 (m, 2H), 8.30-8.20 (m, 6H), 5.71 (s, 2H), 4.47-
4.38 (m, 4H), 3.62 (s, 3H), 1.45-1.40 (m, 6H), 0.46 ppm (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 173.9, 166.5, 165.9, 154.7, 154.3, 150.8, 140.5, 133.1, 
132.5, 131.9, 130.0, 129.9, 129.8, 129.7, 129.6, 73.3, 61.4, 61.1, 57.9, 14.3, 14.3, -1.7 ppm. 
MS (70 eV, EI): m/z (%) = 532 (72), 531 (100), 517 (72), 502 (34), 501 (33), 487 (82), 89 
(32), 73 (38), 45 (68). 
HRMS (EI): m/z calc. for [C28H32N4O5Si] 532.2142; found: 532.2206. 
 
Synthesis of 9-(methoxymethyl)-8-(3-methoxyphenyl)-6-(3-(trifluoromethyl)phenyl)-2-
(trimethylsilyl)-9H-purine (21f) 
 
 
9-(Methoxymethyl)-8-(3-methoxyphenyl)-2-(trimethylsilyl)-9H-purine (19a, 342 mg, 
1.0 mmol) was metalated according to TP4 and the resulting solution was added dropwise to 
a solution of Pd(dba)2 (12 mg, 2 mol%, 0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.04 mmol) 
and 1-iodo-3-(trifluoromethyl)benzene (462 mg, 1.7 mmol) in THF (1 mL) at 25 °C. The 
reaction mixture was stirred for 24 h, NH4Cl(sat) (10 mL) was added. The aqueous layer was 
extracted with EtOAc (2 x 20 mL), the combined organic layers were washed with NaCl(sat) 
(20 mL) and dried (Na2SO4). The solvents were evaporated in vacuo. The crude material was 
purified by flash column chromatography (silicagel, pentane/ CH2Cl2 gradient = 4:1, 2:1) to 
afford 9-(methoxymethyl)-8-(3-methoxyphenyl)-6-(3-(trifluoromethyl)phenyl)-2-(trimethyl-
silyl)-9H-purine (21f, 268 mg, 55%) as an off-white powder. 
 
mp (°C): 167-169. 
IR (ATR) ν~  (cm-1): 3078 (vw), 3002 (vw), 2962 (vw), 2902 (vw), 2838 (vw), 1576 (m), 
1494 (m), 1464 (w), 1442 (w), 1412 (w), 1340 (m), 1314 (m), 1302 (m), 1288 (m), 1262 (m), 
1242 (m), 1216 (w), 1200 (w), 1188 (w), 1158 (m), 1124 (s), 1112 (s), 1094 (m), 1072 (m), 
1048 (w), 920 (w), 904 (w), 878 (m), 842 (vs), 802 (m), 790 (m), 780 (m), 762 (w), 726 (w), 
698 (m), 682 (w), 626 (vw), 610 (vw). 
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1H-NMR (300 MHz, CDCl3): δ = 9.30 (s, 1H), 9.24 (d, J = 7.8 Hz, 1H), 7.79-7.68 (m, 4H), 
7.48 (t, J = 8.3 Hz, 1H), 7.12 (m, 1H), 5.74 (s, 2H), 3.91 (s, 3H), 3.64 (s, 3H), 0.48 ppm (s, 
9H). 
13C-NMR (75 MHz, CDCl3): δ = 173.4, 160.0, 155.6, 154.8, 149.8, 137.0, 133.3, 131.0  
(2JC-F=33 Hz), 130.2, 130.1, 129.6, 129.0, 126.9 (3JC-F=4 Hz), 126.6 (3JC-F=4 Hz), 124.3  
(1JC-F=272 Hz), 122.1, 117.4, 114.8, 73.4, 57.9, 55.4, -1.7 ppm. 
19F-NMR (282 MHz, CDCl3): δ = -62.66 ppm. 
MS (70 eV, EI): m/z (%) = 487 (29), 486 (85), 485 (100), 472 (24), 471 (70), 456 (26), 455 
(39), 450 (22), 448 (69), 89 (21), 45 (34). 
HRMS (EI): m/z calc. for [C24H25F3N4O2Si] 486.1699; found: 486.1676. 
 
Synthesis of ethyl 4-(6-(3-(dibutylamino)phenyl)-9-(methoxymethyl)-2-(trimethylsilyl)-
9H-purin-8-yl)benzoate (21g) 
 
 
Ethyl 4-(9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate (19b, 385 mg, 
1.0 mmol) was metalated according to TP3 and the resulting solution added dropwise to a 
mixture of Pd(dba)2 (12 mg, 2 mol%, 0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.04 mmol) 
and N,N-dibutyl-3-iodoaniline (563 mg, 1.7 mmol) in THF (1 mL). After stirring the reaction 
mixture 20 h, NH4Cl(sat) (20 mL) was added, the aqueous layer was extracted with CH2Cl2 (3 
x 25 mL), the combined organic layers were dried (MgSO4) and the solvent was evaporated in 
vacuo. Purification via column chromatography (silicagel, isohexane/ EtOAc = 19:1) afforded 
ethyl 4-(6-(3-(dibutylamino)phenyl)-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)-
benzoate (21g, 365 mg, 62%) as a thick yellow oil. The reaction was also done on a 10 mmol 
scale furnishing the desired compound in 62% yield. 
 
IR (ATR) ν~  (cm-1): 2956 (m), 2933 (w), 2873 (w), 1719 (m), 1600 (m), 1568 (m), 1556 (m), 
1494 (m), 1460 (m), 1398 (w), 1367 (m), 1339 (m), 1272 (s), 1245 (m), 1220 (m), 1186 (m), 
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1155 (m), 1105 (s), 1091 (s), 1017 (m), 914 (w), 840 (vs), 777 (s), 758 (m), 722 (m), 699 (m), 
622 (w), 614 (w). 
1H-NMR (300 MHz, CDCl3): δ = 8.43-8.40 (m, 1H), 8.33-8.19 (m, 5H), 7.39 (t, J = 7.9 Hz, 
1H), 6.80 (dd, J = 8.4, 2.6 Hz, 1H), 5.72 (s, 2H), 4.44 (q, J = 7.2 Hz, 2H), 3.64 (s, 3H), 3.42-
3.37 (m, 4H), 1.74-1.64 (m, 4H), 1.49-1.36 (m, 7H), 1.03-0.94 (m, 6H), 0.49 ppm (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 173.4, 166.0, 154.4, 153.4, 153.0, 148.3, 137.0, 133.6, 
132.1, 129.9, 129.7, 129.6, 129.3, 117.3, 114.1, 113.2, 73.2, 61.3, 57.8, 51.2, 29.6, 20.5, 14.4, 
14.1, -1.7 ppm. 
MS (70 eV, EI): m/z (%) = 587 (25), 546 (13), 545 (37), 544 (100), 503 (13), 503 (10), 502 
(32), 73 (13), 45 (15), 43 (14), 43 (12). 
HRMS (EI): m/z calc. for [C33H45N5O3Si] 587.3292; found: 587.3290. 
 
Synthesis of ethyl 4-(6-(4-chlorophenyl)-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-
8-yl)benzoate (21h) 
 
 
Ethyl 4-(9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate (19b, 385 mg, 
1.0 mmol) was metalated according to TP3 and the resulting solution added dropwise to a 
mixture of Pd(dba)2 (12 mg, 2 mol%, 0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.04 mmol) 
and chloro-4-iodobenzene (405 mg, 1.7 mmol) in THF (1 mL). After stirring the reaction 
mixture for 8 h, NH4Cl(sat) (20 mL) was added, the aqueous layer was extracted with CH2Cl2 
(3 x 25 mL), the combined organic layers were dried (MgSO4) and the solvent was evaporated 
in vacuo. Purification via column chromatography (silicagel, isohexane/ EtOAc = 10:1) 
yielded ethyl 4-(6-(4-chlorophenyl)-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)-
benzoate (21h, 288 mg, 58%) as a colorless solid. The reaction was also done on a 5 mmol 
scale furnishing the desired compound in 52% yield. 
 
mp (°C): 145-146. 
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IR (ATR) ν~  (cm-1): 3068 (vw), 2988 (vw), 2960 (vw), 2934 (vw), 2902 (vw), 2830 (vw), 
2360 (vw), 2342 (vw), 1718 (m), 1614 (vw), 1576 (m), 1554 (w), 1520 (vw), 1490 (m), 1466 
(w), 1444 (w), 1430 (w), 1416 (vw), 1404 (w), 1390 (w), 1368 (w), 1340 (w), 1318 (w), 1306 
(w), 1290 (w), 1264 (s), 1248 (m), 1216 (w), 1200 (w), 1186 (w), 1174 (w), 1158 (w), 1102 
(m), 1090 (s), 1034 (w), 1016 (m), 958 (vw), 914 (w), 880 (w), 842 (vs), 808 (m), 788 (m), 
776 (m), 762 (m), 728 (w), 718 (m), 704 (w), 690 (w), 670 (w), 658 (vw), 630 (w), 622 (w). 
1H-NMR (600 MHz, CDCl3): δ = 9.06-8.90 (m, 2H), 8.34-8.18 (m, 4H), 7.61-7.49 (m, 2H), 
5.72 (s, 2H), 4.45 (q, J = 7.1 Hz, 2H), 3.64 (s, 3H), 1.45 (t, J = 7.1 Hz, 3H), 0.47 ppm (s, 9H). 
13C-NMR (150 MHz, CDCl3): δ = 173.8, 165.9, 154.4, 154.0, 150.7, 136.7, 134.8, 133.1, 
132.4, 131.2, 130.0, 129.7, 129.4, 128.7, 73.2, 61.4, 57.8, 14.3, -1.7 ppm. 
HRMS (ESI): m/z calc. for [C25H27ClN4O3Si+H+] 495.1614; found: 495.1612. 
 
Synthesis of ethyl 4-(9-(methoxymethyl)-6-(thiophen-2-yl)-2-(trimethylsilyl)-9H-purin-8-
yl)benzoate (21i) 
 
N
N
N
N
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Ethyl 4-(9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate (19b, 385 mg, 
1.0 mmol) was metalated according to TP3 and the resulting solution added dropwise to a 
mixture of Pd(dba)2 (12 mg, 2 mol%, 0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.04 mmol) 
and 2-iodothiophene (357 mg, 1.7 mmol) in THF (1 mL). After stirring the reaction mixture 
for 40 h, NH4Cl(sat) (20 mL) was added, the aqueous layer was extracted with CH2Cl2 (3 x 
25 mL), the combined organic layers were dried (MgSO4) and the solvent was evaporated in 
vacuo. Purification via column chromatography (silicagel, isohexane/ EtOAc = 19:1) yielded 
ethyl 4-(9-(methoxymethyl)-6-(thiophen-2-yl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate (21i, 
200 mg, 43%) as a yellow solid. 
 
mp (°C): 171-172. 
IR (ATR) ν~  (cm-1): 2983 (w), 2956 (w), 2938 (w), 2903 (w), 1723 (m), 1575 (m), 1472 (w), 
1421 (w), 1397 (w), 1363 (w), 1338 (w), 1273 8m), 1237 (m), 1185 (w), 1101 8m), 1086 (m), 
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1037 (w), 1018 (w), 868 (m), 844 (vs), 838 (s), 809 (m), 776 (m), 758 (m), 714 (s), 694 (m), 
675 (w), 618 (w). 
1H-NMR (300 MHz, CDCl3): δ = 8.74 (dd, J = 3.8, 1.1 Hz, 1H), 8.29-8.20 (m, 4H), 7.56 (dd, 
J = 5.0, 1.1 Hz, 1H), 7.24-7.22 (m, 1H), 5.68 (s, 2H), 4.43 (q, J = 7.2 Hz, 2H), 3.60 (s, 3H), 
1.43 (t, J = 7.2 Hz, 3H), 0.44 ppm (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 174.1, 166.0, 153.9, 153.9, 147.9, 141.3, 133.3, 132.3, 
132.2, 130.3, 130.0, 129.7, 128.6, 127.4, 73.2, 61.4, 57.8, 14.3, -1.8 ppm. 
MS (70 eV, EI): m/z (%) = 466 (87), 465 (58), 451 (63), 436 (48), 435 (65), 433 (36), 421 
(88), 393 (40), 89 (37), 73 (49), 45 (100). 
HRMS (EI): m/z calc. for [C23H26N4O3SSi] 466.1495; found: 466.1483. 
 
Synthesis of ethyl 4-(6-(3-(N-allyl-4-methylphenylsulfonamido)prop-1-yn-1-yl)-9-
(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate (21j) 
 
 
Ethyl 4-(9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-yl)benzoate (19b, 385 mg, 
1.0 mmol) was metalated according to TP3 and the resulting solution was added dropwise to 
a solution of I2 (380 mg, 1.5 mmol) in THF (1.0 mL) at 0 °C. After stirring the reaction 
mixture at 25 °C for 1 h, NEt3 (152 mg, 1.5 mmol), CuI (8 mg, 4 mol%, 0.04 mmol), Pd(dba)2 
(12 mg, 2 mol%, 0.02 mmol), P(o-furyl)3 (9 mg, 4 mol%, 0.04 mmol) and N-allyl-4-methyl-
N-(prop-2-yn-1-yl)benzenesulfonamide (172 mg, 1.3 mmol) were successively added. After 
stirring the resulting mixture for 1 h NH4Cl(sat) (20 mL) was added, the aqueous layer was 
extracted with CH2Cl2 (3 x 30 mL), the combined organic layers were dried (MgSO4) and the 
solvent was evaporated in vacuo. Purification via column chromatography (silicagel, 
isohexane/ EtOAc gradient = 10:1, 9:1, 8:1) yielded ethyl 4-(6-(3-(N-allyl-4-
methylphenylsulfonamido)prop-1-yn-1-yl)-9-(methoxymethyl)-2-(trimethylsilyl)-9H-purin-8-
yl)benzoate (21j, 472 mg, 75%) as a thick colorless oil. 
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IR (ATR) ν~  (cm-1): 2958 (w), 2874 (vw), 2366 (vw), 2238 (vw), 1718 (m), 1644 (vw), 1614 
(vw), 1580 (m), 1522 (vw), 1464 (w), 1428 (w), 1410 (w), 1392 (w), 1346 (s), 1328 (m), 1272 
(s), 1248 (m), 1214 (w), 1180 (m), 1160 (s), 1094 (s), 1068 (w), 1050 (w), 1032 (w), 1016 
(m), 994 (w), 930 (w), 912 (w), 896 (w), 842 (vs), 812 (m), 778 (m), 756 (m), 724 (m), 704 
(m), 692 (m), 664 (s), 624 (m). 
1H-NMR (300 MHz, CDCl3): δ = 8.23 (s, 4H), 7.91-7.78 (m, 2H), 7.16-7.11 (m, 2H), 5.93-
5.76 (m, 1H), 5.66 (s, 2H), 5.55-5.44 (m, 1H), 5.33-5.25 (m, 1H), 4.51 (s, 2H), 4.44 (q, 
J = 7.1 Hz, 2H), 4.04-4.02 (m, 2H), 3.61 (s, 3H), 2.11 (s, 3H), 1.44 (t, J = 7.1 Hz, 3H), 0.42 
ppm (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 174.5, 165.8, 154.8, 153.0, 143.2, 139.2, 135.8, 132.9, 
132.6, 131.8, 130.0, 129.7, 129.5, 127.7, 120.4, 91.1, 81.6, 73.3, 61.4, 57.8, 49.4, 37.1, 23.8, 
21.2, 14.3, -1.8 ppm. 
HRMS (ESI): m/z calc. for [C32H37N5O5SSi+H+] 632.2357; found: 632.2368. 
 
Synthesis of ethyl 4-(2-iodo-9-(methoxymethyl)-8-(3-methoxyphenyl)-9H-purin-6-
yl)benzoate (22a) 
 
 
A microwave vial was charged with CsF (335 mg, 2.2 mmol) which was dried under high 
vacuum (10-3 mbar) at 120 °C for 3 h. Ethyl 4-(9-(methoxymethyl)-8-(3-methoxyphenyl)-2-
(trimethylsilyl)-9H-purin-6-yl)benzoate (21d, 543 mg, 1.1 mmol), I2 (419 mg, 1.65 mmol), 
THF (5 mL) and CH3CN (5 mL) were successively added. The microwave vial was sealed 
and the reaction mixture was stirred under microwave irradiation at 110 °C for 12 h. The 
excess iodine was quenched with Na2S2O3(sat) (5 mL) and the mixture was diluted with EtOAc 
(5 mL). The aqueous layer was extracted with EtOAc (2 x 5 mL), the combined organic layers 
were washed with NaCl(sat) (10 mL) and were dried (Na2SO4). After concentration via rotary 
evaporation, the crude mixture was purified by flash column chromatography (silicagel, 
isohexane/ CH2Cl2 = 1:6) to afford ethyl 4-(2-iodo-9-(methoxymethyl)-8-(3-methoxyphenyl)-
9H-purin-6-yl)benzoate (22a, 484 mg, 80%) as a white powdery solid. 
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mp (°C): 164-165. 
IR (ATR) ν~  (cm-1): 3006 (w), 2980 (w), 2970 (w), 2942 (w), 2908 (w), 2838 (vw), 1706 
(m), 1568 (m), 1556 (m), 1486 (m), 1464 (w), 1382 (w), 1368 (w), 1352 (w), 1320 (s), 1304 
(m), 1274 (s), 1246 (vs), 1210 (m), 1188 (m), 1164 (m), 1136 (s), 1126 (s), 1102 (s), 1080 
(m), 1046 (s), 1020 (m), 948 (m), 910 (m), 892 (m), 880 (m), 872 (m), 848 (w), 796 (m), 772 
(s), 728 (w), 702 (m), 696 (m), 670 (w), 654 (m), 608 (vw). 
1H-NMR (600 MHz, CDCl3): δ = 8.94 (d, J = 8.4 Hz, 2H), 8.18 (d, J = 9.0 Hz, 2H), 7.72 
(ddd, J = 7.2, 1.2, 0.6 Hz, 1H), 7.69 (dd, J = 2.4, 1.2 Hz, 1H), 7.48 (t, J = 7.8 Hz, 1H), 7.13 
(ddd, J = 8.4, 3.0, 1.2 Hz, 1H), 5.62 (s, 2H), 4.42 (q, J = 7.2 Hz, 2H), 3.90 (s, 3H), 3.60 (s, 
3H), 1.43 (t, J = 7.2 Hz, 3H) ppm. 
13C-NMR (150 MHz, CDCl3): δ = 166.2, 159.9, 156.2, 156.0, 153.8, 138.6, 132.6, 130.8, 
130.2, 129.9, 129.7, 129.4, 122.2, 118.9, 117.5, 115.0, 73.5, 61.2, 57.8, 55.5, 14.3 ppm. 
MS (70 eV, EI): m/z (%) = 544 (13), 513 (18), 418 (11), 388 (21), 387 (35), 58 (33), 45 (24), 
44 (13), 43 (100). 
HRMS (EI): m/z calc. for [C23H21IN4O4] 544.0607; found: 544.0594. 
 
Synthesis of ethyl 4-(6-(4-chlorophenyl)-2-iodo-9-(methoxymethyl)-9H-purin-8-
yl)benzoate (22b) 
 
 
A microwave vial was charged with CsF (304 mg, 2.0 mmol) which was dried under high 
vacuum (10-3 mbar) at 120 °C for 3 h. Ethyl 4-(6-(4-chlorophenyl)-9-(methoxymethyl)-2-
(trimethylsilyl)-9H-purin-8-yl)benzoate (21h, 494 mg, 1.0 mmol), I2 (355 mg, 1.4 mmol), 
THF (1 mL) and CH3CN (1 mL) were successively added. The microwave vial was sealed 
and the reaction mixture was stirred under microwave irradiation at 110 °C for 12 h. The 
excess iodine was quenched with Na2S2O3(sat) (5 mL) and the solution was diluted with EtOAc 
(5 mL). The aqueous layer was extracted with EtOAc (2 x 5 mL), the combined organic layers 
were washed with NaCl(sat) (10 mL) and were dried (Na2SO4). After concentration via rotary 
evaporation, the crude mixture was purified by flash column chromatography (silicagel, 
C. Experimental Section 
 
127 
isohexane/ EtOAc = 10:1) to afford ethyl 4-(6-(4-chlorophenyl)-2-iodo-9-(methoxymethyl)-
9H-purin-8-yl)benzoate (22b, 266 mg, 49%) as a white powder. 
 
mp (°C): 162-164. 
IR (ATR) ν~  (cm-1): 3074 (vw), 2982 (w), 2938 (w), 2906 (w), 2874 (vw), 2818 (vw), 1726 
(s), 1586 (m), 1566 (s), 1554 (m), 1492 (m), 1478 (m), 1462 (w), 1444 (w), 1434 (w), 1400 
(m), 1376 (w), 1366 (w), 1342 (w), 1316 (m), 1292 (m), 1274 (s), 1250 (s), 1228 (m), 1196 
(m), 1180 (m), 1156 (w), 1140 (m), 1126 (m), 1110 (s), 1098 (m), 1080 (vs), 1036 (m), 1014 
(m), 966 (m), 940 (m), 876 (m), 866 (w), 838 (m), 804 (w), 794 (m), 774 (m), 716 (m), 694 
(m), 666 (w), 656 (w), 628 (w). 
1H-NMR (300 MHz, CDCl3): δ = 8.79 (d, J = 7.8 Hz, 2H), 8.21 (s, 4H), 7.76 (d, J = 8.4 Hz, 
2H), 5.58 (s, 2H), 4.43 (q, J = 6.9 Hz, 2H), 3.59 (s, 3H), 1.44 ppm (t, J = 6.9 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 165.7, 155.8, 154.5, 154.0, 137.9, 132.9, 132.8, 132.2, 
131.3, 130.2, 130.0, 129.7, 128.8, 119.3, 73.4, 61.4, 57.7, 14.3. 
MS (70 eV, EI): m/z (%) = 548 (48), 520 (17), 518 (49), 517 (100), 391 (18), 130 (11), 128 
(18), 127 (11), 45 (81). 
HRMS (EI): m/z calc. for [C22H18ClIN4O3] 548.0112; found: 548.0105. 
 
Synthesis of ethyl 4-(2-(cyclohex-2-en-1-yl)-9-(methoxymethyl)-8-(3-methoxyphenyl)-9H-
purin-6-yl)benzoate (24a) 
 
 
Ethyl 4-(2-iodo-9-(methoxymethyl)-8-(3-methoxyphenyl)-9H-purin-6-yl)benzoate (22a, 
544 mg, 1.0 mmol) was magnesiated according to TP5 and a solution of CuCN·2LiCl 
(1.65 mL, 1.0 M in THF, 1.65 mmol) was added dropwise to the reaction mixture at -78 °C. 
The solution was warmed up to -40 °C and 3-bromocyclohexene (322 mg, 2.0 mmol) was 
added dropwise. The reaction mixture was warmed up to -10 °C within 3 h and quenched with 
NH4Cl(sat)/ NH3(conc) (9 mL/ 1 mL). The aqueous layer was extracted with EtOAc (2 x 10 mL), 
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the combined organic layers were washed with NaCl(sat) (10 mL) and were dried (Na2SO4). 
After concentration via rotary evaporation, the crude mixture was purified by flash column 
chromatography (silicagel, isohexane/ EtOAc gradient = 27:4, 21:4) to afford ethyl 4-(2-
(cyclohex-2-en-1-yl)-9-(methoxymethyl)-8-(3-methoxyphenyl)-9H-purin-6-yl)benzoat (24a, 
342 mg, 69%) as a pale yellow powdery solid. 
 
mp (°C): 145-147. 
IR (ATR) ν~  (cm-1): 3022 (vw), 2986 (w), 2930 (w), 2910 (w), 2890 (w), 2836 (w), 1714 (s), 
1610 (vw), 1578 (s), 1558 (m), 1510 (w), 1478 (m), 1466 (m), 1448 (w), 1424 (w), 1406 (w), 
1366 (m), 1354 (m), 1314 (m), 1282 (vs), 1248 (s), 1236 (s), 1216 (m), 1206 (m), 1182 (m), 
1154 (m), 1126 (m), 1100 (s), 1086 (s), 1048 (m), 1028 (s), 972 (w), 962 (w), 908 (m), 896 
(m), 876 (m), 860 (w), 816 (w), 796 (m), 776 (m), 758 (m), 734 (w), 716 (w), 700 (s), 666 
(m), 650 (w). 
1H-NMR (300 MHz, CDCl3): δ = 9.05-9.03 (m, 2H), 8.23-8.21 (m, 2H), 7.76-7.73 (m, 2H), 
7.50-7.47 (m, 1H), 7.12 (ddd, J = 8.4, 2.7, 0.9 Hz, 1H), 6.16-6.13 (m, 1H), 5.93-5.90 (m, 1H), 
5.69 (s, 2H), 4.43 (q, J = 7.2 Hz, 2H), 3.95-3.91 (m, 4H), 3.63 (s, 3H), 2.31-2.27 (m, 1H), 
2.22-2.10 (m, 3H), 2.03-1.97 (m, 1H), 1.83-1.76 (m, 1H), 1.44 ppm (t, J = 7.2 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 167.2, 166.5, 159.9, 156.1, 155.6, 152.0, 140.2, 131.9, 
130.3, 130.1, 129.8, 129.6, 129.1, 129.0, 127.8, 122.1, 117.1, 114.9, 73.3, 61.1, 57.8, 55.5, 
44.7, 28.8, 25.0, 21.6, 14.3 ppm. 
MS (70 eV, EI): m/z (%) = 500 (6), 499 (31), 498 (100), 497 (15), 469 (8), 453 (13), 432 (6), 
425 (7), 349 (7), 45 (12). 
HRMS (EI): m/z calc. for [C29H30N4O4] 498.2267; found: 498.2258. 
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Synthesis of ethyl 4-(2-((3-chlorophenyl)(hydroxy)methyl)-9-(methoxymethyl)-8-(3-
methoxyphenyl)-9H-purin-6-yl)benzoate (24b) 
 
 
Ethyl 4-(2-iodo-9-(methoxymethyl)-8-(3-methoxyphenyl)-9H-purin-6-yl)benzoate (22a, 
544 mg, 1.0 mmol) was magnesiated according to TP5 and 3-chlorobenzaldehyde (281 mg, 
2.0 mmol) was added dropwise. The mixture was stirred for 2 h and the temperature was 
slowly risen to 0 °C. The reaction mixture was quenched with H2O (10 mL) and the aqueous 
layer was extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with 
NaCl(sat) (10 mL) and were dried (Na2SO4). After concentration via rotary evaporation the 
crude mixture was purified by flash column chromatography (silicagel, 
isohexane/ EtOAc = 1:2) to afford ethyl 4-(2-((3-chlorophenyl)(hydroxy)methyl)-9-
(methoxymethyl)-8-(3-methoxy-phenyl)-9H-purin-6-yl)benzoate (24b, 524 mg, 94%) as a 
white powder. 
 
mp (°C): 134-136. 
IR (ATR) ν~  (cm-1): 3434 (br, w), 3068 (w), 2990 (m), 2938 (m), 2832 (w), 2360 (m), 2336 
(m), 1738 (w), 1722 (m), 1712 (m), 1692 (m), 1588 (m), 1574 (m), 1462 (m), 1354 (m), 1328 
(w), 1274 (vs), 1244 (s), 1212 (m), 1186 (m), 1154 (m), 1102 (s), 1056 (m), 1020 (m), 904 
(m), 872 (w), 850 (w), 786 (w), 776 (m), 764 (m), 728 (m), 706 (m), 690 (m). 
1H-NMR (300 MHz, CDCl3): δ = 9.01 (d, J = 8.4 Hz, 2H), (d, J = 8.4 Hz, 2H), 7.78-7.68 (m, 
3H), 7.58 (dt, J = 7.2, 1.8 Hz, 1H), 7.49 (t, J = 7.5 Hz, 1H), 7.33-7.20 (m, 2H), 7.13 (brd, 
J = 8.4 Hz, 1H), 6.04 (s, 1H), 5.67 (m, 2H), 5.27 (bs, 1H), 4.45 (q, J = 7.2 Hz, 2H), 3.91 (s, 
3H), 3.58 (s, 3H), 1.46 ppm (t, J = 7.2 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 166.2, 162.7, 159.9, 156.7, 156.0, 151.7, 144.7, 139.0, 
134.0, 132.4, 130.1, 130.0, 129.7, 129.7, 129.6, 129.4, 127.6, 126.8, 124.7, 122.1, 117.3, 
114.9, 74.7, 73.6, 61.2, 57.9, 55.4, 14.3 ppm. 
HRMS (ESI): m/z calc. for [C30H27ClN4O5+H+] 559.1748; found: 559.1751. 
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Synthesis of ethyl 4-(2-((dimethylamino)methyl)-9-(methoxymethyl)-8-(3-
methoxyphenyl)-9H-purin-6-yl)benzoate (24c) 
 
 
Ethyl 4-(2-iodo-9-(methoxymethyl)-8-(3-methoxyphenyl)-9H-purin-6-yl)benzoate (22a, 
544 mg, 1.0 mmol) was magnesiated according to TP5 and ZnCl2 (1.65 mL, 1.0 M in THF, 
1.65 mmol) was added dropwise to the reaction mixture at -78 °C. The solution was warmed 
up to 0 °C within 1 h. The reaction mixture was added dropwise to a solution of N-methyl-N-
methylenemethanaminium 2,2,2-trifluoroacetate100 (2.0 mL, 1.0 M solution in CH2Cl2, 
2.0 mmol) at 0 °C, was stirred for 2 h and then quenched with H2O (10 mL). After extraction 
of the aqueous layer with EtOAc (2 x 10 mL), the combined organic layers were washed with 
NaCl(sat) (10 mL) and were dried (Na2SO4). After concentration via rotary evaporation, the 
crude mixture was purified by flash column chromatography (silicagel, EtOAc/ MeOH = 9:1) 
to afford ethyl 4-(2-((dimethylamino)methyl)-9-(methoxymethyl)-8-(3-methoxyphenyl)-9H-
purin-6-yl)benzoate (24c, 406 mg, 86%) as an orange powdery solid. 
 
mp (°C): 120-121. 
IR (ATR) ν~  (cm-1): 3096 (vw), 3070 (vw), 2976 (w), 2936 (w), 2820 (w), 2770 (w), 1714 
(s), 1578 (s), 1558 (m), 1508 (w), 1484 (m), 1472 (m), 1354 (m), 1336 (m), 1314 (m), 1280 
(vs), 1256 (s), 1238 (s), 1208 (m), 1182 (m), 1156 (m), 1124 (m), 1100 (s), 1086 (s), 1046 (s), 
1026 (s), 976 (w), 910 (w), 896 (w), 868 (m), 860 (m), 798 (w), 772 (m), 758 (m), 736 (m), 
722 (w), 700 (s), 672 (m). 
1H-NMR (300 MHz, CDCl3): 9.05-9.01 (m, 2H), 8.24-8.20 (m, 2H), 7.77-7.73 (m, 2H), 7.49 
(t, J = 8.0 Hz, 1H), 7.13 (ddd, J = 8.4, 2.6, 1.0 Hz, 1H), 5.72 (s, 2H), 4.42 (q, J = 7.1 Hz, 2H), 
4.07 (s, 2H), 3.92 (s, 3H), 3.61 (s, 3H), 2.57 (s, 6H), 1.43 ppm (t, J = 7.1 Hz, 3H). 
                                                 
100
 (a) Ahond, A.; Cavé, A.; Kann-Fan, C.; Husson, H.; de Rostolan, J.; Potier, P. J. Am. Chem. Soc. 1968, 90, 
5622; (b) Holy, N.; Fowler, R.; Burnett, E.; Lorenz, R. Tetrahedron 1979, 35, 613. 
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13C-NMR (75 MHz, CDCl3): δ = 166.4, 159.9, 156.1, 155.9, 152.2, 139.8, 132.1, 130.1, 
130.0, 129.8, 129.6, 129.5, 122.1, 117.2, 114.9, 73.3, 65.4, 61.1, 57.5, 55.5, 45.3, 14.3 ppm. 
MS (70 eV, EI): m/z (%) = 474 (0.5), 433 (28), 432 (100), 402 (8), 401 (10), 388 (10), 45 (9). 
HRMS (EI): m/z calc. for [C26H29N5O4] 475.2220; found: 475.2140. 
 
Synthesis of ethyl 4-(9-(methoxymethyl)-8-(3-methoxyphenyl)-2-(3-(trifluoromethyl)-
phenyl)-9H-purin-6-yl)benzoate (24d) 
 
 
Ethyl 4-(2-iodo-9-(methoxymethyl)-8-(3-methoxyphenyl)-9H-purin-6-yl)benzoate (22a, 
544 mg, 1.0 mmol) was magnesiated according to TP5 and ZnCl2 (1.65 mL, 1.0 M in THF, 
1.65 mmol) was added dropwise to the reaction mixture at -78 °C. The solution was warmed 
up to -20 °C within 1 h, Pd(dba)2 (17 mg, 3 mol%, 0.03 mmol), P(o-furyl)3 (14 mg, 6 mol%, 
0.06 mmol) and 3-iodobenzotrifluoride (505 mg, 1.8 mmol) were added. The solution was 
stirred for 4 h at 25 °C. H2O (10 mL) and EtOAc (10 mL) were added, the aqueous layer was 
extracted with EtOAc (2 x 10 mL), the combined organic layers were washed with NaCl(sat) 
(10 mL) and were dried (Na2SO4). After concentration via rotary evaporation the crude 
mixture was purified by flash column chromatography (silicagel, isohexane/ CH2Cl2 = 1:2) to 
afford ethyl 4-(9-(methoxymethyl)-8-(3-methoxyphenyl)-2-(3-(trifluoromethyl)phenyl)-9H-
purin-6-yl)benzoate (24d, 370 mg, 65%) as a white powdery solid. 
 
mp (°C): 153-154. 
IR (ATR) ν~  (cm-1): 2984 (vw), 2958 (vw), 2936 (vw), 2906 (vw), 1716 (m), 1600 (w), 1580 
(m), 1560 (m), 1506 (vw), 1486 (w), 1472 (w), 1442 (w), 1404 (w), 1380 (w), 1368 (m), 1350 
(w), 1324 (s), 1280 (vs), 1242 (s), 1216 (m), 1170 (m), 1160 (m), 1110 (s), 1098 (s), 1050 
(m), 1022 (m), 958 (vw), 916 (w), 900 (w), 872 (w), 862 (w), 836 (vw), 802 (w), 790 (w), 774 
(m), 754 (w), 730 (w), 694 (m), 674 (m). 
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1H-NMR (600 MHz, CDCl3): δ = 9.13 (d, J = 8.4 Hz, 2H), 8.93 (s, 1H), 8.88 (d, J = 7.8 Hz, 
1H), 8.27 (d, J = 8.4 Hz, 2H), 7.79 (bd, J = 7.8 Hz, 1H), 7.77 (dd, J = 2.4, 1.8 Hz, 1H), 7.75 
(bd, J = 7.8 Hz, 1H), 7.66 (t, J = 7.8 Hz, 1H), 7.51 (t, J = 7.8 Hz, 1H), 7.15 (ddd, J = 8.4, 3.0, 
1.2 Hz, 1H), 5.77 (s, 2H), 4.44 (q, J = 7.2 Hz, 2H), 3.93 (s, 3H), 3.69 (s, 3H), 1.45 ppm (t, 
J = 7.2 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 166.4, 159.9, 156.9, 156.6, 156.3, 152.2, 139.9, 138.9, 
132.2, 131.4, 131.0 (q, 2JC-F = 33 Hz), 130.2, 130.1, 129.9, 129.8, 129.7, 129.0, 126.6 (q, 3JC-
F = 4 Hz), 124.9 (q, 3JC-F = 4 Hz), 124.2 (q, 1JC-F = 272 Hz), 122.1, 117.3, 114.9, 73.5, 61.1, 
57.9, 55.5, 14.3 ppm. 
19F-NMR (282 MHz, CDCl3): δ = -62.6 ppm. 
HRMS (EI): m/z calc. for [C30H25F3N4O4+H+] 563.1906; found: 563.1896. 
 
Synthesis of ethyl 4-(2-(4-bromophenyl)-9-(methoxymethyl)-8-(3-methoxyphenyl)-9H-
purin-6-yl)benzoate (24e) 
 
 
Ethyl 4-(2-iodo-9-(methoxymethyl)-8-(3-methoxyphenyl)-9H-purin-6-yl)benzoate (22a, 
544 mg, 1.0 mmol) was magnesiated according to TP5 and ZnCl2 (1.65 mL, 1.0 M in THF, 
1.65 mmol) was added dropwise to the reaction mixture at -78 °C. The solution was warmed 
up to -20 °C within 1 h, Pd(dba)2 (17 mg, 3 mol%, 0.03 mmol), P(o-furyl)3 (14 mg, 6 mol%, 
0.06 mmol) and 1-bromo-4-iodobenzene (438 mg, 1.8 mmol) were added at -20 °C. The 
solution was stirred for 4 h at 25 °C. H2O (10 mL) and EtOAc (10 mL) were added. The 
aqueous layer was extracted with EtOAc (2 x 10 mL), the combined organic layers were 
washed with NaCl(sat) (10 mL) and were dried (Na2SO4). After concentration via rotary 
evaporation the crude mixture was purified by flash column chromatography (silicagel, 
isohexane/ CH2Cl2 gradient = 1:2 to 1:3) to afford ethyl 4-(2-(4-bromophenyl)-9-
(methoxymethyl)-8-(3-methoxyphenyl)-9H-purin-6-yl)benzoate (24e, 361 mg, 63%) as a 
white powdery solid. 
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mp (°C): 190-194. 
IR (ATR) ν~  (cm-1): 3784 (vw), 3698 (vw), 2988 (w), 2942 (w), 2830 (vw), 2360 (vw), 1714 
(m), 1582 (m), 1562 (m), 1486 (m), 1462 (m), 1398 (w), 1366 (m), 1314 (m), 1280 (vs), 1254 
(m), 1242 (s), 1214 (m), 1194 (w), 1162 (w), 1128 (m), 1100 (s), 1070 (m), 1050 (m), 1022 
(m), 1012 (m), 952 (w), 920 (w), 890 (w), 880 (w), 868 (w), 836 (w), 774 (m), 730 (w), 714 
(w), 698 (m), 674 (w). 
1H-NMR (600 MHz, CDCl3): δ = 9.09 (d, J = 8.4 Hz, 2H), 8.52 (d, J = 9.0 Hz, 2H), 8.23 (d, 
J = 9.0 Hz, 2H), 7.77 (d, J = 7.2 Hz, 1H), 7.75 (bs, 1H), 7.64 (d, J = 9.0 Hz, 2H), 7.49 (t, 
J = 7.8 Hz, 1H), 7.13 (dd, J = 7.8, 2.4 Hz, 1H), 5.70 (s, 2H), 4.43 (d, J = 7.2 Hz, 2H), 3.92 (s, 
3H), 3.66 (s, 3H), 1.44 (t, J = 7.2 Hz, 3H) ppm. 
13C-NMR (125 MHz, CDCl3): δ = 166.4, 159.9, 157.4, 156.3, 156.2, 152.0, 140.0, 137.0, 
132.1, 131.6, 130.1, 130.0, 129.8, 129.7, 129.7, 129.6, 124.8, 122.1, 117.2, 114.9, 73.4, 61.1, 
57.9, 55.5, 14.3 ppm. 
HRMS (ESI): m/z calc. for [C29H2679BrN4O4+H+] 573.1137; found: 573.1132. 
 
Synthesis of ethyl 4-(6-(4-chlorophenyl)-9-(methoxymethyl)-2-(4-methoxyphenyl)-9H-
purin-8-yl)benzoate (24f) 
 
 
Ethyl 4-(6-(4-chlorophenyl)-2-iodo-9-(methoxymethyl)-9H-purin-8-yl)benzoate (22b, 
548 mg, 1.0 mmol) was magnesiated according to TP5 and ZnCl2 (1.65 mL, 1.0 M in THF, 
1.65 mmol) was added dropwise to the reaction mixture at -78 °C. The solution was warmed 
up to -20 °C within 1 h, Pd(dba)2 (17 mg, 3 mol%, 0.03 mmol), P(o-furyl)3 (14 mg, 6 mol%, 
0.06 mmol) and 1-iodo-4-methoxybenzene (416 mg, 1.8 mmol) were added at -20 °C. The 
solution was stirred for 12 h at 25 °C. H2O (10 mL) and EtOAc (10 mL) were added. The 
aqueous layer was extracted with EtOAc (2 x 10 mL), the combined organic layers were 
washed with NaCl(sat) (10 mL) and were dried (Na2SO4). After concentration via rotary 
evaporation the crude mixture was purified by flash column chromatography (silicagel, 
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isohexane/ EtOAc = 21:4) to afford ethyl 4-(6-(4-chlorophenyl)-9-(methoxymethyl)-2-(4-
methoxyphenyl)-9H-purin-8-yl)benzoate (24f, 307 mg, 58%) as an off-white solid. 
 
mp (°C): 234-236. 
IR (ATR) ν~  (cm-1): 2980 (w), 2958 (vw), 2936 (w), 2904 (vw), 2874 (vw), 2834 (vw), 1722 
(s), 1610 (w), 1586 (s), 1556 (m), 1514 (w), 1490 (m), 1476 (w), 1452 (w), 1432 (w), 1398 
(m), 1370 (s), 1346 (m), 1300 (m), 1264 (s), 1250 (vs), 1218 (m), 1210 (m), 1188 (w), 1178 
(w), 1162 (s), 1098 (s), 1086 (s), 1076 (s), 1034 (m), 1014 (m), 960 (w), 950 (vw), 912 (m), 
880 (w), 872 (w), 848 (m), 842 (m), 820 (w), 800 (s), 778 (m), 748 (w), 726 (m), 718 (m), 
706 (m), 690 (m), 648 (w), 638 (vw). 
1H-NMR (600 MHz, CDCl3): δ = 9.00 (d, J = 8.4 Hz, 2H), 8.60 (d, J = 9.0 Hz, 2H), 8.27 (d, 
J = 9.0 Hz, 2H), 8.24 (d, J = 8.4 Hz, 2H), 7.55 (d, J = 8.4 Hz, 2H), 7.04 (d, J = 9.0 Hz, 2H), 
5.70 (s, 2H), 4.45 (q, J = 7.2 Hz, 2H), 3.91 (s, 3H), 3.67 (s, 3H), 1.45 ppm (t, J = 7.2 Hz, 3H). 
13C-NMR (125 MHz, CDCl3): δ = 165.9, 161.6, 158.6, 156.1, 154.2, 152.5, 137.0, 134.6, 
133.0, 132.3, 131.2, 130.8, 130.0, 129.8, 129.6, 128.8, 128.7, 113.8, 73.3, 61.3, 57.8, 55.4, 
14.3 ppm. 
MS (70 eV, EI): m/z (%) = 630 (24), 529 (22), 528 (67), 500 (12), 499 (37), 498 (35), 497 
(100), 484 (12), 483 (11), 349 (17), 175 (16), 45 (34). 
HRMS (EI): m/z calc. for [C29H25ClN4O4] 528.1564; found: 528.1560. 
 
Synthesis of ethyl 4-(9-(methoxymethyl)-8-(3-methoxyphenyl)-2-(pyridin-4-yl)-9H-
purin-6-yl)benzoate (24g) 
 
 
Ethyl 4-(2-iodo-9-(methoxymethyl)-8-(3-methoxyphenyl)-9H-purin-6-yl)benzoate (22a, 
544 mg, 1.0 mmol) was magnesiated according to TP5 and ZnCl2 (1.65 mL, 1.0 M in THF, 
1.65 mmol) was added dropwise to the reaction mixture at -78 °C. The solution was warmed 
up to -20 °C within 1 h, Pd(dba)2 (17 mg, 3 mol%, 0.03 mmol), P(o-furyl)3 (14 mg, 6 mol%, 
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0.06 mmol) and 4-iodopyridine (380 mg, 1.8 mmol) were added at -20 °C. The solution was 
stirred for 4 h at 25 °C. H2O (10 mL) and EtOAc (10 mL) were added. The aqueous layer was 
extracted with EtOAc (2 x 10 mL), the combined organic layers were washed with NaCl(sat) 
(10 mL) and were dried (Na2SO4). After concentration via rotary evaporation, the crude 
mixture was purified by flash column chromatography (silicagel, CH2Cl2/ EtOAc 
gradient = 5:1, 1:1) to afford ethyl 4-(9-(methoxymethyl)-8-(3-methoxyphenyl)-2-(pyridin-4-
yl)-9H-purin-6-yl)benzoate (24g, 268 mg, 55%) as a white solid. 
 
mp (°C): 147-148. 
IR (ATR) ν~  (cm-1): 3444 (vw), 3070 (vw), 2988 (vw), 2936 (w), 2906 (vw), 2832 (vw), 
2360 (vw), 2342 (vw), 2332 (vw), 1712 (m), 1692 (m), 1588 (s), 1580 (m), 1562 (m), 1510 
(w), 1488 (m), 1474 (m), 1466 (m), 1426 (w), 1416 (w), 1354 (m), 1322 (w), 1274 (vs), 1238 
(s), 1212 (m), 1186 (m), 1154 (m), 1104 (s), 1056 (s), 1030 (m), 1020 (m), 902 (m), 872 (m), 
850 (w), 812 (vw), 786 (m), 776 (m), 764 (m), 728 (m), 706 (m), 690 (m). 
1H-NMR (300 MHz, CDCl3): δ = 9.11 (d, J = 8.7 Hz, 2H), 8.81 (d, J = 4.2 Hz, 2H), 8.50 (d, 
J = 6.0 Hz, 2H), 8.23 (d, J = 8.7 Hz, 2H), 7.78 (m, 2H), 7.50 (t, J = 8.1 Hz, 1H), 7.15 (ddd, 
J = 8.4, 2.7, 0.9 Hz, 1H), 5.75 (s, 2H), 4.43 (q, J = 7.2 Hz, 2H), 3.92 (s, 3H), 3.68 (s, 3H), 
1.44 ppm (t, J = 7.2 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 166.3, 160.0, 157.0, 156.2, 155.9, 152.2, 150.2, 145.5, 
139.7, 132.3, 130.6, 130.2, 129.8, 129.7, 129.7, 122.2, 122.1, 117.4, 115.0, 73.6, 61.2, 57.9, 
55.5, 14.3 ppm. 
HRMS (ESI): m/z calc. for [C28H25N5O4+H+] 496.1985; found: 496.1975. 
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Synthesis of ethyl 4-(9-(methoxymethyl)-8-(3-methoxyphenyl)-2-((trimethylsilyl)-
ethynyl)-9H-purin-6-yl)benzoate (24h) 
 
N
N N
N
OMe
CO2Et
MeO
TMS
 
Pd(dba)2 (17 mg, 3 mol%, 0.03 mmol), P(o-furyl)3 (14 mg, 6 mol%, 0.06 mmol), CuI (6 mg, 
3 mol%, 0.03 mmol), NEt3 (122 mg, 1.2 mmol) and trimethylsilylacetylene (98 mg, 
1.0 mmol) were successively added to a solution of ethyl 4-(2-iodo-9-(methoxymethyl)-8-(3-
methoxyphenyl)-9H-purin-6-yl)benzoate (22a, 544 mg, 1.0 mmol) in THF (10 mL). The 
solution was stirred for 24 h and H2O (10 mL) was added. After extraction with EtOAc (2 x 
10 mL), the combined organic layers were washed with NaCl(sat) (10 mL) and dried (Na2SO4). 
The solvents were evaporated in vacuo. Purification via column chromatography (silicagel, 
isohexane/ CH2Cl2 = 1:1) yielded ethyl 4-(9-(methoxymethyl)-8-(3-methoxyphenyl)-2-
((trimethylsilyl)-ethynyl)-9H-purin-6-yl)benzoate (24h, 388 mg, 76%) as an off-white solid. 
 
m.p (°C): 175-177. 
IR (ATR): 3000 (vw), 2984 (vw), 2964 (vw), 2940 (vw), 2836 (vw), 2164 (vw), 1720 (m), 
1612 (w), 1586 (w), 1572 (m), 1560 (m), 1468 (m), 1434 (w), 1400 (w), 1360 (s), 1308 (w), 
1276 (s), 1252 (m), 1210 (w), 1180 (w), 1152 (m), 1124 (w), 1104 (m), 1086 (m), 1058 (w), 
1032 (m), 996 (w), 916 (w), 900 (w), 866 (s), 844 (vs), 794 (m), 772 (s), 758 (m), 730 (m), 
722 (w), 702 (m), 696 (m), 674 (w), 646 (w). 
1H-NMR (CDCl3, 600 MHz): δ = 9.00 (d, J = 9.0 Hz, 2H), 8.21 (d, J = 9.0 Hz, 2H), 7.75 
(ddd, J = 7.8 Hz, 1.2 Hz, 0.6 Hz, 1H), 7.72 (dd, J = 2.4 Hz, 1.2 Hz, 1H), 7.48 (t, J = 8.4 Hz, 
1H), 7.13 (ddd, J = 8.4 Hz, 3.0Hz, 1.2 Hz, 1H), 5.69 (s, 2H), 4.42 (q, J = 7.2 Hz, 2H), 3.90 (s, 
3H), 3.61 (s, 3H), 1.43 (t, J = 7.2 Hz, 3H), 0.36 ppm (s, 9H). 
13C-NMR (CDCl3, 125 MHz): δ = 166.3, 159.9, 157.0, 155.3, 152.8, 145.5, 139.2, 132.3, 
130.2, 130.1, 130.0, 129.7, 129.6, 122.2, 117.4, 114.9, 103.5, 92.1, 73.3, 61.1, 57.6, 55.5, 
14.3, -0.2 ppm. 
HRMS (ESI): m/z calc. for [C28H31N4O4Si+H+] 515.2115, found: 515.2104. 
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3. Functionalization of the benzo[c][1,2,5]thiadiazole and 
benzo[c][1,2,5]oxadiazole scaffold 
3.1. Functionalization of the benzo[c][1,2,5]thiadiazole scaffold via Zn-, 
Mg- and Mn-Intermediates  
 
Synthesis of 5,6-dibromo-4-iodobenzo[c][1,2,5]thiadiazole (29) 
 
 
In a Schlenk-tube TMPMgCl·LiCl (1.0 mL, 1.1 M in THF, 1.1 mmol) was added dropwise to 
a solution of 5,6-dibromobenzo[c][1,2,5]thiadiazole (28, 294 mg, 1.0 mmol) in THF (4 mL) at 
-20 °C. After stirring at this temperature for 10 min, I2 (2.0 mL, 1.0 M in THF, 2.0 mmol) was 
added dropwise and the reaction mixture was slowly warmed up to 25 °C in 5 h. NH4Cl(sat) 
(10 mL) and Na2S2O3(sat) (5 mL) were added, the aqueous layer was extracted with CH2Cl2 (3 
x 30 mL), the combined organic layers were dried (MgSO4) and the solvent was evaporated in 
vacuo. The crude residue was purified by flash chromatography (silicagel, 
pentane/ Et2O = 200:1), providing the compound 29 (200 mg, 48%) as a yellow solid. 
 
mp (°C): 171-172. 
IR (ATR) ν~  (cm-1): 3066 (vw), 2922 (w), 2852 (vw), 1712 (w), 1560 (w), 1472 (m), 1418 
(m), 1368 (w), 1330 (w), 1296 (w), 1244 (w), 1230 (s), 1176 (w), 1160 (w), 1118 (w), 1104 
(m), 1096 (m), 964 (w), 952 (m), 908 (m), 876 (m), 856 (vs), 840 (s), 758 (w), 734 (w), 718 
(m), 682 (w), 622 (w). 
1H-NMR (300 MHz, CDCl3): δ = 8.38 (s, 1H) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 156.2, 150.7, 135.5, 126.2, 124.6, 95.8 ppm. 
MS (70 eV, EI): m/z (%) = 422 (56), 420 (100), 418 (53), 214 (25), 212 (23), 133 (19), 128 
(42), 127 (33), 80 (20), 43 (22). 
HRMS (EI): m/z calc. for [C6HBr2IN2S] 417.7272; found: 417.7274. 
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Synthesis of 5,6-bis((trimethylsilyl)methyl)benzo[c][1,2,5]thiadiazole (30) 
 
 
In a Schlenk-tube TMSCH2MgCl (3.39 mL, 1.18 M in Et2O, 4.0 mmol) was added dropwise 
to dry ZnCl2 (550 mg, 4.0 mmol) in THF (4 mL) at 0 °C and the mixture was warmed up to 
25 °C. 5,6-Dibromobenzo[c][1,2,5]thiadiazole (28, 294 mg, 1.0 mmol), Pd(OAc)2 (5 mg, 
2 mol%, 0.02 mmol) and SPhos (16 mg, 4 mol%, 0.04 mmol) were successively added. After 
stirring for 30 min, NH4Cl(sat) (10 mL) was added, the aqueous layer was extracted with 
CH2Cl2 (3 x 30 mL), the combined organic layers were dried (MgSO4) and the solvent was 
evaporated in vacuo. The crude residue was purified by flash chromatography (silicagel, 
pentane/ Et2O = 100:1), providing the compound 30 (283 mg, 92%) as a colorless solid. 
 
mp (°C): 90-91. 
IR (ATR) ν~  (cm-1): 2954 (w), 2898 (vw), 1492 (w), 1458 (w), 1420 (w), 1400 (w), 1268 
(w), 1246 (m), 1160 (w), 1140 (m), 1084 (w), 886 (w), 868 (m), 834 (vs), 820 (s), 778 (m), 
758 (w), 712 (w), 694 (m), 664 (w). 
1H-NMR (300 MHz, CDCl3): δ = 7.53 (s, 2H), 2.24 (s, 4H), 0.04 (s, 18H) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 153.6, 142.7, 117.7, 25.5, -1.4 ppm. 
MS (70 eV, EI): m/z (%) = 308 (11), 295 (6), 294 (11), 291 (43), 74 (9), 73 (100), 45 (17), 43 
(12). 
HRMS (EI): m/z calc. for [C14H24N2SSi2] 308.1199; found: 308.1192. 
 
Synthesis of 4-bromo-7-(4-methoxyphenyl)benzo[c][1,2,5]thiadiazole (32) 
 
 
In a Schlenk-tube dry LiCl (106 mg, 2.5 mmol), Mg (61 mg, 2.5 mmol), ZnCl2 (2.5 mL, 1.0 M 
in THF, 2.5 mmol) and THF (5 mL) were successively added. At 0 °C 4,7-
dibromobenzo[c][1,2,5]thiadiazole (31, 588 mg, 2.0 mmol) was added and the reaction 
mixture stirred for 2 h. The resulting brown solution was canulated to a mixture of Pd(dba)2 
(30 mg, 2 mol%, 0.04 mmol), P(o-furyl)3 (16 mg, 4 mol%, 0.08 mmol) and 4-iodoanisole 
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(374 mg, 1.6 mmol) in THF (2 mL). After stirring at 25 °C for 5 h, NH4Cl(sat) (20 mL) was 
added, the aqueous layer was extracted with CH2Cl2 (3 x 40 mL), the combined organic layers 
were dried (MgSO4) and the solvent was evaporated in vacuo. The crude residue was purified 
by flash chromatography (silicagel, pentane/ Et2O = 50:1), providing the compound 32 
(300 mg, 58%) as a yellow solid. 
 
mp (°C): 133-136. 
IR (ATR) ν~  (cm-1): 3048 (vw), 2990 (vw), 2934 (vw), 2896 (vw), 2836 (vw), 1896 (vw), 
1608 (m), 1530 (w), 1508 (m), 1482 (m), 1462 (w), 1454 (w), 1438 (w), 1342 (vw), 1308 (w), 
1282 (m), 1272 (w), 1248 (s), 1180 (s), 1152 (w), 1116 (w), 1084 (w), 1030 (s), 972 (vw), 
942 (w), 930 (w), 880 (s), 838 (m), 826 (vs), 796 (m), 732 (w), 654 (vw), 628 (vw). 
1H-NMR (300 MHz, CDCl3): δ = 7.91-7.84 (m, 3H), 7.52 (d, J = 7.5 Hz, 1H), 7.09-7.04 (m, 
2H), 3.90 (s, 3H) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 160.1, 153.9, 153.2, 133.6, 132.3, 130.3, 129.0, 127.4, 
114.1, 112.2, 55.4 ppm. 
MS (70 eV, EI): m/z (%) = 323 (16), 322 (100), 321 (15), 320 (98), 307 (35), 305 (35), 279 
(20), 277 (21), 198 (26). 
HRMS (EI): m/z calc. for [C13H9BrN2OS] 319.9619; found: 319.9615. 
 
Synthesis of 4,5,7-tribromobenzo[c][1,2,5]thiadiazole (33) 
 
 
In a Schlenk-tube TMP2Mn·2MgCl2·4LiCl (7.5 mL, 0.5 M in THF, 3.75 mmol) was added 
dropwise to a solution of 4,7-dibromobenzo[c][1,2,5]thiadiazole (31, 1.47 g, 5.0 mmol) in 
THF (5 mL) at 0 °C. After stirring at this temperature for 3 h, (BrCl2C)2 (7.5 mL, 1.0 M in 
THF, 7.5 mmol) was added dropwise and the reaction mixture was slowly warmed up to 
25 °C in 5 h. NH4Cl(sat) (20 mL) was added, the aqueous layer was extracted with CH2Cl2 (3 x 
40 mL), the combined organic layers were dried (MgSO4) and the solvent was evaporated in 
vacuo. The crude residue was purified by flash chromatography (silicagel, 
pentane/ Et2O = 100:1), providing compound 33 (1.3 g, 70%) as a yellow solid. 
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mp (°C): 153-154. 
IR (ATR) ν~  (cm-1): 1736 (vw), 1570 (w), 1540 (vw), 1508 (vw), 1488 (w), 1478 (w), 1452 
(w), 1368 (vw), 1302 (w), 1294 (w), 1260 (vw), 1222 (m), 1184 (w), 1138 (w), 1124 (w), 972 
(m), 940 (w), 878 (vs), 864 (m), 844 (m), 750 (w), 690 (w). 
1H-NMR (300 MHz, CDCl3): δ = 8.08 (s, 1H) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 153.5, 153.0, 135.9, 127.1, 116.6, 113.7 ppm. 
MS (70 eV, EI): m/z (%) = 376 (32), 374 (100), 372 (97), 370 (30), 295 (15), 293 (29), 291 
(14), 216 (18), 214 (19), 58 (24), 43 (67). 
HRMS (EI): m/z calc. for [C6HBr3N2S] 369.7411; found: 369.7413. 
 
Synthesis of (3-chlorophenyl)(4,6,7-tribromobenzo[c][1,2,5]thiadiazol-5-yl)methanone 
(35) 
 
N
S
N
Br Br
Br
O
Cl
 
In a Schlenk-tube TMP2Zn·2MgCl2·2LiCl (2.0 mL, 0.5 M in THF, 1.0 mmol) was added 
dropwise to a solution of 4,6,7-tribromobenzo[c][1,2,5]thiadiazole (33, 373 mg, 1.0 mmol) in 
THF (1 mL). After stirring for 3 h, CuCN·2LiCl (0.5 mL, 1.0 M in THF, 50 mol%, 0.5 mmol), 
3-chlorobenzoyl chloride (263 mg, 1.5 mmol) were successively added at -15 °C and the 
reaction mixture stirred for 3 h. NH4Cl(sat) (20 mL) and NH3(conc) (5 mL) were added, the 
aqueous layer was extracted with CH2Cl2 (3 x 40 mL), the combined organic layers were 
dried (MgSO4) and the solvent was evaporated in vacuo. The crude residue was purified by 
flash chromatography (silicagel, pentane/ Et2O = 20:1), providing the compound 35 (233 mg, 
46%) as a yellow solid. 
 
mp (°C): 195-198. 
IR (ATR) ν~  (cm-1): 3096 (w), 3072 (w), 2930 (w), 2872 (w), 1748 (w), 1722 (m), 1680 (s), 
1644 (m), 1622 (m), 1588 (m), 1570 (m), 1466 (w), 1448 (m), 1422 (m), 1380 (m), 1370 (m), 
1346 (w), 1278 (m), 1264 (vs), 1246 (vs), 1188 (s), 1172 (s), 1132 (s), 1074 (m), 1052 (m), 
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1000 (w), 968 (w), 942 (w), 908 (m), 884 (s), 846 (w), 810 (m), 788 (m), 758 (s), 738 (vs), 
720 (s), 672 (s), 604 (w). 
1H-NMR (300 MHz, CDCl3): δ = 7.89-7.88 (m, 1H), 7.74-7.71 (m, 1H), 7.66-7.63 (m, 1H), 
7.49-7.46 (m, 1H) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 190.7, 153.1, 151.4, 141.8, 135.7, 135.6, 134.7, 130.6, 
129.5, 129.4, 128.0, 123.8, 118.8, 111.3 ppm. 
MS (70 eV, EI): m/z (%) = 510 (28), 433 (55), 431 (78), 429 (33), 401 (16), 399 (16), 141 
(31), 139 (100), 111 (65), 75 (35). 
HRMS (EI): m/z calc. for [C13H4Br3ClN2OS] 507.7283; found: 507.7275. 
 
4-bromo-6-phenyl-8H-[1,2,5]thiadiazolo[3,4-g]indazole (36) 
 
 
In a round bottom flask, N2H4·H2O (0.5 g, 10.0 mmol) was added dropwise to a solution of 
(4,7-dibromobenzo[c][1,2,5]thiadiazol-5-yl)(phenyl)methanone (34, 398 mg, 1.0 mmol) in 
EtOH/ CHCl3 (6 mL each). The reaction mixture was stirred at 60 °C for 10 h, the solvent was 
evaporated in vacuo and the crude residue was purified by flash chromatography (silicagel, 
isohexane/ EtOAc gradient = 5:1 to 3:1), providing the compound 36 (214 mg, 65%) as a 
yellow solid. 
 
mp (°C): 270-272. 
IR (ATR) ν~  (cm-1): 3264 (m), 1746 (vw), 1610 (vw), 1516 (vw), 1496 (w), 1446 (w), 1396 
(w), 1362 (m), 1338 (w), 1274 (vw), 1246 (w), 1230 (w), 1140 (vw), 1112 (w), 1104 (w), 
1074 (w), 978 (w), 888 (m), 870 (vs), 838 (m), 764 (w), 718 (s), 694 (s), 674 (m), 634 (w). 
1H-NMR (400 MHz, d6-DMSO): δ = 8.47 (m, 1H), 7.99-7.90 (m, 2H), 7.63-7.45 (m, 3H) 
ppm. 
MS (70 eV, EI): m/z (%) = 333 (16), 332 (100), 331 (20), 330 (92), 329 (5), 218 (9), 164 (5), 
77 (15). 
HRMS (EI): m/z calc. for [C13H7BrN4S] 329.9575; found: 329.9566. 
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3.2. Synthesis of the BTD-COF precursor 40 
 
Synthesis of 4,7-bis(4-(trimethylsilyl)phenyl)benzo[c][1,2,5]thiadiazole (42) 
 
 
In a 250 mL Schlenk-flask bis(di-tert-butyl(4-dimethylaminophenyl)phosphine) 
dichloropalladium(II) (28 mg, 0.04 mmol) and 4,7-dibromobenzo[c][1,2,5]thiadiazole (31, 
1.47 g, 5.0 mmol) were successively added to a solution of (4-(trimethylsilyl)phenyl)zinc(II) 
chloride (36.4 mL, 0.55 M in THF, 20 mmol) and the resulting greenish reaction mixture was 
stirred at 50 °C for 3 h. After addition of NH4Cl(sat) (100 mL), the aqueous layer was extracted 
with CH2Cl2 (3 x 200 mL), the combined organic layers were dried (MgSO4) and the solvent 
was evaporated in vacuo. Purification via column chromatography (silicagel, pentane) 
afforded 4,7-bis(4-(trimethylsilyl)phenyl)benzo[c][1,2,5]thiadiazole (42, 1.6 g, 75%) as a 
bright yellow solid. 
 
mp (°C): 151-153. 
IR (ATR) ν~  (cm-1): 3016 (w), 2952 (w), 2894 (w), 1554 (w), 1480 (w), 1400 (w), 1247 (m), 
1095 (w), 837 (vs), 818 (s), 813 (s), 757 (m), 721 (m), 691 (w). 
1H-NMR (300 MHz, CDCl3): δ = 7.96-7.92 (m, 4H), 7.79 (s, 2H), 7.73-7.70 (m, 4H), 0.34 
ppm (s, 18H). 
13C-NMR (75 MHz, CDCl3): δ = 154.2, 140.8, 137.8, 133.7, 133.5, 128.5, 128.1, -1.1 ppm. 
MS (70 eV, EI): m/z (%) = 434 (10), 433 (32), 432 (79), 419 (17), 418 (40), 417 (100), 202 
(14), 201 (35), 73 (18), 57 (10). 
HRMS (EI): m/z calc. for [C24H28N2SSi2] 432.1512; found: 432.1509. 
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Synthesis of 4,7-bis(4-iodophenyl)benzo[c][1,2,5]thiadiazole (43) 
 
 
In a 500 mL round bottom flask 4,7-bis(4-(trimethylsilyl)phenyl)benzo[c][1,2,5]thiadiazole 
(42, 10 g, 23 mmol) was dissolved in CH2Cl2 (200 mL) and cooled to 0 °C. ICl (2.0 mL, 
excess) was added dropwise and the reaction mixture was stirred at 0 °C for 10 min. After 
warming up to 25 °C the solution was stirred for further 2 h. Filtration afforded 4,7-bis(4-
iodophenyl)benzo[c][1,2,5]thiadiazole (43, 11.6 g, 93%) as a yellow solid. 
 
mp (°C): 214-218. 
IR (ATR) ν~  (cm-1): 2920 (w), 2851 (w), 1586 (w), 1552 (w), 1472 (m), 1402 (w), 1116 (w), 
1102 (w), 1060 (w), 1006 (m), 972 (w), 943 (w), 886 (w), 849 (w), 806 (vs), 710 (w). 
1H-NMR (300 MHz, CDCl3): δ = 7.90-7.85 (m, 4H), 7.76 (s, 2H), 7.73-7.68 ppm (m, 4H). 
13C-NMR (75 MHz, CDCl3): δ = 153.8, 137.8, 136.7, 132.6, 131.0, 127.9, 94.6 ppm. 
MS (70 eV, EI): m/z (%) = 542 (6), 541 (21), 540 (100), 288 (11), 286 (9), 143 (6). 
HRMS (EI): m/z calc. for [C18H10I2N2S] 539.8654; found: 539.8650. 
 
Synthesis of 4,7-bis(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo 
[c][1,2,5]thiadiazole (40) 
 
 
In a 250 mL Schlenk-flask equipped with a  big stirring bar KOAc (4.9 g, 50 mmol) was dried 
under high vacuum (10-3 mbar) at 100 °C. After successive addition of 1,4-dioxane (100 mL), 
4,7-bis(4-iodophenyl)benzo[c][1,2,5]thiadiazole (43, 5.4 g, 10 mmol), and 4,4,4',4',5,5,5',5'-
octamethyl-2,2'-bi(1,3,2-dioxaborolane) (10.2 g, 40 mmol) the reaction mixture was degassed 
for 30 min. Pd(OAc)2 (90 mg, 0.4 mmol) and P(Cy)3 (220 mg, 0.8 mmol) were added and the 
resulting greenish reaction mixture was stirred at 80 °C for 24 h. After addition of NaHCO3(sat) 
(100 mL) the aqueous layer was extracted with Et2O (4 x 200 mL), the combined organic 
layers were dried (MgSO4) and the solvent was evaporated in vacuo. Recrystallization from 
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Et2O afforded 4,7-bis(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[c][1,2,5] 
thiadiazole (43, 4.1 g ,74%) as a bright yellow solid. 
 
mp (°C): 184-186. 
IR (ATR) ν~  (cm-1): 2975 (w), 1609 (w), 1550 (w), 1519 (w), 1396 (m), 1356 (vs), 1320 (m), 
1294 (m), 1214 (w), 1143 (s), 1122 (m), 1105 (m), 1084 (m), 1020 (w), 961 (w), 890 (w), 856 
(m), 821 (s), 744 (w), 657 (m). 
1H-NMR (600 MHz, CDCl3): δ = 8.00-7.95 (m, 8H), 7.80 (s, 2H), 1.37 ppm (s, 24H). 
13C-NMR (150 MHz, CDCl3): δ = 154.0, 140.0, 135.0, 133.5, 128.5, 128.2, 83.9, 24.9 ppm. 
MS (70 eV, EI): m/z (%) = 542 (10), 541 (34), 540 (100), 539 (44), 441 (14), 440 (11), 341 
(24), 340 (22), 339 (9). 
HRMS (EI): m/z calc. for [C30H34B2N2O4S] 540.2425; found: 540.2419. 
 
3.3. Synthesis of perylenedye precursors  
 
3.3.1. Typical procedures 6-8 
TP6: Typical procedure for the synthesis of reagent 44 
 
 
In a Schlenk-tube TMP2Mg·2LiCl (23.0 mL, 0.6 M in THF, 13.8 mmol) was added dropwise 
to a solution of benzo[c][1,2,5]thiadiazole (25, 1.4 g, 10 mmol) in THF (10 mL) at -40 °C. 
After 14 h of stirring at -40 °C, ZnCl2 (15 mL, 1.0 M in THF, 15 mmol) was added dropwise. 
Further stirring at -40 °C for 30 min and warming up to 25 °C provides the zinc reagent 44 in 
ca 85% yield as a dark brown solution (0.2 M in THF). 
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TP7: Typical procedure for the synthesis of reagent 47 
 
 
In a Schlenk-tube LiCl (170 mg, 4.0 mmol) was dried under vacuum (10-3 mbar) at 140 °C. 
After cooling, Mg (97 mg, 4.0 mmol), ZnCl2 (4.0 mL, 1.0 M in THF, 4.0 mmol) and 4-(4-
iodophenyl)benzo[c][1,2,5]thiadiazole (46, 676 mg, 2 mmol) were successively added. The 
reaction mixture was stirred for 2 h at 25 °C. Canulation to a second Schlenk-tube furnishes 
the zinc reagent 47 in ca 80% yield as a dark brown solution (0.3 M in THF). 
 
TP8: Typical procedure for the metalation of benzo[c][1,2,5]oxadiazole (51) 
 
 
In a Schlenk-tube TMPMgCl·LiCl (1.7 mL, 1.2 M in THF, 2.0 mmol) was added dropwise to 
a solution of benzo[c][1,2,5]oxadiazole (51, 220 mg, 1.8 mmol) in 2 mL THF at -5 °C. After 
14 h of stirring, ZnCl2 (2.1 mL, 1.0 M in THF, 2.1 mmol) was added dropwise. Further 
stirring at -5 °C for 30 min and warming up to 25 °C provides the desired zinc reagent in ca 
80% yield as a dark brown solution (0.25 M in THF). 
 
3.3.2. Synthesis of compounds 45-58 
Synthesis of 4-(4-(trimethylsilyl)phenyl)benzo[c][1,2,5]thiadiazole (45) 
 
 
Pd(dba)2 (35 mg, 2 mol%, 0.06 mmol), P(o-furyl)3 (28 mg, 4 mol% 0.12 mmol) and (4-
iodophenyl)trimethylsilane (1.24 g, 4.5 mmol) were successively added to the zinc reagent 44 
prepared by TP6 (15 mL, 0.2 M in THF, 3 mmol). After stirring at 25 °C for 24 h, the reaction 
mixture was quenched by the addition of NH4Cl(sat) (10 mL). The aqueous layer was extracted 
with CH2Cl2 (3 x 30 mL), the combined organic layers were dried (MgSO4) and the solvent 
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was evaporated in vacuo. Purification via column chromatography (silicagel, pentane) 
afforded 4-(4-(trimethylsilyl)phenyl)benzo[c][1,2,5]thiadiazole (45, 355 mg, 42%) as a bright 
yellow solid. 
 
mp (°C): 120.6-122.4. 
IR (ATR) ν~  (cm-1): 3058 (w), 1946 (w), 1912 (w), 1874 (w), 1798 (w), 1727 (w), 1656 (w), 
1595 (w), 1580 (w), 1537 (w), 1491 (w), 1474 (w), 1412 (w), 1377 (w), 1351 (w), 1168 (w), 
1064 (w), 1003 (w), 896 (m), 850 (m), 834 (m), 825 (m), 799 (vs), 751 (s), 713 (w). 
1H-NMR (300 MHz, CDCl3): δ = 8.01-7.97 (m, 1H), 7.91-7.88 (m, 2H), 7.71-7.66 (m, 4H), 
0.32 ppm (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 155.6, 153.6, 140.9, 137.7, 134.7, 133.6, 129.6, 128.5, 
127.7, 120.6, -1.1 ppm. 
MS (70 eV, EI): m/z (%) = 286 (3), 285 (5), 284 (22) [M+], 272 (2), 271 (9), 270 (19), 269 
(100), 253 (2), 239 (6), 135 (4). 
HRMS (EI): m/z calc. for [C15H16N2SSi] 284.0803; found: 284.0799. 
 
Synthesis of 4-(4-iodophenyl)benzo[c][1,2,5]thiadiazole (46) 
 
 
In a round bottom flask ICl (2 mL) was added dropwise to a solution of 4-(4-
(trimethylsilyl)phenyl)benzo[c][1,2,5]thiadiazole (284 mg, 1 mmol) in CH2Cl2 (2 mL) at 0 °C 
and stirred for 3 h. The reaction mixture was quenched by the addition of Na2S2O3(sat) 
(10 mL). The aqueous layer was extracted with CH2Cl2 (3 x 30 mL), the combined organic 
layers were dried (MgSO4) and the solvent was evaporated in vacuo. Purification via column 
chromatography (silicagel, pentane/ Et2O = 200:1) afforded 4-(4-iodophenyl)-
benzo[c][1,2,5]thiadiazole (46, 316 mg, 93%) as a bright yellow solid. 
 
mp (°C): 71-73. 
IR (ATR) ν~  (cm-1): 3063 (w), 3014 (w), 2953 (w), 2894 (w), 1594 (w), 1544 (w), 1482 (w), 
1408 (w), 1381 (w), 1249 (m), 1130 (w), 1107 (w), 1096 (w), 895 (w), 840 (s), 823 (s), 803 
(s), 756 (vs), 723 (m), 696 (m), 678 (m). 
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1H-NMR (300 MHz, CDCl3): δ = 8.06-8.00 (m, 1H), 7.90-7.85 (m, 2H), 7.72-7.67 ppm (m, 
4H). 
13C-NMR (75 MHz, CDCl3): δ = 155.6, 153.2, 137.8, 136.8, 133.4, 131.0, 129.6, 127.6, 
121.0, 94.5 ppm. 
MS (70 eV, EI): m/z (%) = 339 (15), 338 (100), 212 (10), 211 (57), 178 (15), 165 (7), 152 
(9), 140 (12), 58 (11), 43 (39). 
HRMS (EI): m/z calc. for [C12H7IN2S] 337.9375; found: 337.9370. 
 
Synthesis of 2-(4-benzo[c][1,2,5]thiadiazol-4-ylphenyl)-9-(1-hexylheptyl)anthra[2,1,9-
def;6,5,10-d'e'f']diisoquinoline-1,3,8,10-tetraon (49) 
 
 
 
Pd(dba)2 (12 mg, 0.02 mmol), P(o-furyl)3 (9 mg, 0.04 mmol) and 2-(1-hexylheptyl)-9-(4-
iodophenyl)anthra[2,1,9-def;6,5,10-d'e'f']diisoquinoline-1,3,8,10-tetraone (48, 100 mg, 
129 µmol) were successively added to the zinc reagent 44 prepared by TP6 (4.3 mL, 0.2 M in 
THF, 0.85 mmol). After stirring at 25 °C for 24 h, the reaction mixture was quenched by the 
addition of NH4Cl(sat) (5 mL). The aqueous layer was extracted with CH2Cl2 (3 x 30 mL), the 
combined organic layers were dried (MgSO4) and the solvent was evaporated in vacuo. The 
crude solid was dissolved in CH2Cl2 and precipitated with MeOH. Filtration afforded  
2-(4-benzo[c][1,2,5]thiadiazol-4-ylphenyl)-9-(1-hexylheptyl)anthra[2,1,9-def;6,5,10-d'e'f']-
diisoquinoline-1,3,8,10-tetraon (49, 47 mg, 47%) as a bright red solid. 
 
mp (°C): > 300. 
IR (ATR) ν~  (cm-1): 3476 (w), 2956 (m), 2926 (m), 2857 (m), 1696 (s), 1660 (s), 1594 (s), 
1578 (m), 1543 (w), 1512 (w), 1483 (w), 1466 (w), 1434 (w), 1406 (m), 1352 (s), 1254 (s), 
1178 (m), 1138 (w), 1126 (w), 1111 (w), 1067 (w), 1024 (w), 965 (w), 900 (w), 874 (w), 
864 (m), 841 (w), 810 (s), 793 (m), 746 (m), 726 (w), 688 (w). 
1H-NMR (600 MHz, CDCl3): δ = 8.74-8.64 (m, 8 H), 8.18 (d, J = 8.3 Hz, 2 H, 8.05 (d, 
J = 8.8 Hz, 2 H), 7.81 (d, J = 7.1 Hz, 2 H), 7.73 (m, 2 H), 7.53 (d, J = 8.2 Hz, 1 H), 5.23 -5.16 
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(m, 1 H), 2.29-2.23 (m, 2 H), 1.92-1.83 (m, 2 H), 1.39-1.19 (m, 16 H), 0.83 ppm (t, 
J = 7.0 Hz, 6 H). 
13C-NMR (100 MHz, CDCl3): δ = 163.6, 135.3, 132.0, 130.3, 129.6, 128.8, 128.1, 123.4, 
123.1, 54.8, 32.4, 31.8, 29.7, 29.2, 26.9, 22.6, 14.0 ppm. 
MS (70 eV, EI): m/z (%) = 783 (36), 600 (100). 
HRMS (EI): m/z calc. for [C49H42N4O4S] 782.2927; found: 782.2845. 
UV/VIS (CHCl3): λmax (ε) = 315.9 (17400), 352.0 (10500), 459.1 (19100), 491.0 (52700), 
527.4 nm (87900). 
Fluorescence (CHCl3): λmax (Irel) = 534.2 (1.00), 576.8 (0.51), 625.1 nm (0.12). 
 
Synthesis of 8-(benzo[c][1,2,5]thiadiazol-4-yl)-2-(1-hexylheptyl)-1H-perylo[3,4-
cd]pyridine-1,3(2H)-dione (51) 
 
 
 
Pd(OAc)2 (5 mg, 0.02 mmol), SPhos (16 mg, 0.04 mmol) and 8-bromo-2-(1-hexylheptyl)-1H-
perylo[3,4-cd]pyridine-1,3(2H)-dione (50, 63 mg, 0.13 mmol) were successively added to the 
zinc reagent 44 prepared by TP6 (4.3 mL, 0.2 M in THF, 0.85 mmol). After stirring at 25 °C 
for 24 h, the reaction mixture was quenched by the addition of NH4Cl(sat) (5 mL). The aqueous 
layer was extracted with CH2Cl2 (3 x 30 mL), the combined organic layers were dried 
(MgSO4) and the solvent was evaporated in vacuo. Purification via column chromatography 
(silicagel, CH2Cl2) afforded a red solid which was dissolved in CH2Cl2 and precipitated with 
MeOH. Filtration provided 8-(benzo[c][1,2,5]thiadiazol-4-yl)-2-(1-hexylheptyl)-1H-
perylo[3,4-cd]pyridine-1,3(2H)-dione (51, 39 mg, 47%) as a red solid. 
 
mp (°C): 184-185. 
IR (ATR) ν~  (cm-1): 3050 (w), 2953 (m), 2924 (s), 2855 (m), 1688 (s), 1650 (s), 1616 (w), 
1592 (s), 1576 (s), 1542 (w), 1507 (w), 1487 (w), 1456 (m), 1434 (w), 1349 (w), 1374 (w), 
1352 (s), 1295 (m), 1247 (m), 1214 (w), 1174 (w), 1139 (w), 1105 (w), 1028 (w), 980 (w), 
902 (w), 854 (m), 841 (m), 808 (s), 752 (s), 726 (w), 688 (w), 668 (w). 
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1H-NMR (600 MHz, CDCl3): δ = 8.59-8.47 (m, 3H), 8.39 (m, 3H), 8.17 (dd, J = 8.7, 1.2 Hz, 
1H), 7.84-7.80 (m, 1H), 7.77-7.72 (m, 2H), 7.63 (d, J = 8.4 Hz, 1H), 7.47 (m, 1H), 5.24-5.17 
(m, 1H), 2.31-2.22 (m, 2H), 1.91-1.83 (m, 2H), 1.40-1.20 (m, 16H), 0.83 ppm (t, J = 7.0 Hz, 
6 H). 
13C-NMR (100 MHz, CDCl3): δ = 165.1, 164.1, 155.1, 154.3, 138.1, 136.8, 136.5, 133.2, 
132.8, 132.0, 131.1, 130.3, 129.8, 129.7, 129.5, 129.4, 129.1, 128.8, 128.3, 127.0, 126.5, 
123.7, 123.0, 121.6, 120.4, 120.3, 54.4, 32.4, 31.8, 29.3, 27.0, 22.6, 14.1 ppm. 
MS (70 eV, EI): m/z (%) = 637 (42), 455 (100). 
HRMS (EI): m/z calc. for [C41H39N3O2S] 637.2763; found: 637.2751. 
UV/VIS (CHCl3): λmax (ε) = 314.0 (15600), 489.5 (37500), 513.3 nm (38400). 
Fluorescence (CHCl3): λmax = 557.3 nm. 
 
Synthesis of 4-(benzo[c][1,2,5]thiadiazol-4-yl)aniline (52a) 
 
 
 
Pd(OAc)2 (14 mg, 2 mol%, 0.06 mmol), SPhos (49 mg, 4 mol%, 0.12 mmol) and 4-
iodoaniline (855 mg, 3.9 mmol) were successively added to the zinc reagent 44 prepared by 
TP6 (15 mL, 0.2 M in THF, 3.0 mmol). After stirring at 50 °C for 24 h, the reaction mixture 
was quenched by the addition of NH4Cl(sat) (15 mL). The aqueous layer was extracted with 
CH2Cl2 (3 x 50 mL), the combined organic layers were dried (MgSO4) and the solvent was 
evaporated in vacuo. Purification via column chromatography (silicagel, CH2Cl2) afforded 4-
(benzo[c][1,2,5]thiadiazol-4-yl)aniline (52a, 415 mg, 61%) as an orange solid. 
 
mp (°C): 132-133. 
IR (ATR) ν~  (cm-1): 3441 (w), 3349 (w), 3216 (w), 2924 (w), 2853 (w), 1738 (w), 1627 (m), 
1608 (m), 1541 (w), 1512 (s), 1479 (m), 1327 (w), 1297 (m), 1276 (m), 1181 (m), 1167 (w), 
1124 (m), 1078 (w), 894 (w), 827 (m), 802 (s), 753 (vs). 
1H-NMR (400 MHz, d6-DMSO): δ = 7.94-7.88 (m, 1H), 7.76-7.67 (m, 4H), 6.72-6.68 (m, 
2H), 5.40 ppm (br s, 2H). 
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13C-NMR (100 MHz, d6-DMSO): δ = 155.3, 152.8, 149.2, 134.0, 130.3, 129.9, 125.4, 123.9, 
118.3, 113.6 ppm. 
MS (70 eV, EI): m/z (%) = 229 (5), 228 (15), 227 (100), 226 (15), 211 (5), 194 (5), 181 (4), 
168 (3), 140 (4), 114 (5). 
HRMS (EI): m/z calc. for [C12H9N3S] 227.0517; found: 227.0517. 
 
Synthesis of 3-(benzo[c][1,2,5]thiadiazol-4-yl)aniline (52b) 
 
 
 
Pd(OAc)2 (14 mg, 2 mol%, 0.06 mmol), SPhos (49 mg, 4 mol%, 0.12 mmol) and 3-
iodoaniline (855 mg, 3.9 mmol) were successively added to the zinc reagent 44 prepared by 
TP6 (15 mL, 0.2 M in THF, 3 mmol). After stirring at 50 °C for 24 h, the reaction mixture 
was quenched by the addition of NH4Cl(sat) (15 mL). The aqueous layer was extracted with 
CH2Cl2 (3 x 50 mL), the combined organic layers were dried (MgSO4) and the solvent was 
evaporated in vacuo. Purification via column chromatography (silicagel, 
pentane/ EtOAc = 3:1) afforded 3-(benzo[c][1,2,5]thiadiazol-4-yl)aniline (52b, 414 mg, 61%) 
as an orange solid. 
 
mp (°C): 93-95. 
IR (ATR) ν~  (cm-1): 3435 (m), 3346 (m), 3214 (w), 3041 (w), 1738 (w), 1623 (m), 1607 (m), 
1582 (m), 1541 (w), 1494 (w), 1478 (m), 1454 (m), 1331 (w), 1288 (w), 1247 (w), 1165 (m), 
994 (w), 908 (w), 881 (w), 850 (m), 827 (m), 813 (m), 778 (s), 760 (vs), 698 (s). 
1H-NMR (400 MHz, d6-DMSO): δ = 8.03 (dd, J = 8.6, 1.4 Hz, 1H), 7.78-7.71 (m, 2H), 
7.18-7.14 (m, 2H), 7.05-7.03 (m, 1H), 6.67-6.64 (m, 1H), 5.20 ppm (br s, 2H).  
13C-NMR (100 MHz, d6-DMSO): δ = 155.1, 152.8, 148.7, 137.5, 134.4, 130.1, 128.9, 127.5, 
119.9, 116.8, 114.6, 114.0 ppm. 
MS (70 eV, EI): m/z (%) = 229 (4), 228 (11), 227 (100), 226 (14), 211 (5), 200 (3), 199 (3), 
194 (2), 181 (3), 140 (3), 114 (3). 
HRMS (EI): m/z calc. for [C12H9N3S] 227.0517; found: 227.0503. 
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Synthesis of 5-(benzo[c][1,2,5]thiadiazol-4-yl)pyridin-2-amine (52c) 
 
 
Pd(OAc)2 (14 mg, 2 mol%, 0.06 mmol), SPhos (49 mg, 4 mol%, 0.12 mmol) and 5-
iodopyridin-2-amine (885 mg, 3.9 mmol) were successively added to the zinc reagent 44 
prepared by TP6 (15 mL, 0.2 M in THF, 3 mmol). After stirring at 50 °C for 24 h, the reaction 
mixture was quenched by the addition of NH4Cl(sat) (15 mL). The aqueous layer was extracted 
with CH2Cl2 (3 x 50 mL), the combined organic layers were dried (MgSO4) and the solvent 
was evaporated in vacuo. Purification via column chromatography (silicagel, EtOAc) afforded 
5-(benzo[c][1,2,5]thiadiazol-4-yl)pyridin-2-amine (52c, 360 mg, 53%) as a red solid. 
 
mp (°C): 195-197. 
IR (ATR) ν~  (cm-1): 3451 (w), 3292 (w), 3158 (w), 1640 (s), 1628 (s), 1605 (m), 1594 (m), 
1554 (w), 1545 (w), 1506 (m), 1482 (s), 1414 (s), 1382 (m), 1355 (w), 1316 (m), 1272 (m), 
1146 (w), 1131 (w), 1020 (w), 895 (w), 852 (w), 827 (m), 805 (s), 755 (vs). 
1H-NMR (400 MHz, d6-DMSO): δ = 8.60 (dd, J = 2.5, 0.7 Hz, 1H), 8.03 (dd, J = 8.6, 
2.5 Hz, 1H), 7.98-7.93 (m, 1H), 7.75-7.70 (m, 2H), 6.59 (dd, J = 8.7, 0.7 Hz, 1H), 6.25 ppm 
(br s, 2H). 
13C-NMR (100 MHz, d6-DMSO): δ = 159.6, 155.1, 152.6, 148.2, 137.4, 131.4, 130.3, 125.5, 
120.7, 119.0, 107.5 ppm. 
MS (70 eV, EI): m/z (%) = 229 (11), 228 (100), 227 (21), 201 (11), 200 (7), 69 (8), 57 (10), 
55 (10), 43 (8), 41 (6). 
HRMS (EI): m/z calc. for [C11H8N4S] 228.0470; found: 228.0461. 
 
Synthesis of 4-(benzo[c][1,2,5]oxadiazol-4-yl)aniline (54a) 
 
 
Pd(OAc)2 (7 mg, 2 mol%, 0.03 mmol), SPhos (25 mg, 4 mol%, 0.06 mmol) and 4-iodoaniline 
(372 mg, 1.7 mmol) were successively added to the zinc reagent prepared by TP8 (5.6 mL, 
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0.25 M in THF, 1.4 mmol). After stirring at 50 °C for 24 h, the reaction mixture was quenched 
by the addition of NH4Cl(sat) (10 mL). The aqueous layer was extracted with CH2Cl2 (3 x 
30 mL), the combined organic layers were dried (MgSO4) and the solvent was evaporated in 
vacuo. Purification via column chromatography (silicagel, pentane/ EtOAc = 4:1) afforded 4-
(benzo[c][1,2,5]oxadiazol-4-yl)aniline (54a, 175 mg, 59%) as an orange solid. 
 
mp (°C): 115-117. 
IR (ATR) ν~  (cm-1): 3453 (w), 3364 (m), 3217 (w), 1626 (m), 1603 (s), 1544 (w), 1510 (s), 
1447 (w), 1423 (w), 1373 (w), 1302 (m), 1276 (m), 1178 (w), 1141 (w), 1016 (w), 892 (w), 
871 (w), 836 (m), 815 (m), 797 (s), 754 (vs). 
1H-NMR (400 MHz, d6-DMSO): δ = 7.82-7.79 (m, 3H), 7.65-7.56 (m, 2H), 6.72-6.69 (m, 
2H), 5.58 ppm (brs, 2H). 
13C-NMR (100 MHz, d6-DMSO): δ = 150.1, 149.7, 148.2, 133.2, 129.3, 129.1, 125.3, 121.6, 
113.8, 112.1 ppm. 
MS (70 eV, EI): m/z (%) = 212 (13), 211 (100), 210 (7), 194 (8), 182 (10), 181 (53 ), 179 (7), 
155 (11), 154 (10), 153 (9), 127 (10). 
HRMS (EI): m/z calc. for [C12H9N3O] 211.0746; found: 211.0741. 
 
Synthesis of 3-benzo[c][1,2,5]oxadiazol-4-yl)aniline (54b) 
 
 
 
Pd(OAc)2 (7 mg, 2 mol%, 0.03 mmol), SPhos (25 mg, 4 mol%, 0.06 mmol) and 3-iodoaniline 
(372 mg, 1.7 mmol) were successively added to the zinc reagent prepared by TP8 (5.6 mL, 
0.25 M in THF, 1.4 mmol). After stirring at 50 °C for 24 h, the reaction mixture was quenched 
by the addition of NH4Cl(sat) (10 mL). The aqueous layer was extracted with CH2Cl2 (3 x 
30 mL), the combined organic layers were dried (MgSO4) and the solvent was evaporated in 
vacuo. Purification via column chromatography (silicagel, pentane/ EtOAc = 2:1) afforded 3-
benzo[c][1,2,5]oxadiazol-4-yl)aniline (54b, 160 mg, 55%) as an orange solid. 
 
mp (°C): 95.8-97.4. 
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IR (ATR) ν~  (cm-1): 3400 (w), 3301 (w), 3196 (w), 1738 (w), 1637 (w), 1602 (m), 1583 (m), 
1545 (w), 1489 (w), 1459 (w), 1433 (w), 1311 (w), 1297 (w), 1248 (w), 1140 (w), 1018 (w), 
994 (w), 988 (w), 889 (w), 870 (m), 859 (m), 784 (s), 746 (vs), 694 (s). 
1H-NMR (400 MHz, d6-DMSO): δ = 9.96 (dd, J = 8.8, 1.0 Hz, 1H), 7.71-7.64 (m, 2H), 
7.23-7.16 (m, 2H), 7.12-7.09 (m, 1H), 6.70-6.67 (m, 1H), 5.30 ppm (br s, 2H). 
13C-NMR (100 MHz, d6-DMSO): δ = 149.6, 149.1, 148.2, 135.4, 133.0, 129.7, 129.4, 128.5, 
115.6, 114.8, 114.4, 113.4 ppm. 
MS (70 eV, EI): m/z (%) = 212 (10), 211 (76), 182 (16), 181 (100), 179 (9), 168 (11), 154 
(17), 153 (8), 149 (8), 127 (12). 
HRMS (EI): m/z calc. for [C12H9N3O] 211.0746; found: 211.0737. 
 
Synthesis of 5-(benzo[c][1,2,5]oxadiazol-4-yl)pyridin-2-amine (54c) 
 
 
Pd(OAc)2 (7 mg, 2 mol%, 0.03 mmol), SPhos (25 mg, 4 mol%, 0.06 mmol) and 5-
iodopyridin-2-amine (375 mg, 1.7 mmol) were successively added to the zinc reagent 
prepared by TP8 (5.6 mL, 0.25 M in THF, 1.4 mmol). After stirring at 50 °C for 24 h, the 
reaction mixture was quenched by the addition of NH4Cl(sat) (10 mL). The aqueous layer was 
extracted with CH2Cl2 (3 x 30 mL), the combined organic layers were dried (MgSO4) and the 
solvent was evaporated in vacuo. Purification via column chromatography (silicagel, EtOAc) 
afforded 5-(benzo[c][1,2,5]oxadiazol-4-yl)pyridin-2-amine (54c, 160 mg, 54%) as a red solid. 
 
mp (°C): 166.9-168.8. 
IR (ATR) ν~  (cm-1): 3414 (m), 3322 (w), 3118 (m), 1653 (s), 1612 (m), 1600 (s), 1545 (w), 
1505 (vs), 1395 (s), 1372 (m), 1334 (w), 1322 (m), 1298 (m), 1269 (m), 1139 (m), 1081 (w), 
1011 (w), 889 (w), 872 (w), 815 (w), 797 (m), 759 (w), 744 (s), 713 (w), 661 (w). 
1H-NMR (400 MHz, d6-DMSO): δ = 8.69-8.68. (m, 2H), 8.06 (dd, J = 8.7, 2.6 Hz, 1H), 7.87 
(dd, J = 8.9, 0.7 Hz, 1H), 7.71 (dd, J = 6.9, 0.8 Hz, 1H), 7.62 (dd, J = 8.9, 6.9 Hz, 1H), 6.60 
(dd, J = 8.7, 0.7 Hz, 1H), 6.41ppm (br s, 2H). 
13C-NMR (100 MHz, d6-DMSO): δ = 160.1, 149.6, 148.0, 147.9, 136.3, 133.2, 126.8, 125.9, 
118.6, 113.0, 107.9 ppm. 
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MS (70 eV, EI): m/z (%) = 213 (15), 212 (100), 196 (9), 185 (8), 182 (11), 155 (17), 142 (8), 
128 (8), 57 (8). 
HRMS (EI): m/z calc. for [C11H8N4O] 212.0698; found: 212.0690. 
 
Synthesis of 4,7-bis(4-(trimethylsilyl)phenyl)benzo[c][1,2,5]thiadiazol-5-amine (56) 
 
N
S
N
NH2
TMSTMS
 
 
Pd(OAc)2 (5 mg, 4 mol%, 0.04 mmol), SPhos (33 mg, 8 mol%, 0.08 mmol) and 4,7-
dibromobenzo[c][1,2,5]thiadiazol-5-amine (309 mg, 1.0 mmol) were added successively to a 
solution of (4-(trimethylsilyl)phenyl)zinc(II) chloride (7.3 mL, 0.55 M in THF, 4.0 mmol) and 
the resulting reaction mixture was stirred at 40 °C for 13 h. After addition of NH4Cl(sat) 
(10 mL), the aqueous layer was extracted with CH2Cl2 (4 x 40 mL), the combined organic 
layers were dried (MgSO4) and the solvent was evaporated in vacuo. Purification via column 
chromatography (silicagel, pentane/ CH2Cl2 = 4:1) afforded 4,7-bis(4-
(trimethylsilyl)phenyl)benzo[c][1,2,5]thiadiazol-5-amine (54, 220 mg, 49%) as a bright 
yellow solid. 
 
mp (°C): 235-236. 
IR (ATR) ν~  (cm-1): 3440 (vw), 3344 (w), 2954 (w), 2896 (vw), 1620 (w), 1594 (m), 1548 
(w), 1508 (vw), 1416 (w), 1382 (w), 1358 (w), 1336 (vw), 1276 (w), 1248 (m), 1176 (w), 
1126 (w), 1090 (w), 884 (w), 834 (vs), 816 (vs), 762 (m), 752 (m), 730 (m), 722 (m), 692 (w), 
632 (w.) 
1H-NMR (300 MHz, CDCl3): δ = 7.93-7.89 (m, 2H), 7.75-7.70 (m, 4H), 7.63-7.60 (m, 2H), 
7.30 (s, 1H), 4.26 (br s, 2H), 0.35 ppm (s, 18H). 
13C-NMR (75 MHz, CDCl3): δ = 156.5, 149.4, 144.0, 140.9, 140.2, 137.5, 135.2, 134.2, 
133.8, 133.6, 129.3, 128.4, 122.9, 111.5, -1.1, -1.1 ppm. 
HRMS (ESI): m/z calc. for [C24H29N3SSi2+H+] 448.1693; found: 448.1702. 
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